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SUMMARY 
In the last decade, there has been an increasing prevalence of obesity and metabolic-
associated diseases. In view of this fact, finding preventive therapies, as well as 
treatments for these diseases is of great interest for public health. Gut hormones 
secreted from enteroendocrine cells (EECs) play a key role in the regulation of food 
intake and glucose homeostasis. In this context, the research of this thesis has focused 
on the role of natural bioactive compounds on the enteroendocrine system. 
Our research group reported in previous studies that grape seed proanthocyanidin 
extract (GSPE) increased GLP-1 plasma levels in rats. In this thesis, we elucidated that 
such increase might be in part explained by the direct action of GSPE on 
enteroendocrine cells. Moreover, we demonstrate that GSPE also modulates the 
secretion of the main gut hormones by directly acting on EECs, inducing an increase of 
GIP and PYY release, while reducing CCK release. 
The results obtained in this thesis using organoids culture demonstrated that GSPE up-
regulate the main markers of L-cell and modulate transcription factors involved in L-
cell differentiation, and thereby point out that the promotion of L-cell differentiation is 
a mechanism by which GSPE act in prolonged treatments. Moreover, our findings in 
mid-term treatments revealed that gut microbiota composition is modulated by GSPE 
and such microbial composition profile correlates with host metabolic parameters, and 
remarkably with increased active GLP-1 plasma levels. 
Furthermore, we found a new source of natural bioactive compounds from chicken feet 
protein, chicken feet hydrolyzate, and demonstrated that it acts as antihyperglycemic 
agent in disrupted-glucose homeostasis animals due to the capacity of inhibiting DPP-
IV activity and enhancing endogenous GLP-1 release . 
In conclusion, the findings obtained in this thesis show that natural bioactive 
compounds act through different mechanisms on the enteroendocrine system, and 
thereby could be good therapeutic agents to treat obesity and glucose homeostasis 
disruption. 
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RESUM 
En els últims anys ha augmentat la presència de l’obesitat i de malalties associades a 
aquesta. En vista d’aquest fet, la cerca de teràpies preventives així com tractaments per 
aquestes malalties esdevé de gran interès per la salut pública. Les hormones intestinals 
secretades per les cèl·lules enteroendocrines juguen un paper clau en la regulació de la 
ingesta i la homeòstasis de la glucosa. En aquest marc, la recerca d’aquesta tesi 
doctoral s’ha centrat en l’acció dels compostos naturals bioactius sobre el sistema 
enteroendocrí.  
En estudis previs, el nostre grup de recerca va observar que un extracte de 
proantocianidines del pinyol del raïm (GSPE) augmentava els nivells plasmàtics de 
GLP-1 en rates. En aquesta tesi doctoral, s’ha esbrinat  que aquest augment podria ser 
en part explicat per l’acció directa del GSPE sobre les cèl·lules enteroendocrines. 
D’altra banda, s’ha demostrat que l’acció directa del GSPE també modula la secreció de 
les principals hormones intestinals, induint un augment de la secreció de GIP i PYY, així 
com una reducció de la secreció de CCK. 
Els resultats obtinguts en el cultiu d’organoids han demostrat que el GSPE incrementa 
els principals marcadors de les cèl·lules L i modula els factors de transcripció 
involucrats en la diferenciació d’aquestes cèl·lules. Conseqüentment, aquests resultats 
senyalen que promoure la diferenciació de les cèl·lules L és un mecanisme d’acció del 
GSPE en tractament prolongats. D’altra banda, la recerca realitzada en tractaments 
subcrònics ha revelat que el GSPE modifica la composició de la biota intestinal i que el 
perfil microbià correlaciona amb els paràmetres metabòlics de l’hoste,  del qual 
destaca la correlació amb els nivells plasmàtics incrementats de la hormona GLP-1 
activa. 
Altrament, s’ha trobat una nova font de compostos naturals bioactius procedents de la 
pota de pollastre, l’hidrolitzat de pota de pollastre, la qual s’ha demostrat que actua 
com un agent antihiperglicèmic en rates que presenten una homeòstasis de la glucosa 
alterada, degut a la capacitat d’inhibir l’activitat de DPP-IV i d’augmentar la secreció 
endògena de GLP-1. 
En conclusió, els resultats obtinguts en aquesta tesi doctoral mostren que els 
compostos naturals bioactius actuen en el sistema enteroendocrí per mitjà de diferents 
mecanismes, i per tant aquests podrien ser uns agents terapèutics adequats per al 
tractament de la obesitat i la homeòstasis de glucosa alterada. 
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ABBREVIATIONS 
2-OG 2-oleoylglycerol 
Arx Aristaless related homeobox factor 
bHLH Basic helix-loop-helix 
BMP Bone morphogenetic protein 
BP Bioactive peptides 
CaSR Calcium-sensing receptor 
CBC Crypt base columnar 
CCK Cholecystokinin 
ChgA Chomogranin A 
CNS Central neuronal system 
DPP-IV Dipeptidyl peptidase IV enzyme  
EEC Enteroencodrine cells  
EGC  (-)-epigallocatechin 
EGCg (-)-epigallocatechin gallate 
EGF Epidermal growth factor 
Elf3 E47-like factor 3 
FFA Fatty acid 
FFAR Fatty acid receptor 
Foxa ½ Forkhead box A2, transcript variant 1  
Gcg Proglucagon 
GI Gastrointestinal  
GIP Gastric inhibitory polypeptide  
GLP-1 Glucagon-like peptide-1 
GLP-1R Glucagon-like peptide-1receptor 
GPCR G-protein-coupled receptors  
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GSPE Grape seed proanthocyanidin extract 
HES1  hairy/enhancer of split genes 
Insm-1 Insulinoma-associated 1, IA-1  
Klf4 Kruppel-like factor 4 
LCFA  Long-chain fatty acids 
LPS Lipopolysaccharides 
Math1 Mouse atonal homologue 1 (transcription factor) 
MCFA Medium- chain fatty acids  
Muc2 Mucin 2 
NCID Notch intracellular domain 
NeuroD1 Neurogenic differentiation 1 
Ngn3 Neurogenin 3 
NPY Neuropeptide Y 
OGTT Oral glucose tolerance test 
Pax4 Paired box 4 
Pax6 Paired box 6 
Pdx1 Pancreas/duodenum homeobox gene-1 
PP Pancreatic polypeptide  
Ptk6 Protein tyrosine kinase 6 
PYY Peptide YY 
SCFA Short-chain fatty acid 
SLGT-1 Sodium-dependent glucose transporter 1  
T2DM Type 2 diabetes mellitus 
TA Transit-amplifying  
Tgf-βRII Growth factor β type II receptor  
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1. Gastrointestinal tract 
The gastrointestinal (GI) tract is an open-ended tube that extends through the body 
from the mouth to the anus. The lumen, the inside space of this tubular structure, can 
be defined as a tunnel environment through the body, and the wall of the GI tract as the 
physical interface between the external environment and the circulation. The main 
functions of the GI tract are to digest and absorb nutrients and other substances, as 
well as the propulsion of material through the digestive tract [1]. 
Food enters the mouth, which is the entrance of the GI tract, and continues through the 
pharynx and oesophagus to the stomach and intestines and finally into the rectum and 
anus. The small intestine, the relevant site for absorption, is divided into unequally 
sized sections: the duodenum, the jejunum and the ileum. The large intestine has two 
main sections: the cecum (whose size and functions differ between species) and the 
colon [2].  
The intestinal lumen is lined with a single layer of specialized epithelial cells that carry 
out the main functions of the GI tract, i.e. digestion and absorption of nutrients. It also 
forms a barrier against luminal pathogens. Moreover, the GI-tract cooperates in 
controlling the metabolism through hormones secreted from enteroendocrine cells 
(EEC), which are the largest endocrine organ of the body. 
The intestinal surface has an uneven architecture composed of villus and crypt 
structures. Proliferative cells, stem cells and transit-amplifying (TA) cells reside in the 
crypts and are triggered to differentiate into one of the four main specialized cells: 
entrocytes, paneth cells, goblet cells, and EEC [3]. A complex network of molecular 
signals and pathways regulate the differentiating process of the gut cells in the adult 
intestine, which will be described in the following sections.  
1.1. Differentiation in the intestinal epithelium 
The adult intestinal epithelium undergoes rapid renewal to maintain optimal 
functioning. Regeneration relies on the crypt base, where adult stem cells continually 
divide to produce highly proliferative progenitors known as TA cells. The nascent TA 
cells migrate upwards from the depths of the crypt onto the surface of the villi and 
divide 4-5 times before they commit to the absorptive and secretory cell lineages. Cell 
proliferation terminates when differentiated cells leave the crypt, where they are 
exposed to the gut contents and finally sloughed from the villus trips. This renewal 
cycle operates continually and the cells take 2-7 days to make the journey [4].  
1.1.1. Proliferating intestinal cells: Stem cells  
Intestinal epithelial homeostasis is based on the balance between self-renewal and 
differentiation, which is maintained by a complex interplay of multiple regulatory 
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mechanisms. The intestinal stem cells are cycling, long-lived and multipotent cells. 
They play an important role in the self-renewal process. Over the past four decades, 
two models of intestinal stem cell identity have been proposed. The ‘stem cell zone 
model’, by Leblond, Cheng and Bjerknes [5], suggests that the slender crypt base 
columnar (CBC) cells at the crypt bottom and intercalated between Paneth cells are the 
resident stem cells. The Wnt target gene Lgr5 has been identified as an excellent 
marker for CBC cells. The Lgr5-CBC cells generally undergo symmetrical division, after 
which individual daughter cells stochastically adopt a stem cell or TA cell fate, 
depending on the available niche space [6, 7]. The second model describes an 
alternative stem cell population that has been postulated to reside at position +4 
relative to the crypt bottom, above the Paneth cells [8]. These +4 cells are considered 
to be relatively quiescent and resistant to acute injury [9]. Therefore, this stem cell 
pool does indeed play a role in intestinal homeostasis, but can restore the LGR5+ CBC 
stem cell compartment following injury [10]. 
The Wnt pathway is the first primary force implicated in controlling the maintenance 
of the crypt cell population in the proliferative state. The central player in the 
canonical Wnt cascade is β-catenin, which is regulated by a degradation complex 
consisting of caseine kinase-1 and GSK3-β, both residing in the adenomatous polyposis 
coli (APC) tumour suppressor. When Wnt ligands are not engaged with their Frizzled 
and low-density lipoprotein receptor-related protein (LRP) receptor, β-catenin is 
targeted for ubiquitination and proteasomal degradation. In contrast, the Wnt-Fz-LRP 
complex transduces a signal into the cell, resulting in unphosphorylated β-catenin 
translocation into the nucleus and subsequent activation of the T-cell 
factor/lymphocyte enhancer factor (TCF/LEF) family (Fig.1), thus activating a genetic 
program that supports stemness [11, 12]. 
Other molecular pathways that play important roles during embryogenesis are 
involved in the regulation of intestinal epithelium homeostasis in adult organisms. 
These include the hedgehog pathway, which is required for the formation of villi [13] 
and the repair phase after the injury[14]. Bone morphogenetic protein (BMP) 
signalling mediates the action of the hedgehog pathway, blocking ectopic crypt 
formation, and the expression of BMP antagonist noggin in the neighbourhood crypts, 
enabling a crypt-permissive environment[15]. BMP receptors by BMP, which is 
expressed in the intravillus and intercrypt mesenchymal cells, lead to complexes 
between Smad1/5/8 and Smad 4 blocking stemness genes in the nucleos (Fig.1). 
Moreover, the BMP pathway antagonizes the Wnt pathway within the differentiated 
compartment, thereby positioning TA cells in the crypt pockets [16]. Epidermal 
growth factor (EGF) signals induce mitogenic effects in stem cells and TA cells. When 
EGF is bound to their receptor, the Ras/Raf/Mek/Erk signalling axis is active in crypt 
epithelium; whereas the inhibition of Mek ablates intestinal stem cells [17] (Fig.1). The 
main protein of the Hippo pathway is the Yes-associated protein (YAP), which is 
found in the crypts and has Wnt antagonizing effects, thereby contributing to the 
prevention of proliferation. Although under normal conditions the YAP does not 
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contribute to proliferation, it regulates tissue regeneration caused by injury and 
tumorigenesis [18, 19]. The Notch pathway is also needed to maintain the crypt 
compartment in its undifferentiated and proliferative state, and is involved in the 
intestinal cell fate decision. This pathway will be discussed further in the following 
section. 
 
 
Figure 1. Histological location and biological interaction of intestinal stem cells and their niche, adapted 
from [20]. 
1.1.2. Cell lineage specification: Secretory Lineages versus Absorptive 
Lineage 
As mentioned above, TA cells terminally differentiate into the four main epithelial cell 
linages of the GI tract; that is, the absorptive enterocytes and three other cell types that 
belong to the secretory lineages: the goblet cells, the Paneth cells, and the 
enteroendocrine cells. Apart from these four main cell types, there are also some lesser-
known cell types, such as M-cells and Tuft cells [21, 22]. 
The Notch pathway plays a central function in the fate decision and differentiation 
process of the intestinal epithelial cells. The key players of the Notch pathway in 
mammals are the Notch receptor (Notch 1 though 4) and its ligands of the Delta and 
Serrate/Jagged subfamilies. These are transmembrane proteins that mediate 
communication between cells that are in contact (Fig.1). Interaction of one of the four 
Notch receptors with any of five Notch ligands results in activation of proteolytic 
cleavage and the Notch intracellular domain (NCID) is released from the cell surface 
[23]. The NICD translocates into the nucleous and binds to the transcription factor 
RBP-Jk to activate target gene transcriptors [24].  
The Wnt and Notch signals cooperate to keep the crypt in the stemness state. 
Moreover, the Notch pathway in the transit-amplifying compartment controls 
absorptive versus secretory fate decisions in the intestinal epithelium. Increased Notch 
INTRODUCTION 
 
14 
 
signalling activity through constitutive expression of NICD in the gut epithelium results 
in a severe reduction of all three secretory cell types [25]. In contrast, inhibition of 
Notch signalling through pharmacological gamma secretase inhibitors has the opposite 
effect on intestinal differentiation and results in complete conversion of all epithelial 
cells into goblet cells [26]. The cells that become secretory are those that escape Notch 
activation and are also the ones that express Delta proteins, enabling them to activate 
Notch signalling in their neighbours. Therefore, the Notch pathway controls intestinal 
fate decisions to mediate lateral inhibition between adjacent cells, preventing 
neighbouring cells from adopting the same fate [27]. 
The active Notch pathway results in transcription of the hairy/enhancer of split genes 
(HES) family, which encodes transcriptional repressors. Hes1 represses the 
transcription of the basic helix-loop-helix (bHLH) transcription factor Math1 (mouse 
atonal homologue 1)[28] (Fig.2). Lineage tracing studies have shown that all the 
secretory cell lineages are derived from Math1-expressing precursor cells [29]. While 
Math1 is required for all three secretory cell lineages, downstream lineage-specific 
transcription factors, such as Sox9 for Paneth cells [30], Klf4 (Kruppel-like factor 4) for 
goblet cells [31] and Ngn3/NeuroD1 for EEC  [32] (Fig.2) are needed for the correct 
differentiation of these secretory cell lineages. 
1.1.2.1. Enterocytes:  
The most populous cell on the intestinal villus is the absorptive enterocyte, which 
represents more than 80 % of all intestinal epithelial cells. Absorptive cells are highly 
polarized cells joined together by a tight junction. Adequate protein sorting and 
addressing are necessary for establishing and maintaining cell polarity to maintain the 
integrity of the epithelial barrier [33]. Their apical surfaces have characteristic 
microvilli that comprise an elaborate brush border responsible for absorbing and 
transporting the nutrients across the epithelium. Enterocytes express a high number of 
genes related to the carbohydrate metabolism (i.e. Phosphofructokinase, Aldolase, 
Fructose-Bisphosphate B, Glyoxalase), and fatty acid metabolism (i.e. Apolipoprotein 
A1, Apolipoprotein A4, fatty acid Coenzyme A ligase 5), as well as the dipeptidyl 
peptidase IV enzyme (DPP-IV), which plays an important role in enterohormone 
regulation, especially GLP-1[34]. 
Although the Notch pathway was thought to be needed for absorptive cell 
specification, recent studies have reported that it is not required, while, in contrast, the 
repression of Math1 expression and thus secretory cell fate is required [35, 36]. 
Therefore, deletion of Hes1 results in a decreased number of enterocytes and an 
increased number of all secretory lineages [28]. Downstream of Hes1, diverse 
transcription factors are involved in the enterocyte differentiation process, such as 
Elf3 (E47-like factor 3), Tgf-βRII (growth factor β type II receptor), and Ptk6 (protein 
tyrosine kinase 6) (Fig. 2).  
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1.1.2.2. Paneth cells:  
Paneth cells have a function in innate immunity and contain extensive apical secretory 
granules that are filled with a variety of antimicrobial proteins, including lysozymes 
and cryptdins [37]. They are renewed every 3-6 weeks, so they are the exception to the 
rapid self-renewal in the epithelium intestine [38]. Paneth cells represent the only 
differentiated cells that escape the upward migration, so they localize to the base of the 
crypt, where canonical Wnt signalling is active. The Fizzled-5 receptor plays a role in 
the transduction of Wnt signals in the Paneth cells, which interpret these signals for 
their specification, differentiation and maturation. The conditional deletion of this 
receptor results in mispositioned Paneth cells scattered along the villus, due to the lack 
of expression of the Tcf4 target gene EphB3. Thus, this receptor allows the correct 
positioning of epithelial cells to be achieved in a Wnt gradient along the crypt-villus 
axis [39]. Moreover, studies suggest that FGFR-3 (fibroblast growth factor receptor-3) 
is essential for Paneth cell emergence and lineage allocation [40]. The Wnt 
transcriptional factor target Sox9, which is expressed in all cells at the crypt bottom, 
was identified as an essential factor for Paneth cell differentiation [30] (Fig.2). 
Moreover, Paneth cells have a determinant role in the stem cell niche homeostasis. 
They are the Wnt source that induces the formation of a new stem cell as well as 
Paneth cells, and there is a Wnt-driven positive-feedback loop that could lead to ever-
expanding crypts [41]. 
1.1.2.3. Goblet cells: 
The goblet cell population is the most abundant secretory lineage among all types of 
epithelial cells and increases between the duodenum (~4%) and colon (~16%). These 
cells secrete protective mucus and trefoil proteins that are needed for the effective 
expulsion of gut contents, and protect against shear stress and chemical damage [42]. 
As discussed above, Hes1 is expressed in proliferative crypt cells, while Math1 is only 
expressed in secretory cells. Inhibition of Notch signalling results in a lack of Hes1 
expression and the consequent induction of Math1 expression, leading to the 
conversion of all proliferative cells into goblet cells [26]. Goblet cell differentiation also 
depends on a zinger-finger transcription factor Kfl4, whose deletion results in the loss 
of goblet cells [31] (Fig.2). Likewise, the inactivation of the goblet cell marker, 
gastrointestinal mucin 2 (Muc2), leads to the development of adenomas in the small 
intestine. However, goblet cells of Muc2 -/- mice still express the intestinal trefoil 
factor, which suggests that some aspects of the differentiation program persist [43]. 
1.1.2.4. Enteroendocrine cells: 
EECs comprise the largest population of hormone-producing cells in the body [44]. 
They represent approximately 1% of the cells lining the small and large intestinal 
lumen. Unlike many endocrine glands, gastrointestinal endocrine cells are scattered as 
individual cells throughout the mucosa and surrounded by non-endocrine cells [5]. 
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Enteroendocrine cells regulate gut functioning through specific hormone secretion. 
There are more than 15 subtypes of enteroendocrine cells defined according to their 
morphology and the hormones that they produce. 
Three proendocrine bHLH transcription factors (Math1, Neurogenin 3 (Ngn3) and 
Neurogenic differentiation 1 (NeuroD1)) all target Notch signalling. They function in 
cascade, which means one factor activates later factors to control both the initial 
specification of the enteroendocrine cells and their final differentiation. Ngn3 over-
expression in the developing intestinal epithelium results in increased numbers of 
enteroendocrine cells at the expense of goblet cells [45], which demonstrates the 
importance of Ngn3. The requirement of Ngn3 differs between intestine and stomach. 
While all intestinal enteroendocrine cells are Ngn3-dependent, its role in the stomach 
is more limited, where deletion of Ngn3 expression reduces the number of glucagon-, 
somatostatin- and gastric- secreting cells, but serotonin-, histamine-, and ghrelin-
expressing cells are still present [32].  
 
Figure 2. Schematic overview of the genetic hierarchy of epithelial cell lineage commitment in the 
intestine. Adapted from [42].  
A set of transcription factors downstream of Ngn3 have also been shown to play a 
critical role in the specification of the various subsets of enteroendocrine cells, 
similarly to pancreatic differentiation. NeuroD1, which acts directly downstream of 
Ngn3, has been shown to control terminal differentiation of the secretin and 
Paneth cells Goblet cells Enteroendocrine cells Enterocyte
Stem cells
+ +Wnt pathway Notch pathway
Math1 Hes1
Gfti1 Ngn3
Lzy1 Muc2
Sox9
NeuroD, Arx, Pax4
Pax6, Foxa ½, Nk2.2
Pdx1, Insm1
Chga 
Elf3
Tgf-βRII, 
Ptk6
Fabp2, SIS
Klf4
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cholecystokinin (CCK) producing subset of enteroendocrine cells [46]. Other factors 
that have been implicated in enteroendocrine cell fate specification include the zinc-
finger transcription factors and homodominan transcription factors, such as Insm-1, 
Pdx1, Nkx2.2, ARX, Foxa ½, Pax4 and Pax6 [47–51]. Among these, it has been reported 
that gastric inhibitory polypeptide (GIP) secreting cells are Pax6-dependent [47], while 
other studies indicate that Pax6 acts together with Foxa1/2 to regulate the 
transcription of the preglucagon gene [50]. Besides the deletion of Pax4 expression in 
mice, an increase in glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) transcripts 
has also been shown, suggesting an increase in the number of L cells. However, 
deletion of Arx expression resulted in an almost complete loss of GLP1-, GIP- and CCK-
expressing cells [51]. Mechanisms for generating the diversity and regional specificity 
of enteroendocrine cells rely on a complex network of transcription factors and further 
studies are needed to elucidate the pathways involved in enteroendocrine cell 
specification. 
1.2. Enterohormones: synthesis by EE cells, secretion and 
function 
As mentioned above, the GI tract is the largest endocrine organ of the body. At least 15 
types of EECs have been described, which secrete more than 20 different regulatory 
hormones that are involved in the regulation of a number of physiological processes 
and exert their effect on tissues including exocrine glands, smooth muscle and the 
peripheral nervous system [52].  
It was generally accepted that EECs could be classified into discrete classes of cells 
with specific secretory profiles, mainly secreting peptides derived from a single 
peptide precursor. In this traditional classification, EECs were located in certain 
segments of the GI tract. Examples of previously described cell family groups include 
CCK-secreting I-cells located in the duodenum, GLP-1- and PYY-secreting L-cells 
located in the ileum and colon, among others [53]. However, recent studies have 
revealed that there are a wide range of EEC types that are capable of expressing a huge 
combination of different hormone precursors [54]. Based on this knowledge, 
Engelstoft et al. suggest organising the enteroendocrine system in pan-GI tract 
enteroendocrine cell types, gastro-selective cell types and a joint multi-capable 
intestinal-selective cell lineage, which in certain segments of the intestine is divided 
into specialized cell types that express a range of hormones as previously described in 
the classical classification [55](Fig.3). 
The individual hormone gene could be expressed in multiple forms because of tandem 
genes encoding different hormonal peptides, alternative splicing or differential 
processing [44, 56]. Some of the gastrointestinal hormones are synthesized from 
precursor proteins called prehormones, which undergo post-translational processes to 
produce mature hormones prior to secretion. The post-translational modifications 
consist in proteolytic cleavage by endopeptidases and exopeptidases and are followed 
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by the amidation process. The variety of these hormones is derived from a single 
prehormone that may exhibit different activities like gastrin peptides do (gastrin-6, 
gastrin-14, gastrin_17, gastrin-34, and gastrin-71) [57].  
 
Figure 3. EEC type classification: for each of the cell types the main secretory product and the original 
Wiesbaden nomenclature (W-type) are indicated. In intestinal EE cell types, the six defined cell types 
could be considered to be one cell type specialized in various segments or at least one cell lineage, which is 
indicated by the common maroon colour and the lighter maroon colour indicates that the peptides are less 
expressed in these segments. The gastric ghrelin cells are significantly different from the ghrelin-motilin 
cells of the small intestine. Extracted from [55]. 
EECs are capable of responding to luminal content because their apical side has 
chemosensing machinery, including taste receptors (TASR), G protein-coupled 
receptors (GPCR), plus specific transporters and channels, among others. Their 
secretory products are stored in characterized secretory vesicles, which are the large 
dense-core type or the smaller synaptic-like type, prior to their secretion through the 
basolateral membrane by exocytosis [56, 58]. This model is especially appropriate for 
the open type EECs that reach the luminal surface, whereas the closed type EECs, 
which do not reach the lumen, can be indirectly regulated by content through neural 
and humoral mechanisms [59].  
When luminal content move through the GI tract, specific macronutrients stimulate the 
chemosensors machinery. That stimulation leads the modulation of gut hormones 
release. These hormones, which mainly are GLP-1, CCK, PYY, GIP, and ghrelin, influence 
the functioning of digestive tract, but also modulate insulin secretion of liver, energy 
storage of adipose tissue and influence neuronal signaling in appetite centers in the 
brain to mediate the regulation of food intake, such as the termination of hunger and 
the induction of satiety. The gut hormones exert their effect via vagal nerve or 
endocrine signalling, through the interaction of specific receptor expressed in different 
tissues of the body. In the next section, we focus on describing main gut hormones and 
their actions. 
1.2.1. Glucagon-like peptide 1 
Proglucagon is expressed in L-cells of the intestine, pancreatic α-cells and various 
areas of the central neuronal system (CNS), mainly in the brainstem and 
hypothalamus. Although a single gene encodes this precursor in all tissue types, 
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different sets of hormones are synthesized in each tissue due to tissue-specific 
posttranslational processing. This posttranslational processing produces a number of 
biologically active peptides, including glucagon, glicentin-related polypeptide (GRPP), 
intervening peptide-1 (IP-1), GLP-1, and GLP-2, among others. In L-cells, GLP-1 is 
produced as an inactive 37-amino acid peptide (GLP-11-37), which is further cleaved to 
form active GLP-17-37. Both forms can be amidated at the C-terminal residue, resulting 
in GLP-11-37amide and GLP-17-37amide. Although GLP-1 exists in several forms, the most 
secreted form is GLP-17-37amide. Both GLP-11-37amide and GLP-17-37amide are truncated by 
DPPIV, forming inactive forms [60–62]. 
DPP-IV is a ubiquitous aminodipeptidase that exists essentially as a membrane-
anchored cell-surface enzyme [63]. Its expression is widely distributed along the body 
tissues, such as kidneys, the GI tract, liver, and pancreas, among others. But DPP-IV is 
also expressed on endothelial and epithelial cells along the vascular bed. Its soluble 
form is found in plasma and therefore it is in close proximity with hormones 
circulating in the blood [64, 65]. The main activity of DPP-IV is to remove N-terminal 
dipeptides from polypeptides [66], which preferably have a proline or alanine in their 
second position from the N-terminal. The main DPP-IV substrates include GLP-1, and 
the other incretin hormone GIP, which are peptides with N-terminal Tyr–Ala and His–
Ala respectively [67]. The intact GLP-1 is rapidly hydrolysed by DPP-IV into a shorter 
and inactive form. Once it reaches the plasma, with a half-life of 1-2 minutes [66]. Only 
25% of the active GLP-1 reaches the portal circulation and subsequently the liver, 
where a further 40-50% is digested by DPP-IV present on hepatocytes. This means that 
only 15% enters the systemic circulation and may reach other tissues, such as the 
pancreas or the brain [60]. Therefore, DPP-IV is responsible for inactivating more than 
80 % of the secreted GLP-1 [66]. 
Nutrient ingestion is the primary physiological stimulus for inducing GLP-1 secretion 
by L-cells. GLP-1 secretion occurs in a biphasic pattern, which consists in a rapid 
release in 15-30 min after a meal, followed by a second minor peak that occurs in 60-
120 min. Both glucose and fat have been reported to be a strong GLP-1-secretagoge 
after their ingestion [68], after direct administration into intestine [69, 70][69, 70] or 
into perfused ileal segments [71]. In the murine model, glucose-stimulated GLP-1 
release is blocked using sodium-dependent glucose transporter 1 (SLGT-1) knockout 
mice and SLGT-1 inhibitor [72, 73] , suggesting that glucose metabolism involves 
glucose transport via SGLT-1 to induce GLP-1 secretion. It has also been proposed that 
the sweet taste receptors (T1R2, T1R3) are involved in the glucose-sensing 
mechanism, but there is still controversy about this [74, 75]. On the other hand, G-
protein-coupled receptors (GPCRs) have been reported to be activated by dietary fat to 
stimulate GLP-1 release, including GPR40 and GPR120 by medium- chain fatty acids 
(MCFAs), long-chain fatty acids (LCFAs) and long-chain unsaturated FAs; and GPR41 
and GPR43 by short-chain fatty acids (SCFAs) (reviewed in [76, 77]). Finally, proteins 
are the macronutrient commonly considered the least effective for stimulating GLP-1 
secretion (this will be discussed further in Section 2 (2.2.2.2)).  
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Although EECs in duodenum can release GLP-1, several authors have suggested that 
the initial rapid rise in the GLP-1 secretion pattern can also be mediated indirectly by 
neuro/endocrine pathways (reviewed in [78, 79]). A proximal-distal loop has been 
described to be GLP-1-release signalling. It has been reported in rats that after a 
duodenal fat treatment, GIP plasma release is followed by GLP-1 plasma release, and 
this effect is mediated by the vagus nerve [69, 70]. Some neurotransmitters, including 
acetylcholine, glycine, GABA and epinephrine, as well as the adrenergic activation of L-
cells have been described to be involved in GLP-1 secretion [80–82]. 
The biological activity of GLP-1 is mediated by its interaction with GLP-1 receptors 
(GLP-1R), which are expressed in several tissues, including pancreatic islets, kidneys, 
and lungs, among others and in different sections of the peripheral and central nervous 
system [78, 83, 84]. GLP-1 together with GIP is responsible for the incretin effect, so it 
binds to GLP-1R in β-cells in the pancreas leading to an increase in intra-cellular 
calcium and a subsequent insulin secretion in response to glucose [85]. Moreover, it 
has been shown that GLP-1 enhances markers of proliferation and differentiation, and 
decreases markers of apoptosis in the pancreas of Zucker diabetic rats [86, 87]. GLP-1 
also improves the glycemic profile by inhibiting glucagon secretion and may also 
improve glucosal disposal in peripheral tissues [88]. Moreover, like PYY, exogenous 
GLP-1 administration decreases gastric emptying as well as the speed of intestinal 
transit (reviewed in [89]). On the other hand, the effects of anoretic GLP-1 on food 
intake could be mediated via the arcuate nucleus, where proopiomelanocortin (POMC) 
neurons express the GLP-1R. However, there is a physiological debate about whether 
GLP-1 can reach central GLP-1R in the hypothalamus through systemic regulation due 
to their short half-life [90]. Interestingly, Rüttimann et al.  [91] reported that 
intraperitoneal administration of GLP-1 reduces the sensitivity to the anoretic effects 
of GLP-1 in rats that undergo subdiaphragmatic vagal deafferation, while these effects 
were not affected when GLP-1 was administered in the vena cava and hepatic portal 
vein. This suggests that the role of the vagus system in intraperitoneally GLP-1, which 
acts similarly to endogenous GLP-1 secreted from L-cells, whereas exogenous 
circulating GLP-1 could bind directly at central receptors. 
1.2.2. Cholecystokinin 
The I-like cells in mammals and humans are the main CCK-secreting cells, and are 
located in the upper intestinal tract. Multiple molecular forms have been identified as 
CCK58 (the most abundant molecular form), CCK33, CCK22, and CCK8 (the most 
potent molecular form), all of which share the same carboxyl domain and are derived 
from a 115 amino acid prepropeptide. This carboxyl domain, which has an amidated 
carboxyl-terminal, is the biologically active portion of the hormone and full potency is 
not achieved unless the tyrosine residue at position 7 from the carboxyl terminus is 
sulphated. The CCK length depends on the CCK producing-cell synthesized, EEC of the 
small intestine and neurons in the GI tract and central nervous system [92, 93]. 
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CCK is secreted from the small intestine in response to the presence of luminal 
nutrients. Several protein hydrolystates and individual amino acids (phenylalanine, 
leucine and glutamic acid) have been reported as stimulators of CCK release [94, 95], 
as well as a LCFA, which also promotes CCK release through LCFA receptors [96, 97]. 
CCK has different physiological GI functions, including the stimulation of pancreatic 
secretion, gallbladder contraction, intestinal motility, and inhibition of gastric 
emptying [98]. These CCK functions are mediated by endocrine, paracrine and/or 
neurocrine modes of action [99]. Another function attributed to the CCK is the 
regulation of food intake, which could be mediated by the cholecystokinin 1 (CCK1) 
receptor on the vagal nerve. It has been described that Otsuka Long-Evans Tokushima 
Fatty rats, which do not have a CCK1 receptor, are hyperphagic and obese rats and 
present a lack of normal satiating response to intestinal nutrients [100, 101]. In this 
line, the administration CCK1 receptor antagonist increase food intake in rodents 
[102]. However, the CCK satiating property remained unclear for a considerable period 
of time. 
1.2.3. Gastric inhibitory polypeptide 
GIP is released from K-like cells that are located in the duodenum. GIP is a 42-residue 
peptide that is derived by proteolytic processing of a 153-amino acid precursor in 
humans and 144-aminoacid precursor in rodents [103]. This hormone belongs to the 
glucagon superfamily that includes secretin, glucagon and the vasoactive intestinal 
peptide (VIP) [104]. 
GIP secretion is primarily in response to direct interaction with ingested carbohydrate 
or fat, and is proportional to the amount of calories ingested and to the glucose 
absorption rate [105, 106]. The SGLT1 and KATP channels are involved in glucose-
triggered GIP release, while facilitative glucose transporter GLUT5 is involved in 
fructose-induced GIP release [107, 108]. It has been reported that GIP release depends 
on the nature of the fatty acid and the monounsaturated FFAs seem to induce a higher 
GIP secretion than saturated FFAs [109]. Lipids may exert their effect on GIP secretion 
by activating the G-protein-coupled receptors GPR40, GPR119 and GPR120 [108, 110].  
The first physiological role of GIP described was its ability to inhibit gastric acid 
secretion. Subsequent studies reported that GIP promotes glucose-induced insulin 
release from β-cells through the activation of adenylyl cyclase and mitogen-activated 
protein kinase [111, 112]. Following glucose ingestion, GIP and GLP-1 are responsible 
for 50% of the insulin released, a phenomenon called, as above mentioned, the incretin 
effect [113]. The two incretin hormones transduce their action by binding G-protein-
coupled receptors expressed in pancreatic cells and in peripheral tissues, such as the 
central nervous system, GI tract, heart, lungs, kidneys, bones and adipose tissue. The 
two incretin hormones are rapidly cleaved and inactivated by the DPP-IV enzyme. In 
the pancreas, the incretin engagement also enhances proliferative pathways and has 
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anti-apoptotic beneficial effects on pancreatic islets cells in both rodents and humans 
[114, 115].   
Moreover, GIP is involved in regulating the lipid metabolism and, unexpectedly, the 
inhibition of the GIP axis may function as therapeutic treatment against the 
development of obesity [116]. Miyawaki et al. showed that GIP receptor-deficient mice 
did not develop insulin resistance or obesity in high-fat-fed and ob/ob models, 
suggesting that GIP stimulated fat deposition into adipocytes [117]. Similar effects 
were observed in the chronic inhibition of the GIP pathway, including beneficial effects 
on body weight, insulin sensitivity and glucose tolerance in different obesity models 
[118–120]. 
1.2.4. Peptide YY 
PYY is secreted by L-like cells that are found along the gut, especially in more distal 
parts. The structure of PYY has a significant sequence homology with neuropeptide Y 
(NPY) and pancreatic polypeptide (PP); that is, all peptides have the PP fold structural 
motif [121–123]. Two endogenous forms, PYY (PYY1-36) and PYY3-36, are released into 
the circulation. The full-length PYY1-36 is derived by proteolytic processing of a large 
molecule precursor, and PYY3-36 is further produced by the digestion of PYY1-36 by DPP-
IV [124].  
PYY is secreted into the circulation after food intake and is reduced by fasting. Like GIP, 
the magnitude of PYY release is proportional to the calories ingested, and is stimulated 
by a high fat diet [125]. It has been reported that propionate enhances PYY secretion 
from rodents in vivo and in vitro through the FFAR2 receptor [126]. Also in rodents, 
colonic infusion of SCFAs increases PYY levels in vivo [127]. Besides fatty diets, PYY is 
secreted in response to glucose in humans [128, 129] and Mace et al. showed that PYY 
is secreted by L-amino acids phenylalanine, tryptophan, asparagine, arginine and 
glutamine through CaSR activation [130]. 
PYY, PP and NPY bind to G-protein coupled receptors Y1, Y2, Y4, Y5 and Y6 due to their 
shared PP motif structure [89]. The affinity between ligand and receptor, and the 
specific tissue expression of Y receptors determine the different biological activities of 
each hormone. The Y1 and Y5 receptors are expressed in the hypothalamus and have 
affinity with NPY and PYY1-36. On the other hand, PYY3-36 binds selectively to the Y2 
receptor and PP is selective to Y4 [52, 131].  
PYY may be involved in the regulation of glucose homeostasis through the 
coordination of pancreatic islets functions. Peripheral administration of exogenous 
PYY3-36, together with food or glucose, stimulates insulin secretion in mice through Y2 
receptor activation. However, the activation of Y1 receptor by PYY1-36 in murine islets 
inhibits glucose-stimulated insulin secretion [132, 133]. Moreover, both forms of PYY 
decrease gastric emptying, and PYY3-36 is mainly responsible [134]. 
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In addition to pancreatic regulation, PYY also regulates the appetite via a direct central 
effect and via its effects on gut motility. PYY is involved in the ‘ileal brake’, decreased 
gastric emptying and also the speed of intestinal transit (reviewed in [89]). The two 
PYY forms play opposite roles in the regulation of food intake. The central 
administration of PYY1-36 results in stimulation of feeding, while peripheral 
administration does not seem to influence appetite, which suggests that the effects are 
mediated by Y1R located in the hypothalamus (reviewed in [52]). In addition, PYY3-36 
plays a role as anoretic peptide and the effect of peripheral PYY3-36 seems to be 
mediated by Y2 receptor because the effect is absent when Y2R knockout mice are 
used and attenuated by Y2 receptor antagonists. Although it has been suggested that 
peripheral PYY3-36 could act through Y2 receptor expressed in vagal afferents of rats, 
conflicting evidence has been reported about whether PYY3-36 induce anorexigenic 
effects via vagal stimulation [135, 136].  
1.2.5. Ghrelin 
The X/A-like cells in mammals or D1 cells in humans are the main ghrelin-secreting 
cells. However, the highest content of ghrelin is in the gastric fundus. Ghrelin-
containing cells have also been found in the EEC of rats and humans throughout the GI 
tract, from duodenum to the colon. They can be classified into open-type cells, which 
are located in the stomach, and closed-type cells, which gradually increase along the GI 
tract [137]. 
Preproghrelin is composed of 117 amino acid peptides in humans and rodents, and 
after a post-translational process there is a 28-amino acid sequence, which is uniquely 
modified by the addition of an octanoyl group in third serine residue by O-
acyltransferase (GOAT) [138]. This modification is required for ghrelin to bind to the 
growth-hormone-secretagogue receptor (GHS-R) and to cross the blood-brain barrier 
[139], where ghrelin can act on growth hormone-releasing hormone (GHRH) neurons 
and others [140]. 
The patterns of ghrelin release show that circulating ghrelin levels increase during 
fasting periods and before meals, and fall after eating. For this reason ghrelin is often 
defined as the ‘hunger hormone’. It has been shown that both the feeling of hunger and 
food intake increase in humans after intravenous infusion or subcutaneous injection of 
ghrelin. Different regulatory molecular mechanisms of ghrelin secretion have been 
described, including, agents released by sympathetic neurons during fasting periods 
acting directly on β-receptors on the ghrelin-secreting cells of the stomach [141], 
circadian regulation mechanisms [142], several chemosensory receptors expressed by 
ghrelin-secreting cells that interact with luminal content [143], and the regulation by 
other enterohormones (GIP, secretin, somatostatin, and insulin) [144]. Controversial 
results have been found for nutrient sensing, such as glucose, SCFA and LCFA decrease 
ghrelin secretion, while tryptophan, peptones and the artificial sweetener sucralose 
increase ghrelin secretion [143, 145]. 
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Administering peripheral ghrelin results in weight gain by attenuating fat utilization, 
and chronic central ghrelin infusion enhances the expression of enzymes that promote 
fat storage in adipose tissue [146]. Therefore, using GHS-R antagonists to block ghrelin 
signalling is an interesting idea for preventing obesity. Moreover, ghrelin is also 
involved in regulating gastric motility and the neuronal orexigenic pathway [147, 148]. 
1.3. The role of gut microbiota in intestinal epithelial cell 
function 
Gut microbiota is described as the microbial community that inhabits the length of the 
GI tract, and particularly the distal gut. The human intestinal gut hosts trillions of 
microorganisms, including more than 1014 bacteria, which belong to 1000 different 
bacterial species classified in the bacterial taxonomy, a rank-based classification 
system [149, 150]. The genome size of the microbiome is 100- to 150-fold more 
numerous than the human genomes, providing the organisms with additional 
biological and metabolic functions for maintaining homeostasis in the body [151]. 
Therefore, the gut microbiota can be considered as an organ that plays a role in 
controlling energy homeostasis, regulating the immune system, and also in vitamin 
synthesis and digestion [152–156]. 
The main taxonomic bacteria in human gut microbiota belong to three major groups: 
Firmicutes (including Clostridium, Enterococcus, Lactobacillus, Ruminococcus, and 
Faecalibacterium genera), Bacteroidetes (including Bacteroides and Prevotella genera) 
and Actinobacteria. These are the dominant bacterial phyla that together represent 
>95% of the total microbiota. The composition of gut microbiota is modulated during a 
person’s lifespan from infancy to old-age by several environmental factors, including 
life style, use of antibiotics, and dietary pattern [157–159]. Due to several direct and 
indirect interactions with the host organism, the gut microbiota and the modulation of 
its composition are closely linked to the health of the host. Hereafter, we focus on the 
interactions between intestinal microbiome and the GI tract. 
There are different mechanisms through which gut microbiota can interact with the GI 
tract. One of these mechanisms is the fundamental role of the gut microbiota in the 
fermentation of non-digestible dietary polysaccharides into SCFA. SCFAs produced by 
gut microbiota fermentation are mainly acetate, propionate and butyrate [160]. SCFAs 
can act as host signalling molecules by binding to GPR41 and GPR43, expressed by 
enteroendocrine cells [161]. The activation of GPCR41 by SCFA promotes the secretion 
of PYY, whereas the activation of the two receptors (GPR41 and GPR43) by SCFA 
promotes GLP-1 secretion [162, 163]. Moreover, the fermentation of non-digestible 
carbohydrates can promote differentiation in the proximal colon and consequently 
increase the number of L-cells in rats [164]. The endocannabinoid-like compound, 2-
oleoylglycerol (2-OG), also acts as a key compound linking gut microbiota and the 
intestine. The 2-OG can bind to GPR119 receptors and trigger GLP-1 secretion. Everard 
et al.[165] have demonstrated that gut microbiota modulates the tone of the intestinal 
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endocannabinoid system and that a specific species of bacteria, Akkermansia 
muciniphila, is able to regulate intestine endocannabinoid-like compounds such as 2-
OG. Bile acids, which are produced in the liver and are secreted into the duodenum 
upon ingestion of a meal, also act as molecules linking the intestine and microbiota. 
TGR5, a bile acid receptor, is expressed by L-cells and its activation increases GLP-1 
secretion. Interestingly, the gut microbiota is an important regulator of bile acid 
metabolism, including the regulation of synthesis and the production of secondary bile 
acids. Consequently, variations in the composition of microbiota could modulate 
specific bile acid profiles, thereby their capacity to activate TGR5 and GLP-1 secretion 
(reviewed in [166]). 
Besides mechanisms involving GLP-1 secretion, there are other mechanisms involved 
in the crosstalk between microbes and host cells. Gut microbiota can increase the 
absorption of monosaccharides from the gut by facilitating the extraction of calories 
from ingested dietary substances [167]. In this sense, the carbohydrate response 
element-binding protein (ChREBP) has been demonstrated to be implicated in the 
absorption of monosaccharides in the intestine induced by gut microbiota [168]. The 
intestinal gluconeogenesis (IGN) may be another link between gut microbiota and the 
intestine. DeVadder et al.[169] reported that the SCFAs butyrate and propionate, which 
are generated by the fermentation of soluble fibre by gut microbiota, stimulate the 
expression of the IGN gene via the cAMP-dependent mechanism and gut-brain axis 
respectively. Finally, another mechanism that has been proposed to link gut microbiota 
and the intestine is lipopolysaccharides (LPS) of gram-negative bacteria. LPS, together 
with other molecules, such as peptidoglycan and lipoteichoic acid, originate from gut 
microbiota and can cause alterations in intestine permeability, immune system 
activation and related metabolic disorders [170]. 
Numerous putative mechanisms linking gut microbiota and the GI tract have now been 
discovered. However, more mechanisms involved in this interaction are still under 
investigation.  
1.4. The enteroendocrine system in disease: obesity and 
diabetes mellitus 
Obesity is a primary risk factor for the most prevalent diseases affecting the worldwide 
population, including cardiovascular disease, type 2 diabetes mellitus (T2DM) and 
inflammation [171]. Obesity is regulated by a complex biochemical process, and its 
pathological mechanisms have been studied widely in adipose tissue, the liver, and 
muscle [172, 173]. However, the intestine also plays an important role in the pathology 
of obesity because energy intake from food is involved in the regulation of body 
weight, and over-nutrition is considered to be the main cause for becoming obese over 
other environmental factors [174, 175]. 
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The increase in these life-style diseases highlights the need to search for new 
therapeutic strategies. The GI tract plays a role in controlling the metabolism through 
peptide hormones secreted from enteroendocrine cells. These hormones from the gut 
play a central role in nutrient intake signalling, regulating appetite and energy 
expenditure. As mentioned above, all gut hormones have anoretic effects, they 
promote satiation (causing the meal to end) and/or satiety (postponing the initiation 
of the next meal), while ghrelin is the only one that stimulates appetite and food intake. 
There is evidence that specific enterohormone administered at physiological 
concentrations can influence the appetite of rodents and humans (reviewed in [174]). 
Likewise, the effects of gut hormones on food intake and body weight have been 
observed in bariatric surgery (such as Roux-en-Y gastric bypass), which induces a huge 
increase in GLP-1 and PYY secretion, and is used to treat obesity. Therefore, the 
modulation of enterhormone signalling may represent an important target for 
preventing obesity and related/associated pathologies. Moreover, endogenous gut 
hormones regulate appetite physiologically, unlike the drugs that are currently 
available, which are mainly based on influencing the central neurotransmitter systems 
to reduce appetite. Therefore, gut hormone-based therapies might lead to fewer side 
effects [174].  
Furthermore, the incretin hormones (GLP-1 and GIP) could represent an interesting 
strategy in the prevention and/or management of T2DM. T2DM is the most common 
endocrine disorder, characterised by impaired insulin secretion and insulin resistance, 
and one of the fastest growing non-communicable diseases in the world [176]. The 
main goal in the treatment of T2DM is to keep blood glucose levels within the normal 
physiological range. In this sense, GLP-1 and GIP are therapeutically interesting 
peptides because they are important mediators of glycemic homeostasis, as they are 
responsible for approximately 50-70% of the total insulin secreted following glucose 
intake [113]. However, the strategy is mainly focused on increasing GLP-1 levels rather 
than stimulating the GIP because in patients with T2DM there is a decreased 
responsiveness of β-cells to GIP action [177]. Accordingly, many incretin-based 
therapies are focused on using GLP-1 analogues, promoting endogenous GLP-1 
secretion or using DPP-IV inhibitors. As mentioned before, DPP-IV is responsible for 
inactivating more than 80 % of the secreted GLP-1; therefore, DPP-IV inhibitors 
provide an alternative approach to enhance GLP-1-mediated glucose control and 
consequently to preventing T2DM.  
The response to nutrients differs between obese and non-obese individuals, with 
changes in digestion, absorption and hormone release. These changes may be a 
consequence of differences in the intestinal epithelial morphology and function caused 
by types of diets that leads to obesity. Some studies on diets associated with obesity 
suggest that these diets might modulate intestinal cell differentiation. A recent study 
shows that over-nutrition in animals and high glucose or FFA in cultured intestinal 
epithelial cells prevents β-catenin degradation and thereby intestinal cell proliferation. 
In contrast, food restriction in db/db mice decreased intestinal cell proliferation and 
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absorption, suggesting that increased food intake induces activation of Wnt signalling 
and could contribute to enhancing the intestinal absorptive capacity and the 
development of obesity [178]. While there are a few studies that suggest the EECs 
number can be changed by nutrient stimulation. Controversial results have recently 
been reported between high-fat diet and L-cell differentiation. Duca et al. [179] 
reported that a high-fat diet decreases the L-cell population and GLP-1 secretion 
through up-regulation of HES gene expression and downregulation of Math1 
expression. Similarly, it has been reported that the density of cells staining for 
chomogranin A (ChgA) and GLP-1 is reduced in high-fat diet fed rodents, together with 
a reduction of proglucagon (Gcg) and PYY expressions [179–181]. On the contrary, 
Aranias et al. [182] showed that the GLP-1 cell density increased after high fat 
consumption in humans.  Furthermore, high fiber diet enhances the number of L-cells 
in rodent [183] and increased L-cell has been observed in intestinal organoids culture 
after the exposition of SCFA [184]. These findings indicate a potential link between 
diets that lead to obesity and intestinal differentiation/metabolism. Concomitantly, the 
results suggest a new strategy in obesity prevention, the possibility to increase L-cell 
number in order to increase enterohormone release, and thereby improve glucose 
homeostasis and satiety. 
Recent evidence in mice and humans has described that gut microbiota is linked to the 
development of metabolic diseases, such as obesity and T2DM [185–187]. Studies 
using germ-free mice demonstrated that gut microbiota plays a causal role in the 
development of obesity, because germ-free mice transplanted with the microbiome of 
obese donors gained significantly more weight than germ-free mice transplanted with 
the microbiome of lean donors [167]. Similarly, gut microbiota from obese mice 
transplanted to germ-free mice leads to a significant increase in body fat content and 
insulin resistance in recipient mice [167, 188]. These changes were associated with 
dysbiosis (alteration in the types and numbers of bacteria in the gut). However, 
controversial patterns in these alterations have been reported. In obese mice and in 
T2DM patients, an increase in Firmicutes and a reduction in Bacteroidetes have been 
observed [189–191]. Similarly, some human studies have documented a reduced 
representation of Bacteroidetes accompanied by a rise in Lactobacillus species 
belonging to the Firmicutes phylum in obese subjects [190, 191]. However, some 
studies have reported other results, such as an increase in species of both Firmicutes 
and Bacteroidetes in overweight women or a decrease in Bacteroidetes with no 
differences in Firmicutes phylum in obese individuals [192, 193]. Although the 
alteration of the gut microbiota composition has been associated with obesity and 
T2DM, further studies are needed to establish specific compositions. Nevertheless, the 
association between the composition of gut microbiota and the development of 
metabolic disease has been taken into consideration as a possible novel strategy for 
preventing and/or managing obesity and T2DM. 
The health benefits of dietary components have recently attached interest to disease 
prevention and health maintenance. Although studies are being carried out on 
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pharmacological compounds, natural compounds could be used to prevent the 
development of overweight and obesity-related problems from early preclinical stages. 
As mentioned above, dietary compounds can modulate enterhormone secretion; for 
example, glutamine is reported to increase GLP-1 and GIP secretion in humans [194, 
195], proanthocyanids are reported to enhance GLP-1 secretion in rats [196], and pea 
proteins are shown to increase CCK, GLP-1 and PYY levels in humans [197], among 
others. On the other hand, as mentioned above, SCFAs have been reported to stimulate 
GLP-1 secretion by promoting L-cell differentiation and increasing the L-cell 
population, and thus this is a novel strategy for enhancing enterhormone secretion. 
Moreover, recent studies have shown that specific nutrients could play a potential role 
in controlling obesity by modulating gut microbiota [198]. For these reasons, screening 
natural compounds to find new therapies could be useful, and it is also recommended 
to study their action mechanisms to prevent disease in a target population.  
Hereafter, we focus on the action of specific bioactive food compounds, polyphenols 
and peptides, on different elements of GI tract involved in the modulation of the 
enteroendocrine system and that could have beneficial health implications.  
2. Natural compounds with bioactivity in the GI 
tract 
2.1. Polyphenols 
Polyphenols are plant secondary metabolites and are generally involved in defence 
against UV radiation, herbivores, aggression by pathogens, etc. Unlike traditional 
nutrients, these plant-derived compounds are not essential dietary molecules for 
short-term animal well-being, but they may exert a positive long-term impact on 
health through their capacity to modify enzymatic and chemical reactions in animal 
systems [199, 200]. 
2.1.1. Structure, classification and bioavailability 
These bioactive compounds are present in a wide range of fruits and vegetables, as 
well as in processed foods and beverages, such as black tea, matured red wine, coffee, 
and cocoa. Based on their chemical structure [201], they are classified into two main 
groups: flavonoids and non-flavonoids [199]. 
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Flavonoids are characterized as containing two aromatic rings (A and B) connected by 
three-carbon atoms that form an oxygenated heterocycle (C). The basic flavonoid 
skeleton is comprised of 15 carbons 
and can have numerous substitution 
patterns resulting in several 
subgroups. Depending on the 
hydroxylation pattern, the 
distribution of the C6-C3-C6 
structures, their index of hydrogen 
deficiency (IHD), and/or their no-
hydroxylated functional groups, 
flavonoids are classified into 
flavones, flavonols, flavanols, 
isoflavones, flavanones, and 
anthocyanidins [202]. 
Figure 4. Basic structure of flavonoids and their different type 
molecules depending on their hydroxylation pattern [203]. 
 
Flavanols, also known as flavan-3-ols, are the most structurally complex subclass of 
flavonoids and represent one of the main phenolic components of the human diet. 
They can be found in beans, nuts, apples, grapes, cocoa, tea and wine. Unlike other 
classes of flavonoids, which are usually found in nature in glycoside forms, flavanols 
are usually present in the aglycone form or esterified with Gallic acid, the commonest 
non-flavonoid structure [204]. Flavanols exist in the monomer form and the oligomer 
and polymer form (proanthocyanidins). The two chiral centres, C2 and C3, of flavan-3-
ol monomers produce 4 isomers, and the most common structures are (+)-catechin 
and (-)-epicatechin [201]. Flavan-3-ols monomers can also be found in the gallated 
form, such as (+)-gallocatechin, (-)-epigallocatechin (EGC), (-)-epicatechin gallate (ECg) 
and (-)-epigallocatechin gallate (EGCg). Conversely, proanthocyanidins (also known as 
condensed tannins) are oligomeric and polymeric structures of flavanols, which 
include an additional chiral centre at C4 in the upper and lower units. Dimer (B-type) 
and trimer (C-type) proanthocyanidins are formed by oxidative coupling between C-4 
of the flavan-3-ol upper unit and C-6 or C-8 of the lower unit [201]. Type A 
proanthocyanidins have an additional ether bond [C-2 (upper unit)–O–C-7 (lower 
unit)] [199]. 
Over the years, in vitro, ex vivo and in vivo studies as well as clinical trials have 
provided ever increasing evidence of the role polyphenols play as potential health 
compounds [199, 205]. However, the scientific evidence shows that the beneficial 
effects on health of polyphenols are directly linked to their absorption, distribution, 
metabolism and excretion. Therefore, considerable attention has been paid to their 
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bioavailability, as an essential factor for understanding their biological activity, and has 
been a topic of increasing research in recent years [12, 199, 206].  
Polyphenols are recognized as xenobiotics by the organism and are metabolised 
following the typical detoxification pathway. After ingestion, the small intestine is the 
first organ relevantly involved in the metabolism and absorption of the polyphenols. It 
is estimated that only 5%-10% of the total intake of polyphenols, especially those with 
a low degree of polymerization (monomeric flavan-3-ols and dimer 
proanthocyanidins), can be absorbed in the small intestine by both passive and 
facilitated diffusion [207]. Once absorbed, they are extensively metabolized by the 
action of phase II enzymes (uridine 5′-diphospho-glucuronosyltransferases, 
sulphotransferases, and catechol-O-methyltransferase), producing their 
glucuronidated, sulfated, and/or methylated conjugates respectively [206]. This 
conjugation step first takes place in the small intestine and subsequently occurs in the 
liver. Next, the conjugates can be returned to the lumen via bile (enterohepatic 
circulation) or can reach the systemic circulation to be distributed to tissues or 
excreted by urine [208]. 
The 90-95% of unmodified polyphenols, mainly oligomers and polymers, are not 
absorbed by the small intestine and proceed through the gastrointestinal tract. 
Together with the conjugated metabolites they return through the enteropatic 
circulation, reach the colon where they are accumulated at high concentrations (up to 
the mM range) and are exposed to the microbial metabolism [209]. In the colon, 
favanols can be biotranformed via three metabolic pathways: the production of valeric 
acid by meta-substitution of the flavanol A ring, the formation of valerolactone 
compounds by the microbial cleavage of flavanol C- and A- rings, and the breakdown of 
polymeric flavan-3-ols into their monomers by microbial cleavage of the interflavanic 
bond C4–C8 [210]. It has been described that gallated flavanols can also reach the 
colon and are metabolised to the respective flavanol form (monomer or even dimers) 
and the respective Gallic acid residue by the cleavage of the gallated moiety [211]. In 
addition, microbial dehydroxylation transforms monomeric forms to propan-2-ol 
metabolites, which may become valerolactones by microbial A-ring cleavage [210]. The 
valerolactones can be converted by acidic hydrolysis into valeric acids, which are 
rapidly transformed into phenylpropionic, phenylacetic, and benzoic acids. Then, 
microbial metabolites are absorbed and can be metabolized by phase II enzymes, to 
finally enter the circulation or be eliminated in urine [206]. 
It has been reported that polyphenol absorption, metabolism and their fate in the 
organism are affected by external factors, such as polyphenol structure, source, food 
processing, and the quantity, as well as by internal factors, such as age, sex and health 
status of the host [212]. Therefore, their bioactivity could be modulated under 
different situations. 
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Figure 5. The fate of dietary polyphenols after their ingestion. Extracted from [206]. 
2.1.2. Flavonoids and the enteroendocrine system 
As mentioned before, polyphenols and especially flavonoids have been described as 
potential bioactive compounds that exhibit a wide array of beneficial effects on health. 
They can act as antigenotoxic [213], antimicrobial [214], antioxidant [215], 
antiinflamatori [216, 217] and anti-cancer/anti-proliferative [218, 219] molecules. 
Among their effects, polyphenols have been reported to have antihypertensive effects 
[220] and also improve lipid metabolism [221]. 
Furthermore, flavonoids have been shown to improve glucose homeostasis. However, 
controversial results have been reported in different glucose-disrupted animal models, 
because their antihyperglicemic effect seems to be exerted by different mechanisms 
depending on the molecular origin of the glucose homeostasis disruption. Apart from 
their insulin mimetic effect on liver and peripheral tissues, some mechanisms used by 
flavonoids are exerted in the intestine, such as the inhibition of the enzymes that 
participate in carbohydrate digestion and the reduction of glucose absorption by 
inhibiting the transporters involved in glucose uptake (reviewed in [222]). Moreover, 
flavonoids have also been reported to have effects on the incretin system, which could 
be another mechanism for improving glucose homeostasis (reviewed in [223]). Our 
research group has previously shown that grape seed proanthocyanidin extract (GSPE) 
(1 mg/kg BW) increases GLP-1 plasma levels in rats, partly due to inhibition of DPP-IV 
but also due to enhanced secretion [196]. However, the mechanism of action on L-cells 
of flavonoids, especially GSPE, and whether they could modulate other 
enterohormones are not yet determined (review [224]). 
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2.1.2.1. Effects of flavonoids on enterohormone secretion and on EE cells 
differentiation 
It is well known that the secretion of gut hormones is strongly influenced by dietary 
compounds. Macronutrients are the most marked example, but polyphenols and other 
micronutrients have also described as important regulators of enterhormones 
secretion. There are few studies suggesting that flavonoids might modulate 
enterohormone secretion, some of them reviewed in [224]. 
Ghrelin is the only enterhormone that exhibits orexigenic effects, inducing the 
stimulation of appetite and food intake. The effect of isoflavones on ghrelin has been 
described, whereas there are a few studies using other types of flavonoids. In healthy 
postmenopausal women, the administration of isoflavones did not modify fasting 
ghrelin plasma levels, body weight and food intake [225, 226]. In a smaller study, the 
supplementation of 114 mg/day of isolated isoflavonoids for three months resulted in 
the inhibition of the age-dependent rise of the fasting plasma ghrelin levels in 
postmenopausal women with a history of breast cancer [227]. However in that study 
the lipid profile or insulin sensitivity was not modified, and the body composition and 
food intake were not assessed. Thus, in human studies clear results are not observed. 
Instead, animal studies suggest that the isoflavones supplementation can modify the 
levels of ghrelin and that such modification results in changes of body weight. In 
ovariectomized rats under a high-fat diet, the administration of different doses (26, 74, 
206 mg/kg bw) of soy isoflavones for 4 weeks decreased plasma ghrelin, increased 
CCK and tended to increase PYY levels. These findings were accompanied with a 
reduction of body weight and food intake at the higher doses, but with an increased 
body weight at the lower dose [228]. Similarly, plasma ghrelin levels were reduced by 
the daily administration of isoflavone genistein (8 mg/kg) for 8 weeks in female mice, 
but not in males. In this study, the treatment decreased the relative food consumption 
in female at 1 and 5 weeks and in male at 5 weeks [229]. In studies with other families 
of flavonoids, an extract rich in naringenin (Citrus grandis) was administered during 
12 weeks at different doses (300, 600, 1200 mg/kg bw) in obese zucker rats under a 
high fat/high cholesterol diet. The results showed that the extract counteracted the 
reduction of ghrelin induced by the diet. Moreover, the high dose of extract decreased 
the GLP-1 plasma levels (which were not modified by the diet), while any dose did not 
change PYY secretion [230]. Finally, a diet supplemented with tea extract rich in 
monomeric flavanols did not modify fasting ghrelin levels and body weight in T2DM 
and/or obese humans studies [231–233]. However, Chen et al. increased the dose of 
phenolic compounds (856.8 mg ECGC) and observed that green tea extract reduced 
body weight and ghrelin levels in obese women after 12 weeks [234]. 
There are a few studies that evaluate the action of flavonoids on CCK secretion. As 
mentioned above, increased CCK levels were observed after the administration of soy 
isoflavones for 4 weeks in ovariectomized rats [228]. In vitro assays have shown that 
hesperetin and naringenin stimulate CCK release in STC-1 cell line, and that the effect 
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is mediated via the activation of transient receptor potential channels  (TRP channels) 
including TRPA1 and the increase of intracellular calcium levels [235, 236]. Similarly, 
Al Shukor et al. showed that quercetin, kaempferol and apigenin enhance CCK 
secretion in STC-1 cell line, but no effect is observed by rutin and baicalein [237].  
There are limited studies about the effect of flavonoids on PYY and GIP secretion. The 
scarce studies in animals (mentioned above) do not show clear effects on PYY 
secretion. However, Weickert et al. [226] observed that plasma PYY levels increased 
after 8 weeks of isoflavonoid treatment in healthy postmenopausal women. The effect 
of red, white and brown-grained sorghum (which contain anthocyanins, condensed 
tannins and phenolic acids, apart from fiber) was determined in healthy adult 
volunteers (men and women). The area under the plasma concentration-time curve of 
postprandial GLP-1 and GIP in both genders and PYY in men was significantly higher in 
sorghum biscuits groups as compared to the control. The biscuits prepared from red 
sorghum, which contained the highest polypenol content, exerted the strongest 
changes on hormone secretion. These results were accompanied by lower satiety 
ratings after its consumption, although energy intake at a subsequent meal did not 
differ between treatments [238]. Another research group reported that the ingestion 
of bilberry extract (36% w/w anthocynins) did not modify GLP-1 and GIP levels in 
T2DM subjects; although a significant decrease of glucose plasma levels was observed 
in bilberry extract group [239]. On the other hand, the daily administration of 
flavonoid glycosides extract from seabuckthorn leaves (SLG) counteracted the 
increased GIP levels induced by high fat diet in C57BL/6J mice [240]. Our research 
group have reported that an acute dose of GSPE decreased GIP release after oral 
glucose load in rats [196].  
The GLP-1 hormone play an important role in glucose homeostasis enhancing insulin 
secretion; although the incretin effects is its principal action, GLP-1 is also involved in 
the regulation of food intake. There are some in vivo studies that evaluate the action of 
flavonoids on GLP1 secretion, some of them have been mentioned above. The 
consumption of green tea extract (1.5 g/day, 856.8 mg EGCg) significantly increased 
GLP-1 plasma levels after 16 weeks in T2DM subjects [241]. The consumption of berry 
meal (800 mg polyphenols including bilberries, blackcurrants, cranberries, and 
strawberries) with 35 g sucrose in healthy subjects tended to increase GLP-1 and 
decreased glucose concentration, compared with the control meal [242]. Similarly, α-
glycosyl-isoquercitrin also enhance GLP-1 secretion when it is simultaneously 
administered with fructooligosaccharides, but not alone [243]. In the same sense, our 
research group found that the acute dose of GSPE extract (1g/kg BW) increased GLP-1 
plasma levels after an oral glucose load in rats [196]. Also in animal studies, an acute 
dose of 10 µg/kg BW of cinnamtannin A2 (procyanidin tetramer) increased active GLP-
1 and insulin levels in fasted mice [244]. Berberine has been reported to increment 
portal active GLP-1 levels in healthy and STZ mice and to increase GLP-1 secretion 
from human enteroendocrine cell line NCI-H716 cells [245, 246]. In vitro assays using 
the same cell line have shown that genistein and daidzen isoflavonoids (derived from 
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soy fermentation), and glyceollins and phytoalexins (derived from daidzen in soybean 
with a fung infection) can increase GLP-1 release [247, 248]. Although the direct effect 
of isoflavonoid family has been reported, such effect of flavanols has not been reported 
yet. Some studies have shown that flavanols can activate bitter receptors, increase 
intracellular calcium levels and modulate cellular membrane potential [249–252], but 
the enterhormone secretion was not assessed in these studies. Regarding bitter 
receptors, a recent study has reported that Qing-Hua Granule, which is rich in 
flavonoids, enhance GLP-1 secretion via activation of bitter taste receptor (TAS2R) 
pathway in the gastrointestinal tract of db/db mice [253]. 
The increased active GLP-1 levels induced by bioactive compounds can be attributed to 
several mechanisms. As mentioned above, our research group found that GLP-1 plasma 
levels are increased by acute dose of GSPE, and such effect might be partly explained 
for its capacity to inhibit DPP-IV. Gonzalez et al. reported that chronic GSPE treatment 
decreased DPP-IV activity and gene expression in Caco-2 cell line, and decreased 
intestinal gene expression in healthy and diet-induced obese rats [254]. Moreover, 
they assessed that the principal molecules of this extract catechin, epicatechin, B2 
dimer and gallic acid, which are absorbed by intestinal CaCo-2 cells, inhibit  DPP-IV 
activity in endothelial HUVEC cells [196]. Cocoa and products derived from it, which 
contain flavanols, have been shown to inhibit DPP-IV activity in vitro [255]. 
In addition to stimulate secretion and inhibit inactivation, a new strategy to enhance 
endogenous enterohormone levels might be the promotion of endocrine cell 
differentiation and thereby the increase of endocrine cell number. Despite there have 
been no reports of flavonoids and L-cell differentiation, our research group found that 
chronic GSPE treatment increased ChgA, GLP-1 and PYY, and counteracting the effects 
induced by cafeteria diet in rats, and suggesting a possible alteration of intestinal 
differentiation [256]. Moreover, similar extracts have been reported to enhance Muc2 
expression together with an increment of the goblet cell density in mice [257]. Besides, 
flavonoids have been reported to modulate differentiation of other cell lines, such as 
PC12 nerve cell line [258, 259], Treg cells [260], 3T3-L1 cell line [261], bone marrow 
stromal cells [262] and calvarial osteoblast-like (ROB) cells [263]. Although these 
results point that flavonoids could be a good candidate to modulate L-cell 
differentiation, further studies are required. 
2.1.2.2. Effects of flavonoids on gut microbiota 
As mentioned above, gut microbiota might be a potential exteriorised organ that can 
contribute to developing metabolic dysregulation, leading to inflammation in intestinal 
and peripheral tissues, and alteration of glucose and energy homeostasis [154, 198, 
264, 265]. Moreover, gut microbiota might influence directly GI tract trough several 
mechanisms, the principal mechanism is SCFA produced by gut mircobiota, which 
enhance the secretion of GLP-1 and PYY. Studies have indicated that the microbiota 
composition can be influenced by several external disturbances, but dietary changes 
are one of the most important factors and can lead to 57% of the total structural 
INTRODUCTION 
 
35 
 
variation in gut microbiota [266]. There are some dietary strategies for modulating the 
composition and metabolic/immunological activity of the gut microbiota: probiotics, 
which are live microorganisms that its administration in adequate amounts confers a 
health benefits on the host, and prebiotics, which are an ingredient that fermentation 
results in specific changes in the composition and/or activity of gut microbiota [267]. 
In the past few years, dietary polyphenols have been suggested to be potential gut 
microbial modulators, as they induce oscillations in the composition of the microbiota 
populations, such as red wine [268, 269], cocoa [270] and promograde polyphenols 
[271]. It is well known that flavonoids have an antimicrobial effect against pathogenic 
microorganisms. For example, it has been reported that components of tea 
(epigallocatechin gallate, epicatechin gallate, epigallocatechin, gallocatechin, 
epicatechin and catechin) can inhibit the growth of many pathogens, including 
Helicobacter pylori [272], Staphylococcus aureus, E. coli O157:H7 [273, 274], Salmonella 
typhimurium DT104, Listeria monocytogenes, methicillin-resistant S. aureus [275, 276], 
and Pseudomonas aeruginosa [277], among others. Despite their antimicrobial effect, 
there are considerably few studies that evaluate the influence of flavonoids on the 
composition and activity of the non-pathogenic gut microbial community. 
Some in vitro studies have evaluated the effect of flavonoids on the growth pattern of 
intestinal bacteria. It was demonstrated that flavonoid aglycone, but not their 
glycosides, may inhibit the growth of some intestinal bacteria [278]. Similarly, 
naringenin and hesperetin inhibited the growth of almost all bacteria analysed in the 
study, whereas their glycoside forms (naringin and hesperidin) had no impact. In the 
same study, catechin repressed the growth of Clostridium histolyticum and increased 
the growth of Clostridium coccoides–Eubacterium rectale group, Bifidobacterium spp. 
and E. Coli [279]. Lee et al.[280] evaluated the impact of the phenolic compounds of a 
tea extract, rich in catechin and epicatechin, and their fecal bacterial metabolites, 
resulting in a repression in the growth of Clostridium perfringens, Clostridium difficile 
and Bacteroides spp.. Moreover, flavanoids can also influence the gut microbiota by 
affecting the adhesion gut bacteria on intestinal cells [281, 282]. 
The effect of flavonoids on the gut microbiota composition has also been observed in in 
vivo studies, which are summarised in Table 1. In human studies, it has been reported 
that wine polyphenols, cocoa-derived flavanols and isoflavones can modulate the gut 
microbiota after 4-week treatments [283–285]. The daily consumption of 272 ml of 
red wine in adult men decreased the plasma levels, TAG, HDL-cholesterol and the C-
reactive protein, which is considered to be a blood marker of inflammation. These 
significant reductions could be linked to changes in the bifidobacteria number [283]. 
Tzounis et al. [284], who evaluated the effect of cocoa flavonoid in a randomised, 
double-blind, cross-over intervention study, also observed a reduction in plasma C-
reactive protein and TAG, together with an increase in Lactobacillus and 
Bifidobacterium populations. These effects on gut microbiota in the dominant bacterial 
communities were similar to those observed by Clavel et al [285]. 
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Table 1. Summary of studies that evaluate flavonoid effects on gut microbiota composition (adapted from [217]). 
Flavonoid Specie Dose/Time Diet Effects in the microbiota 
composition 
Ref. 
Human studies      
Red wine  
(flavanols, 
anthocyanins, 
flavonols, etc) 
Adult men 272 ml/  
4 weeks 
- Increase the number of 
Enterococcus, Prevotella, 
Bacteroides, Bifidobacterium, 
Bacteroides uniformis, 
Eggerthella lenta, and 
Blautiacoccoides–Eubacterium 
rectal 
[283] 
Cocoa flavonols Human 494mg/ 
4weeks 
- Increase the bifidobacterial and 
lactobacilli and decreased 
clostridia populations 
[284] 
Isoflavones Postmeno
pausal 
women 
100 mg/ 30 
days and 60 
days 
- Increase microorganisms of 
Lactobacillus-Enterococcus 
group, Faecalibacterium 
prausnitzii subgroup, and 
Bifidobacterium genus 
[285] 
Animal studies      
Apple 
procyanidins 
(highly polymeric 
procyanidins (PP)) 
C57Bl/6J 
male mice 
0.5% PP/ 
20weeks 
high fat 
sucrose 
diet 
Decrease the 
Firmicutes/Bacteroidetes ratio 
and increase Akkermansia 
genera. 
[286] 
Cranberry extract 
(flavanols, 
phenolic acids, 
anthocyanins, etc) 
C57Bl/6J 
male mice 
 200mg/kg 
BW/8 weeks 
high 
fat/high 
sucrose 
diet 
Increase the proportion of 
Akkermansia genera. 
[287] 
Green tea leaves 
(flavanols) 
C57BL/6J 
female 
mice 
4 % (w/w)/             
22 weeks 
high-fat 
diet 
Increase the proportion of 
Akkermansia genera. 
[288] 
Grape polyphenols 
(GP) (flavanols, 
anthocyanins, etc) 
C57Bl/6J 
male mice 
1% GP/ 12-
13weeks 
high-fat 
diet 
Increase the growth of 
Akkermansia muciniphila and 
decrease the ratio of 
Firmicutes/Bacteroidetes. 
[289] 
Grape seed 
proanthocyanidin 
extract 
C57Bl/6J 
male mice 
300mg/kg 
BW/7weeks      
high-fat 
diet 
Increase the growth of 
Clostridium XIVa, Roseburia, and 
Prevotella. 
[290] 
Quercetin Wistar 
rats 
30 mg/kg 
BW/6 weeks                   
high fat 
sucrose 
diet 
Decrease Firmicutes 
populations, Erysipelotrichia 
class and Bacillus genus.                                             
Down-regulation of 
Erysipelotrichaceae, Bacillus and 
Eubacterium cylindroides 
species. 
[291] 
Red wine 
polyphenols  
F344  
male rats 
50 mg/kg 
BW/ 
16weeks                     
- Increase Bifidobacterium and 
reduce Clostridium. 
[292] 
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Concerning animal studies, most of the studies evaluate the potential effect of 
flavonoids in animals that have a high fat sucrose diet. In order to evaluate whether 
flavonoids reverse alterations of gut microbial composition associated with diet-
induced obesity, Matsomoto et al. [286] assessed, in C57BL/6J mice, the effect of non-
absorbable apple procyanidins (PP) during 20 weeks and observed a reduction in 
endogenous metabolite levels associated with insulin resistance, in weight gain and in 
inflammatory effects (LPS levels and gut permeability). The administration of PP also 
decreased the Firmicutes/Bacteroidetes ratio and increased the Akkermansia 
population. Similarly, the daily administration of cranberry extract (200mg/kg) for 8 
weeks in mice also increases the proportion of Akkermansia [287]. This change in 
microbial composition was observed in another study, in which the high-fat diet of 
mice was supplemented with powered green tea and Lactobacillus plantarum DSM 
15313 [288]. Likewise, the administration of grape polyphenols (GP) during 13 weeks 
also increased the growth of the Akkermansia population and decreased the 
proportion of Firmicutes to Bacteroidetes in C57BL/6J mice with a high-fat diet. In the 
same study, Roopchand et al. [289] observed that grape polyphenols (GP) 
administration increased intestinal gene expression of proglucagon and decreased a 
gene for glucose absorption (Glut2).  Altogether, GP attenuated several effects of a 
high-fat diet, including weight gain, adiposity, the serum inflammatory markers and 
glucose intolerance, and the authors suggest that the gut microbiota provides the link 
in the mechanisms of action in poorly absorbed dietary polyphenols. The 
administration of a similar extract, grape seed proanthocyanidin extract, during 7 
weeks also modulates the gut microbial composition, including Clostridium XIVa, 
Roseburia and Prevotella in mice with a high-fat diet [290]. 
In summary, the results of these studies suggest that flavonoids can act as prebiotic 
and thereby modulate the gut microbiota composition, inducing the growth of 
beneficial bacteria and reducing the pathogen species population. However, there are 
few studies in this research field and more studies are needed to confirm the results. 
Moreover, nowadays the studies that have reported mechanisms driving the crosstalk 
between gut microbiota and host metabolism in flavonoids field have been focused on 
intestinal permeability and endotoxemia. Although some prebiotics (i.e inulin, 
oligofructosa) has been shown to influence the production of gut hormones through 
the alteration of gut microbial composition (reviewed in [293]), there are scarce 
studies which evaluate that link after flavonoids administration. 
2.2. Bioactive peptides from natural sources 
Over the past few decades, there has been a large increase in scientific research into 
bioactive peptides (BPs) derived from food. These are fragments that are encrypted 
within the primary protein sequence and must be cleaved to exert their function [294]. 
These BPs, or cryptides [295], have a broad range of functions, such as inhibiting 
metabolic enzymes, regulating gene expression and hormonal secretion, and 
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maintaining physiological homeostasis through physical interaction and direct 
removal of metabolites. Several in vitro studies have demonstrated that BPs can 
beneficially modulate health markers [296, 297], and some of these BPs have been 
evaluated in vivo in rodents [298–300] and humans [301–303]. Although their effects 
are less potent than synthetic pharmaceutical drugs, these bioactive peptides are well 
metabolised and confer less side effects. Furthermore, there is a wide range of 
available and inexpensive food, processing by-products and under-utilized resources, 
which can be used as sources to generate these value-added products. These 
characteristics could potentially lead to their category being expanded in the 
nutraceutical food sector [294]. 
The function of bioactive peptides depends substantially on their structure, which in 
turn depends on the nature of their protein precursor and their production conditions.  
Therefore, the selection of the parent proteins and the process to liberate the peptide 
are important. As illustrated in Figure 6, the first step in the classical empirical 
approach involves identifying a suitable protein source, and then releasing bioactive 
peptide fragments through protein hydrolysis by proteolytic enzymes or via bacterial 
fermentation under specific process conditions (such as pH, temperature, time) [304]. 
Subsequent fractionation is necessary to yield enriched bioactive peptide preparation 
and purification steps to isolate peptides with particular bioactivity. For reference for 
the research community, the identified peptides can be deposited in web-based open-
access databases of bioactive peptides, such as BIOPEP and PepBank. 
Recently, in silico approaches have been applied to discover bioactive peptides. 
Examples include computational methods based on knowledge about the structure and 
activity of the peptides reported in the databases (BIOPEP) to determine the potential 
biological activity of the protein and the occurrence frequency of bioactive fragments 
in the protein [305]. Other bioinformatic tools can be used to envisage release of these 
fragments by specific enzymatic cleavage (such as, ExPASy PeptideCutter, PoPS) [295], 
while molecular docking has been used to virtually screen peptide sequences [306, 
307] or to propose the putative mechanisms of action [308, 309]. Predictive models 
can also be generated by PeptideRanker server, which is used to identify structural 
features in large proteins that have previously been associated with known 
bioactivities [310], or by the quantitative structure activity relationship (QSAR) [311, 
312]. These bioinformatics tools could be employed together with the classical 
approach to improve the generation, discovery and validation of bioactive peptides; 
however, there are several limitations in the approach to obtain them. Nevertheless, 
different targeted approaches have attempted to develop alternative strategies to 
overcome these limitations (such as making the method for identifying peptides more 
accurate, and improving in silico tools) [305, 313]. 
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Figure 6. Classical and bioinformatics approaches for the discovery of bioactive peptides in food proteins 
(adapted from [295, 305]) 
2.2.1. Bioactive peptides and GLP-1 enterohormone 
As mentioned in the section ‘GI tract in disease: obesity and diabetes mellitus’, dietary 
compounds are well recognized to play an important role in the prevention and 
management of T2DM. Many of their effects are involved in the incretin effect, mainly 
the increase in GLP-1 plasma levels. Accordingly, one of the therapeutic strategies of 
dietary compounds to enhance insulin secretion is to inhibit DPP-IV in order to 
increase active GLP-1 levels [314]. It is well known that bioactive peptides act as 
modulators of enzyme activity, such Angiotensin-converting enzyme inhibitors that 
have antihypertensive effects [315]. Over the past few years, bioactive peptides have 
shown their potential to act as DPP-IV inhibitors, which is a research area that is 
currently expanding. 
On the other hand, another point of action to enhance insulin secretion by dietary 
compounds is the stimulation of endogenous GLP-1 secretion. Some studies have 
reported that specific amino acids and hydrolysates enhance GLP-1 release [194, 316, 
317]. However, the role played by proteins or individual amino acids in triggering 
incretin secretion remains an area of controversy. Altogether, a few studies have 
Select protein source
Proteolysis to produce 
protein hydrolysates 
Fractionation to recover 
bioactive peptides 
Experimental validation with 
hydrolysates and synthetic 
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evaluated the two properties, bioactive peptides as DPP-IV inhibitors and as GLP-1 
stimulators, to increase active GLP-1 plasma levels and consequently improve glucose 
homeostasis. 
2.2.1.1. Bioactive peptides as DPP-IV inhibitors 
During the past few years, proteins from a variety of food sources have shown their 
potential to act as DPP-IV inhibitors. As shown in Table 2, a variety of food 
commodities from both animal (such as milk, eggs, fish, meat, etc.) and vegetal (such as 
oats, quinoa, amaranth, etc.) sources have been studied and shown to be promising 
sources of DPP-IV inhibitory peptides. As mentioned before, the process to liberate BPs 
is as important as the protein source. In a hydrolysis process, a range of enzymes are 
employed, including enzymes obtained from both animal (e.g. pepsin [318], trypsin 
[319], Corolase PP [320]) and vegetal (e.g. papain [317], protease from pumpkin 
[321]) sources, as well as food-grade proteinases, such as Alcalase, Flavourzyme, and 
Protamex derived from microorganisms [322, 323]. Moreover, in vitro simulated 
gastrointestinal digestion has also been reported to produce protein hydrolysates, 
suggesting that DPP-IV inhibitory peptides could originate during digestion [324, 325]. 
The effect of DPP-IV-inhibiting protein hydrolysates has been evaluated in numerous 
in vitro studies, which have shown that the half-maximal inhibitory concentration 
(IC50) values vary widely and range from 0.075 mg/ml to 5.71 mg/ml (Table 2). Some 
studies have reported that the inhibitory activity varies depending on the specificity of 
the enzyme used, showing differences in the IC50 values between 5.0 and 2.7 mg/ml in 
sodium casein hydrolysates [326], and between 3.71 and 2.21 in barbel hydrolysates 
[327]. A limited number of studies have identified the responsible DPP-IV inhibitory 
BPs through fractionation and/or peptide enrichment techniques (based on 
physicochemical properties such as molecular mass, hydrophobicity or charge), and 
analysis of the most potent fractions by mass spectrometry. As shown in Table 2, these 
peptides have a wide spectrum of potencies (IC50), ranging from 5 µM to >20,000 µM, 
amino acids and length compositions (2-17 amino acids long). In addition to these BPs 
isolated from protein hydrolysates, many other BPs have been identified by in silico 
approaches. Many of the peptides reported are dipeptides and show similar IC50 values 
(4 µM to >20,000 µM) [307, 328–330] to BPs that have been identified in protein 
hydrolysates (Table 2). Although, these BPs have been identified in the sequence of 
dietary proteins, it is unknown whether BPs could in fact be released from dietary 
proteins during digestion or enzymatic treatment.  
Research has shown that the amino acid sequence plays a predominant role in the 
DPP-IV inhibitory activity compared to other physicochemical parameters, including 
length, isoelectric point, hydrophobicity and net charge [307, 331]. DPP-IV 
preferentially cleaves substrates that bear proline or alanine at their P1 position (Xaa-
Pro and Xaa-Ala; where Xaa represents any amino acid) and also acts on substrates 
that bear other residues, such as glycine, serine, valina and leucine [332]. Hydrophobic 
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and basic residues at the P2 position enhance the affinity for cleavage compared with 
acidic residues. A recent analysis revealed that the presence of tryptophan residue at 
the N-terminal position increases the susceptibility to cleavage [330]. Although the 
residues at the N-terminal position may have a major impact by inhibiting DPP-IV, the 
authors pointed out that the C-terminal amino acid also affects the potency of DPP-IV 
because it is implicated in the interaction with the enzyme. 
To date, a few studies have been carried out on the in vivo DPP-IV inhibitory effects of 
the hydrolysates and peptides from dietary proteins. Peptides derived from milk and 
bean proteins, which have been shown to inhibit the activity of DPP-IV in vitro, were 
also found to have glycemic effects on mice [333, 334] as plasma glucose levels were 
found to decrease after an oral glucose tolerance test (OGTT). A β-casein-derived 
peptide LPQNIPPL found in gouda-type cheese with in vitro DPP-IV inhibitory effects 
has also been tested with animal models. Oral administration of this octapeptide 
resulted in lower postpandrial glucose under the curve compared to those that did not 
receive the peptide; however, insulin plasma levels did not differ [335]. In these 
studies, the authors did not measure plasma DPP-IV activity; therefore, it is unknown 
whether the effect of lowering the blood glucose observed was caused by inhibition of 
DPP-IV activity. 
As well as hydrolysates from milk and bean protein, hydrolysate produced by Alcalase 
treatment of the egg protein lysosyme has also been evaluated in in vivo models, 
showing a 25% reduction of blood serum DPP-IV activity and a trend towards higher 
serum GLP-1 levels after 90 min in diabetic rats undergoing a chronic treatment [336]. 
The Streptozotocin-induced rats were used to evaluate the effects of hydrolysates of 
porcine skin gelatin [299], Atlantic salmon skin gelatin [298], and halibut and tilapia 
skin gelatin [300]. In all studies, diabetic animals showed reduced blood glucose levels 
during OGTT, increased plasma insulin and active GLP-1 levels, and reduced plasma 
DPP-IV activity after chronic treatment (42 days with a daily dose of 300 mg/kg of 
porcine skin gelatin [299]; 35 days with a daily dose of 300 mg/kg of Atlantic salmon 
skin gelatin hydrolysate [298]; 30 days with a daily dose of 750 mg/kg of halibut and 
tilapia skin gelatin hydrolysate [300]. Moreover, rodents receiving halibut and tilapia 
skin gelatin hydrolysates also showed increased total GLP-1 levels. Therefore, the 
findings of this study suggest that these hydrolysates exert their anti-hyperglycemic 
effect via dual actions of DPP-IV inhibition and GLP-1 secretion enhancement. 
Similarly, the ileal administration of zein protein hydrolysate to rats was found to 
potentiate the incretin effect when administered prior to an intraperitoneal glucose 
tolerance test, resulting in decreased glucose concentration, increased insulin levels, 
decreased plasma DPP-IV activity, and increased total and active GLP-1 secretion 
[337]. Rice-derived peptides were likewise found to act via dual action. The oral 
administration caused increased plasma GLP-1 levels during intraperitoneal glucose 
tolerance test, together with reduced plasma DPP-IV activity and higher ratio of active 
GLP-1 to total GLP-1 following ileal administration [317]. 
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Protein source   IC50 (mg/ml)           DPPIV inhibitory peptide identified                                Ref. 
      Sequence IC50 (μM)   
Amaranth    1.1 - - [308] 
Beans  Cowpea 0.58 - - [338] 
  Navy; Black; 
Great 
Northern; 
Pinto; Red  
0.093; ~0.1;   
~0.15;  ~0.2;  
~1 
- - [325] 
       
Bovine haemoglobin   3.40-0.74 VAAA 141 [339, 340] 
Brewers’ spent grain    3.57 ILDL; ILLPGAQDGL 1121.1; 145.5 [323] 
Camel milk   1.26-0.52 WK; LPVPQ  [341–343] 
Cow's milk   1.59-0.68 INNQFLPYPY* 40 [342, 344] 
 α-Lactalbumin 0.74 - - [345] 
    0.036 WLAHKALCSEKLDQ; LAHKALCSEKL; 
LCSEKLDQ; TKCEVFRE; 
IVQNNDSTEYGLF; ILDKVGINY; 
LKPTPEGDL 
141; 165; 186; 166; 337; 263; 45 [318, 331] 
        
  β-Lactoglobulin 210 µM VAGTWY 174 [334] 
    
    1.7 - - [345] 
    1.28 - - [318] 
  Lactoferrin 0.38 - - [331] 
    1.088 - - [346] 
  Bovine serum  
albumin 
0.51 - - [318] 
      ER 4480 [347] 
  Sodium casein 1.10; 0.88 - - [346] 
Table 2.  Summary of protein hydrolysates, and peptides isolated from them, reported to have in vitro DPP-IV inhibitory activity (adapted from [376]). 
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    - APFPEVF; APFPE; HPIK; GPFPIIV; 
LPLP; EMPFPK;  LPVP; PFP; PQSVLS; 
YVPEPF; MPLW; LPQYL; LPVPQ; 
GPFP; PLLQ; VPYPQ; VPLGTQ; 
LPVPQK; KVLP; LPL; IPI 
6%; 6%; 9%; 9%; 11%; 12%; 15%; 
20%; 20%; 20%; 23%; 26%; 28%; 
34%; 37%; 51%; 55%; 63%; 98%; 
100%; 100%a 
[322] 
        
        
    5.0-2.7 - - [326] 
  Whey protein 
concentrate or 
isolate 
1.51 VAGTWY; TPEVDDEALEK; IPAVF; 
IPAVFK; VLVLDTDYK 
174.0; 319.5; 44.7; 143.0; 424.4 [319] 
  0.075 WLAHKAL; WLAHKALCSEKLDQ; 
LAHKALCSEKL; TKCEVFRE; 
LKPTPEGDL; LKPTPEGDLEIL; 
IPAVFKIDA 
286; 141; 165; 166; 45; 57; 191 [324, 331] 
          
    0.25; 0.27 IQKVAGTW; LKPTPEGDLEIL; 
LKPTPEGDLE; VLDTDY; LKALPMH; 
LKGYGGVSLPE; WLAHKAL 
329; 57; 42; 471; 193; 486; 286 [348] 
          
    1.43; 0.99 - - [346] 
    1.5; 1.1 - - [349] 
    1.54-0.72 - - [350] 
Cuttlefish  (Sepia 
officinalis) viscera 
  1.03 - - [351] 
        
Goat's milk  Casein - MHQPPQPL; SPTVMFPPQSVL; 
INNQFLPYPY 
350.41; 676.31; 40.08 [344] 
Gouda-type cheese   - VPITPT; LPQNIPP; PQNIPPL; 
VPITPTL; FPGPIPN; PGPIHNS; 
IPPLTQTPV; VPPFIQPE; YPFPGPIPN; 
LPQNIPPL; LPQ 
130; 160; 1500; 110; 260; 1000; 1300; 
2500; 670; 46; 82 
[335] 
        
Hemp   5.71-2.10 - - [352] 
Palmaria palmata   1.47 ILAP; LLAP; MAGVDHI 43.40; 53.67; 159.37 [353] 
Pea    1.08-0.73 - - [352] 
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aValues from [322] are reported in percent relative potency, with 100% and 6% relative potency corresponding to IC50 ~ 5 mM and ~ 120 mM, respectively.
Protein source   IC50 (mg/ml)           DPPIV inhibitory peptide identified                                Ref. 
      Sequence IC50 (μM)   
Lysosyme    1.5-0.4 - - [326] 
Quinoa   0.98; 0.88 - - [354] 
Rice  Bran 2.3 IP; LP 410; 2370 [355] 
  Brown 1.55-0.91 - - [352] 
Skin or scale  Alaska pollock 2.59; 1.53 - - [356] 
collagen/gelatin Atlantic salmon - GPAE; GPGA 49.6; 41.9 [357] 
  Barbel fish 3.71-2.21 - - [327] 
  Deer - GPGSPGGPL; GPVGXAGPPGK; 
GPM(O)GPXGVK; GPVGPSGPXGK; 
GPAGPXGVXGL1 
1638.8; 83.3; 226.9; 93.7; 318.1 [358] 
  Halibut, hake,  - SPGSSGPQGFTG; 
GPVGPAGNPGANGLN; 
PPGPTGPRGQPGNIGF; 
IPGDPGPPGPPGP; LPGERGRPGAPGP; 
GPKGDRGLPGPPGRDGM 
101.6; 81.3; 146.7; 65.4; 76.8; 89.6 [300] 
  tilapia, milkfish       
  Pork-skin, 
cattle-skin,  
fish-scale, 
chicken-feet 
1.61; 1.65;  GAX; GPA; GPX >20000; 5030; 2510 [359] 
  3.50; 3.57       
  Pork 1.5 - - [360] 
Soy   2.21-0.91 - - [352] 
Spanish dry-cured ham   0.69 AAAAG; AAATP; ALGGA; LVSGM 8130; 6470; >10000; >10000 [361] 
Tuna cooking juice   - PGVGGPLGPIGPCYE; 
CAYQWQRPVDRIR; PACGGFWISGRPG 
116.1; 78.0; 96.4 [362] 
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Studies also demonstrate the effect of hydrolysates on GLP-1 action via two different 
mechanisms in in vitro models. The cuttlefish (Sepia officinalis) viscera protein 
hydrolysate and bovine haemoglobin hydrolysate have been reported to enhance CCK 
and GLP-1 secretion from STC-1, together with an inhibition of DPP-IV activity [339, 
351]. Power-Grant et al. [349] demonstrated that whey proteins hydrolysate inhibit 
DPP-IV activity in vitro and induce an insulin secretion from BRIN BD11β-cells, but 
only intact whey proteins enhance GLP-1 secretion from STC-1. The action of 
hydrolysates or peptides on GLP-1 secretion will be detailed in the following section. 
Another glucoregulatory function of hydrolysates has been reported as the dual action 
of α-glucosidase and DPP-IV inhibition [318, 321, 323].  
2.2.1.2. Biopeptides as GLP-1 stimulators 
Although aminoacids, protein and protein hydrolysates have already demonstrated 
their stimulating effect on gut hormone secretion in in vitro and in vivo experiments, 
there is still controversy about their role in triggering incretin secretion. 
Peptones have been shown to induce GLP-1 secretion; for instance, they stimulate GLP-
1 release and increase proglucagon gene expression from native L-cells in isolated 
vascularly perfused rat jejuno-ileum, as well as in STC-1 and GLUTag cell lines [71]. 
Similarly, GLP-1 secretion was triggered by peptones, and less efficiently by di-
/tripeptides and non-hydrolysable Gly-Sar in colonic primary cultures. In this study, 
the authors demonstrated that oligopeptides stimulate GLP-1 secretion through 
PEPT1-dependent electrogenic uptake and activation of CaSR [316]. Furthermore, Pais 
et al. [363] reported that GLP-1 secretion from primary L cells was also associated with 
calcium influx through voltage gate calcium channels (VGCC). They also pointed out 
that different signalling pathways may be involved in GLP-1 secretion by complex 
peptide mixtures. Meanwhile, peptones and mixtures of essential amino acids have 
been reported to activate the ERK1/2 MAPK and p38 MAPK pathway in NCI-H716, and 
might provide a link to GLP-1 release [364]. 
Otherwise, various in vitro [197, 365–367] and in vivo [94, 368, 369] studies have 
reported controversial responses to GLP-1 secretion, involving different protein 
sources and hydrolysis rates. In humans, whey protein induces a major increase in 
postpandrial GLP-1 levels compared to casein protein [368]. In contrast, whey protein 
and another source, pea protein, were ineffective in altering GLP-1 and PYY secretion 
in male Wistar rats [369]. In in vitro studies, intact proteins and egg-hydrolysates are 
more potent than other protein hydrolysates (casein, pea and wheat hydrolysates) for 
increasing GLP-1 and CCK secretion in STC-1 cell line [197]. In contrast, intestinal 
digests of bovine haemoglobin protein exhibited stronger action on GLP-1 release than 
partially digested protein (saliva and gastric digest) [340]. Although a low-molecular 
fraction of wheat protein hydrolysate (LWP) enhances GLP-1 secretion in GLUTag 
cells, a high-molecular fraction did not. Moreover, the authors found that the LWP-
triggered GLP-1 secretion involved activation of the Ca2+/calmodulin-dependent 
kinase II pathway mediated by G protein-coupled receptor family C group 6 subtype A 
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(GPRC6A) [367]. Generally, basic L-amino acids (such as L-lysine, L-arginine and L-
ornithine) are known to be ligands of GPRC6A [370, 371].  
Recently, three peptide sequences, ANVST, TKAVEH and KAAT, were reported to have 
a GLP-1 enhancing secretion capacity [339]. It seems that the incretin effect of proteins 
is associated with the amino acid profile, but the specific amino acid motif that triggers 
GLP-1 secretion stimulation has not yet been determined. In the literature, several 
studies have reported free amino acids as GLP-1 secretion stimulators, such as L-
Phenylalanine, L-alanine and L-glutamine [363], L-asparagine [130], and glutamine 
[372]. The effect of glutamine was confirmed in healthy, obese and diabetic humans 
[194, 195]. Tolhust et al. [373] demonstrated this effect in isolated mouse L cells and 
reported that the mechanisms were associated with an increase in cAMP and cytosolic 
Ca2+ levels. Moreover, they found evidence to suggest that electrogenic sodium coupled 
amino acid uptake is responsible for initiating membrane depolarisation and voltage 
gated Ca2+, while a second pathway involves increasing intracellular cAMP levels. 
Young et al. [374] also reported similar results with L-proline, L-serine, L-alanine, L-
glycine, L-histidine, L-cysteine and L-methionine in STC-1. A tetra-glycine peptide also 
led to an increase in intracellular Ca2+ levels in NCI-H716, resulting in an increase in 
GLP-1 release. In contrast to other studies [373, 375], they observed no changes in 
cAMP.  Therefore, the GLP-1 secretion by amino acids, protein and protein 
hydrolysates and the intracellular signalling pathways underlying stimulus-secretion 
coupling remain uncertain, but a range of potential signalling pathways have been 
postulated.  
Altogether, these results reveal that bioactive peptides could be a potential therapeutic 
dietary compound for the prevention and management of T2DM, as they regulate 
glycemia homeostasis by increasing GLP-1 secretion and inhibiting DPP-IV activity. 
Since there are few studies that have evaluated the dual action of bioactive peptides, 
the screening of new hydrolysates for regulating glucose homeostasis is an area that 
needs to be considered.  
  
INTRODUCTION 
 
47 
 
3. References 
1.  DeSesso JM, Jacobson CF (2001) Anatomical and physiological parameters affecting 
gastrointestinal absorption in humans and rats. Food Chem Toxicol 39:209–228.  
2.  Desesso J, Williams AL, York N (2015) 2 Anatomical and Physiological Parameters that 
Influence Gastrointestinal Absorption. Encycl Drug Metab Interact.  
3.  Schonhoff SE, Giel-Moloney M, Leiter AB (2004) Minireview: Development and 
differentiation of gut endocrine cells. Endocrinology 145:2639–2644.  
4.  Allan DJ, Howell A, Roberts SA, et al (1992) Reduction in apoptosis relative to mitosis in 
histologically normal epithelium accompanies fibrocystic change and carcinoma of the 
premenopausal human breast. J Pathol 167:25–32.  
5.  Cheng H, Leblond CP (1974) Origin, differentiation and renewal of the four main 
epithelial cell types in the mouse small intestine V. Unitarian theory of the origin of the 
four epithelial cell types. Am J Anat 141:537–561.  
6.  Snippert HJ, Flier LG Van Der, Sato T, et al (2010) Intestinal Crypt Homeostasis Results 
from Neutral Competition between Symmetrically Dividing Lgr5 Stem Cells. Cell 
143:134–144. 
7.  Lopez-Garcia C, Klein AM, Simons BD, Winton DJ (2010) Intestinal stem cell replacement 
follows a pattern of neutral drift. Science (80- ) 330:822–825.  
8.  Potten, C. S., Kovacs, L. & Hamilton E (1974) Continuous labeling studies on mouse skin 
and intestine. Cell Tissue Kinet 7:271–283.  
9.  Barker N (2013) Adult intestinal stem cells : critical drivers of epithelial homeostasis 
and regeneration. Nat Publ Gr 15:19–33.  
10.  Tetteh PW, Farin HF, Clevers H (2015) Plasticity within stem cell hierarchies in 
mammalian epithelia. Trends Cell Biol 25:100–108.  
11.  Eisenmann DM (2005) Wnt signaling. WormBook 1–17.  
12.  Crosnier C, Stamataki D, Lewis J (2006) Organizing cell renewal in the intestine: stem 
cells, signals and combinatorial control. Nat Rev Genet 7:349–59.  
13.  Bertrand FE, Angus CW, Partis WJ, Sigounas G (2012) Developmental pathways in colon 
cancer: Crosstalk between WNT, BMP, Hedgehog and Notch. Cell Cycle 11:4344–4351.  
14.  Liang R, Morris P, Cho SSC, et al (2012) Hedgehog signaling displays a biphasic 
expression pattern during intestinal injury and repair. J Pediatr Surg 47:2251–2263.  
15.  Haramis A-PG (2004) De Novo Crypt Formation and Juvenile Polyposis on BMP 
Inhibition in Mouse Intestine. Science 303:1684–1686.  
INTRODUCTION 
 
48 
 
16.  Hardwick JCH, Van Den Brink GR, Bleuming SA, et al (2004) Bone Morphogenetic 
Protein 2 Is Expressed by, and Acts Upon, Mature Epithelial Cells in the Colon. 
Gastroenterology 126:111–121.  
17.  Wong VWY, Jensen KB (2012) Environmental stimuli and intestinal stem cell behavior. 
Landes Biosci 2767–2768. 
18.  Karpowicz P, Perez J, Perrimon N, et al (2010) The Hippo tumor suppressor pathway 
regulates intestinal stem cell regeneration. Development 137:4135–45.  
19.  Chen L, Qin F, Deng X, et al (2012) Hippo pathway in intestinal homeostasis and 
tumorigenesis. Protein Cell 3:305–310. 
20.  Sato T, Clevers H, Flier LG van der, et al (2013) Growing Self-Organizing Mini-Guts from 
a Single Intestinal Stem Cell: Mechanism and Applications. Science (80- ) 340:241–260.  
21.  Miller H, Zhang J, KuoLee R, et al (2007) Intestinal M cells: The fallible sentinels? World J 
Gastroenterol 13:1477–1486.  
22.  Sbarbati A, Osculati F (2005) A new fate for old cells: Brush cells and related elements. J 
Anat 206:349–358.  
23.  Ray WJ, Yao M, Mumm J, et al (1999) Cell Surface Presenilin-1 Participates in the γ -
Secretase-like Proteolysis of Notch Cell Surface Presenilin-1 Participates in the ␥ -
Secretase-like Proteolysis of Notch *. J Biol Chem 274:36801–36807. 
24.  Tamura K, Taniguchi Y, Minoguchi S, et al (1995) Physical interaction between a novel 
domain of the receptor Notch and the transcription factor RBP-J??/Su(H). Curr Biol 
5:1416–1423.  
25.  Fre S, Huyghe M, Mourikis P, et al (2005) Notch signals control the fate of immature 
progenitor cells in the intestine. Nature 435:964–8.  
26.  Milano J, McKay J, Dagenais C, et al (2004) Modulation of Notch processing by ??-
secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes 
known to specify gut secretory lineage differentiation. Toxicol Sci 82:341–358.  
27.  Artavanis-tsakonas S, Rand MD, Lake RJ (2010) Notch Signaling : Cell Fate Control and 
Signal Integration in Development. Science (80- ) 770:770–776. 
28.  Jensen J, Pedersen EE, Galante P, et al (2000) Control of endodermal endocrine 
development by Hes-1. Nat Genet 24:36–44.  
29.  Archer S (2001) Requirement of Mathl for Secretory Cell Lineage Commitment in the 
Mouse Intestine. Science 294:2155–8.  
30.  Mori-Akiyama Y, van den Born M, van Es JH, et al (2007) SOX9 Is Required for the 
Differentiation of Paneth Cells in the Intestinal Epithelium. Gastroenterology 133:539–
546.  
INTRODUCTION 
 
49 
 
31.  Katz JP, Perreault N, Goldstein BG, et al (2008) The zinc-finger transcription factor Klf4 
is required for terminal differentiation of goblet cells in the colon. Development 
129:2619–2628. 
32.  Jenny M, Uhl C, Colette R, et al (2002) Neurogenin3 is differentially required for 
endocrine cell fate specification in the intestinal and gastric epithelium. EMBO J 
21:6338–6347. 
33.  Snoeck V, Goddeeris B, Cox E (2005) The role of enterocytes in the intestinal barrier 
function and antigen uptake. Microbes Infect 7:997–1004. 
34.  Gassler N, Newrzella D, Bohm C, et al (2006) Molecular characterisation of non-
absorptive and absorptive enterocytes in human small intestine. Gut 55:1084–1089.  
35.  Kazanjian A, Noah T, Brown D, et al (2010) Atonal homolog 1 is required for growth and 
differentiation effects of Notch/??-secretase inhibitors on normal and cancerous 
intestinal epithelial cells. Gastroenterology 139:918–928.  
36.  Kim TH, Shivdasani RA (2011) Genetic evidence that intestinal Notch functions vary 
regionally and operate through a common mechanism of math1 repression. J Biol Chem 
286:11427–11433.  
37.  Porter EM, Bevins CL, Ghosh D, Ganz T (2002) The multifaceted Paneth cell. Cell Mol Life 
Sci 59:156–170. 
38.  Van Es JH, Jay P, Gregorieff A, et al (2005) Wnt signalling induces maturation of Paneth 
cells in intestinal crypts. Nat Cell Biol 7:381–386.  
39.  Batlle E, Henderson JT, Beghtel H, et al (2002) β-catenin and TCF mediate cell 
positioning in the intestinal epithelium by controlling the expression of EphB/EphrinB. 
Cell 111:251–263.  
40.  Brodrick B, Vidrich A, Porter E, et al (2011) Fibroblast growth factor receptor-3 (FGFR-
3) regulates expression of paneth cell lineage-specific genes in intestinal epithelial cells 
through both TCF4/??-catenin-dependent and -independent signaling pathways. J Biol 
Chem 286:18515–18525.  
41.  Clevers H (2013) The intestinal crypt, a prototype stem cell compartment. Cell 154:274–
284.  
42.  Van der Flier LG, Clevers H (2009) Stem Cells, Self-Renewal, and Differentiation in the 
Intestinal Epithelium. Annu Rev Physiol 71:241–260.  
43.  Cornelis GR, Gijsegem F Van, Microbiol AR, et al (2002) Colorectal Cancer in Mice 
Genetically Deficient in the Mucin Muc2. Science 295:2000–2003.  
44.  Rehfeld JF (1998) The New Biology of Gastrointestinal Hormones. physological Rev 
78:1087–1108. 
INTRODUCTION 
 
50 
 
45.  López-díaz L, Jain RN, Keeley TM, et al (2007) Intestinal Neurogenin 3 Directs 
Differentiation of a Bipotential Secretory Progenitor to Endocrine Cell Rather than 
Goblet Cell Fate. Dev Biol 309:298–305.  
46.  Naya FJ, Huang H, Qiu Y, et al (1997) Diabetes , defective pancreatic morphogenesis , 
and abnormal enteroendocrine differentiation in BETA2 / NeuroD-deficient mice. genes 
Dev 2323–2334. 
47.  Larsson L, St-onge L, Hougaard DM, et al (1998) Pax 4 and 6 regulate gastrointestinal 
endocrine cell development. Mech Dev 79:153–159. 
48.  Offield MF, Jetton TL, Labosky PA, et al (1996) PDX-1 is required for pancreatic 
outgrowth and differentiation of the rostral duodenum. Development 995:983–995. 
49.  Desai S, Loomis Z, Pugh-bernard A, et al (2008) Nkx2.2 regulates cell fate choice in the 
enteroendocrine cell lineages of the intestine. Dev Biol 313:58–66. 
50.  Ye DZ, Kaestner KH (2009) Foxa1 and Foxa2 Control the Differentiation of Goblet and 
Enteroendocrine L- and D-Cells in Mice. Gastroenterology 137:2052–2062.  
51.  Beucher A, Gjernes E, Collin C, et al (2012) The homeodomain-containing transcription 
factors Arx and Pax4 control enteroendocrine subtype specification in mice. PLoS One.  
52.  Spreckley E, Murphy KG (2015) The L-Cell in Nutritional Sensing and the Regulation of 
Appetite. Front Nutr 2:23.  
53.  Rindi G, Leiter AB, Kopin AS, et al (2004) The “normal” endocrine cell of the gut: 
Changing concepts and new evidences. Ann N Y Acad Sci 1014:1–12.  
54.  Habib AM, Richards P, Cairns LS, et al (2012) Overlap of endocrine hormone expression 
in the mouse intestine revealed by transcriptional profiling and flow cytometry. 
Endocrinology 153:3054–3065.  
55.  Engelstoft MS, Egerod KL, Lund ML, Schwartz TW (2013) Enteroendocrine cell types 
revisited. Curr Opin Pharmacol 13:912–921.  
56.  Sternini C, Anselmi L, Rozengurt E (2008) Enteroendocrine cells: a site of “taste” in 
gastrointestinal chemosensing. Curr Opin Endocrinol Diabetes Obes 15:73–78.  
57.  Kovac S, Shulkes A, Baldwin GS (2009) Peptide processing and biology in human 
disease. Curr Opin Endocrinol Diabetes Obes 16:79–85.  
58.  Gunawardene AR, Corfe BM, Staton CA (2011) Classification and functions of 
enteroendocrine cells of the lower gastrointestinal tract. Int J Exp Pathol 92:219–231.  
59.  Höfer D, Asan E, Drenckhahn D (1999) Chemosensory Perception in the Gut. Physiology 
14:18–23. 
60.  Holst JJ (2007) The Physiology of Glucagon-like Peptide 1. Physiol Rev 1409–1439.  
INTRODUCTION 
 
51 
 
61.  Drucker DJ (2007) The role of gut hormones in glucose homeostasis. Pancreas 117:24–
32.  
62.  Mojsov S, Heinrich G, Wilson IB, et al (1986) Preproglucagon gene expression in 
pancreas and intestine diversifies at the level of post-translational processing. J Biol 
Chem 261:11880–11889. 
63.  Filippatos TD, Athyros VG, Elisaf MS (2014) The pharmacokinetic considerations and 
adverse effects of DDP-4 inhibitors. Expert Opin Drug Metab Toxicol 10:787–812.  
64.  Yu DMT, Yao T, Chowdhury S, et al (2010) The dipeptidyl peptidase IV family in cancer 
and cell biology. FEBS J 277:1126–44.  
65.  Mentlein R (1999) Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory 
peptides. Regul Pept 85:9–24.  
66.  Thoma R, Löffler B, Stihle M, et al (2003) Structural basis of proline-specific 
exopeptidase activity as observed in human dipeptidyl peptidase-IV. Structure 11:947–
959.  
67.  Havale SH, Pal M (2009) Bioorganic & Medicinal Chemistry Medicinal chemistry 
approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 
diabetes. Bioorg Med Chem 17:1783–1802.  
68.  Elliott RM, Morgan LM, Tredger JA, et al (1993) Glucagon-like peptide-1(7-36)amide and 
glucose-dependent insulinotropic polypeptide secretion in response to nutrient 
ingestion in man: Acute post-prandial and 24-h secretion patterns. J Endocrinol 
138:159–166.  
69.  Rocca AS, Brubaker PL (1999) Role of the vagus nerve in mediating proximal nutrient-
induced glucagon- like peptide-1 secretion. Endocrinology 140:1687–1694.  
70.  Roberge N, Brubaker L (1993) Regulation of Intestinal Proglucagon-Derived Peptide 
Secretion by Glucose-Dependent Insulinotropic Peptide in a Novel Enteroendocrine 
Loop. Endocrinology 133:233–40. 
71.  Cordier-Bussat M, Bernard C, Levenez F, et al (1998) Peptones stimulate both the 
secretion of the incretin hormone glucagon- like peptide 1 and the transcription of the 
proglucagon gene. Diabetes 47:1038–1045. doi: 10.2337/diabetes.47.7.1038 
72.  Gorboulev V, Schürmann A, Vallon V, et al (2012) Na +-D-glucose cotransporter SGLT1 is 
pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. 
Diabetes 61:187–196.  
73.  Kuhre RE, Frost CR, Svendsen B, Holst JJ (2015) Molecular mechanisms of glucose-
stimulated GLP-1 secretion from perfused rat small intestine. Diabetes 64:370–382.  
74.  Steinert RE, Gerspach AC, Gutmann H, et al (2011) The functional involvement of gut-
expressed sweet taste receptors in glucose-stimulated secretion of glucagon-like 
peptide-1 ( GLP-1 ) and peptide YY ( PYY ). Clin Nutr 30:524–532.  
INTRODUCTION 
 
52 
 
75.  Kokrashvili Z, Mosinger B, Margolskee RF (2009) T1r3 and ??-gustducin in gut regulate 
secretion of glucagon-like peptide-1. In: Ann. N. Y. Acad. Sci. pp 91–94 
76.  Hirasawa A, Hara T, Katsuma S, et al (2008) Free fatty acid receptors and drug 
discovery. Biol Pharm Bull 31:1847–1851. 
77.  Reimann F (2010) Molecular mechanisms underlying nutrient detection by incretin-
secreting cells. Int Dairy J 20:236–242.  
78.  De León DD, Crutchlow MF, Ham JN, Stoffers DA (2006) Role of glucagon-like peptide-1 
in the pathogenesis and treatment of diabetes mellitus. Int J Biochem Cell Biol 38:845–
859.  
79.  Theodorakis MJ, Carlson O, Michopoulos S, et al (2006) Human duodenal 
enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol 
Endocrinol Metab 290:E550–9.  
80.  Gameiro A, Reimann F, Habib AM, et al (2005) The neurotransmitters glycine and GABA 
stimulate glucagon-like peptide-1 release from the GLUTag cell line. J Physiol 569:761–
72. 
81.  Lim GE, Brubaker PL (2006) Glucagon-like peptide 1 secretion by the L-cell: The view 
from within. Diabetes.  
82.  Claustre J, Brechet S, Plaisancie P, et al (1999) Stimulatory effect of beta-adrenergic 
agonists on ileal L cell secretion and modulation by alpha-adrenergic activation. J 
Endocrinol 162:271–8.  
83.  Girard J (2008) The incretins: from the concept to their use in the treatment of type 2 
diabetes. Part A: incretins: concept and physiological functions. Diabetes Metab 34:550–
559.  
84.  Gautier JF, Fetita S, Sobngwi E, Salaün-Martin C (2005) Biological actions of the incretins 
GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes 
Metab 31:233–242. 
85.  Vilsbøll T, Holst JJ (2004) Incretins, insulin secretion and Type 2 diabetes mellitus. 
Diabetologia 47:357–366.  
86.  Pick A, Clark J, Kubstrup C, et al (1998) Role of apoptosis in failure of b-cell mass 
compansation for insulin resistance and b-cell defects in the male Zucker diabetic fatty 
rat. Diabetes 47:358–364. 
87.  Farilla L, Hui H, Bertolotto C, et al (2002) Glucagon-like peptide-1 promotes islet cell 
growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143:4397–408.  
88.  Kreymann B, Ghatei MA, Williams G, Bloom SR (1987) GLUCAGON-LIKE PEPTIDE-1 7-
36: A PHYSIOLOGICAL INCRETIN IN MAN. Lancet 330:1300–1304.  
89.  De Silva A, Bloom SR (2012) Gut hormones and appetite control: A focus on PYY and 
GLP-1 as therapeutic targets in obesity. Gut Liver 6:10–20.  
INTRODUCTION 
 
53 
 
90.  Hansen L, Deacon CF, Ørskov C, Holst JJ (1999) Peptidase IV in the Capillaries Supplying 
the L Cells of the Porcine Intestine *. Endocrinology 140:5356–5363. 
91.  Rüttimann EB, Arnold M, Hillebrand JJ, et al (2009) Intrameal hepatic portal and 
intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the 
rat via different mechanisms. Endocrinology 150:1174–1181.  
92.  Polak JM, Bloom SR, Rayford PL, et al (1975) Identification of cholecystokinin-secreting 
cells. Lancet 306:1016–1018.  
93.  Liddle RA (1997) Cholecystokinin cells. Annu Rev Physiol 59:221–242.  
94.  Diepvens K, Häberer D, Westerterp-Plantenga M (2008) Different proteins and 
biopeptides differently affect satiety and anorexigenic/orexigenic hormones in healthy 
humans. Int J Obes 32:510–518. 
95.  Daly K, Al-Rammahi M, Moran A, et al (2013) Sensing of amino acids by the gut-
expressed taste receptor T1R1-T1R3 stimulates CCK secretion. Am J Physiol 
Gastrointest Liver Physiol 304:G271–82. 
96.  Feltrin KL, Little TJ, Meyer JH, et al (2004) Effects of intraduodenal fatty acids on 
appetite, antropyloroduodenal motility, and plasma CCK and GLP-1 in humans vary with 
their chain length. Am J Physiol Regul Integr Comp Physiol 287:R524–R533.  
97.  LIOU AP, LU X, SEI Y, et al (2016) The G-Protein–Coupled Receptor GPR40 Directly 
Mediates Long-Chain Fatty Acid–Induced Secretion of Cholecystokinin. 
Gastroenterology 140:903–912.  
98.  Kraly FS, Carty WJ, Smith GP (1978) Effect of pregastric food stimuli on meal size and 
intermeal interval in the rat. Physiol Behav 20:779–784. 
99.  Raybouldb HE, Lloyd KCK (1994) Integration of Postprandial Function in the Proximal 
Gastrointestinal Tract Role of CCK and Sensory Pathways. Ann NEW YORK Acad Sci 
143–156. 
100.  Moran TH, Bi S (2006) Hyperphagia and obesity of OLETF rats lacking CCK1 receptors: 
Developmental aspects. Dev Psychobiol 48:360–367.  
101.  Covasa M, Ritter RC (2001) Attenuated satiation response to intestinal nutrients in rats 
that do not express CCK-A receptors. Peptides 22:1339–1348. 
102.  Reidelberger RD, Hernandez J, Fritzsch B, Hulce M (2004) Abdominal vagal mediation of 
the satiety effects of CCK in rats. Am J Physiol Regul Integr Comp Physiol 286:R1005–12.  
103.  Inagaki N, Seino Y, Takeda J, et al (1989) Gastric Inhibitory Polypeptide : Structure and 
Chromosomal Localization of the Human Gene. Mol Endocrinol 3:1014–1021. 
104.  Bell GI (1986) The glucagon superfamily: Precursor structure and gene organization. 
Peptides 7:27–36.  
INTRODUCTION 
 
54 
 
105.  Ugleholdt R (2011) Glucose-dependent Insulinotropic Polypeptide (GIP): From 
prohormone to actions in endocrine pancreas and adipose tissue. Dan Med Bull 
58:B4368. 
106.  Wachters-Hagedoorn RE, Priebe MG, Heimweg JAJ, et al (2006) The rate of intestinal 
glucose absorption is correlated with plasma glucose-dependent insulinotropic 
polypeptide concentrations in healthy men. J Nutr 136:1511–6. 
107.  Sykes S, Morgan LM, English J, Marks V (1980) Evidence for preferential stimulation of 
gastric inhibitory polypeptide secretion in the rat by actively transported carbohydrates 
and their analogues. J Endocrinol 201–207. 
108.  Parker HE, Habib AM, Rogers GJ, et al (2009) Nutrient-dependent secretion of glucose-
dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 
52:289–298. 
109.  Thomsen C, Rasmussen O, Lousen T, et al (1999) Differential effects of saturated and 
monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy 
subjects. Am J Clin Nutr 69:1135–1143. 
110.  Chu ZL, Carroll C, Alfonso J, et al (2008) A role for intestinal endocrine cell-expressed G 
protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 
and glucose-dependent insulinotropic peptide release. Endocrinology 149:2038–2047.  
111.  Kubota A, Yamada Y, Hayami T, et al (1996) Identification of Two Missense Mutations in 
the GIP Receptor Gene: A Functional Study and Association Analysis with NIDDM. 
Diabetes 45:1701–1705. 
112.  Kubota A, Yamada Y, Yasuda K, et al (1997) Gastric inhibitory polypeptide activates MAP 
kinase through the wortmannin-sensitive and -insensitive pathways. Biochem Biophys 
Res Commun 235:171–5.  
113.  Baggio LL, Drucker DJ (2007) Biology of Incretins: GLP-1 and GIP. Gastroenterology 
132:2131–2157.  
114.  Farilla L, Bulotta A, Hirshberg B, et al (2003) Glucagon-Like Peptide 1 Inhibits Cell 
Apoptosis and Improves Glucose Responsiveness of Freshly Isolated Human Islets. 
Endocrinology 144:5149–5158.  
115.  Trümper A, Trümper K, Hörsch D (2002) Mechanisms of mitogenic and anti-apoptotic 
signaling by glucose-dependent insulinotropic polypeptide in β(INS-1)-cells. J 
Endocrinol 174:233–246.  
116.  Kieffer TJ (2003) GIP or not GIP? That is the question. Trends Pharmacol Sci 24:110–
112. 
117.  Miyawaki K, Yamada Y, Ban N, et al (2002) Inhibition of gastric inhibitory polypeptide 
signaling prevents obesity. Nat Med 8:738–742.  
118.  Althage MC, Ford EL, Wang S, et al (2008) Targeted ablation of glucose-dependent 
insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and 
insulin resistance induced by a high fat diet. J Biol Chem 283:18365–18376. 
INTRODUCTION 
 
55 
 
119.  Irwin N, McClean PL, O’Harte FPM, et al (2007) Early administration of the glucose-
dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the 
development of diabetes and related metabolic abnormalities associated with 
genetically inherited obesity in ob/ob mice. Diabetologia 50:1532–1540.  
120.  McClean PL, Irwin N, Cassidy RS, et al (2007) GIP receptor antagonism reverses obesity, 
insulin resistance, and associated metabolic disturbances induced in mice by prolonged 
consumption of high-fat diet 1317. AmJPhysiol EndocrinolMetab 293:E1746–E1755.. 
121.  Tatemoto K, Nakano I, Makk G, et al (1988) Isolation and primary structure of human 
peptide YY. Biochem Biophys Res Commun 157:713–7. 
122.  Hort Y, Baker E, Sutherland GR, et al (1995) Gene duplication of the human peptide YY 
gene (PYY) generated the pancreatic polypeptide gene (PPY) on chromosome 17q21.1. 
Genomics 26:77–83. 
123.  Nygaard R, Nielbo S, Schwartz TW, Poulsen FM (2006) The PP-fold solution structure of 
human polypeptide YY and human PYY3-36 as determined by NMR. Biochemistry 
45:8350–8357.  
124.  Eberlein A, Grandt D, Goebell H, et al (1989) A new molecular form of PYY: structural 
characterization of human PYY (3–36) and PYY (1–36). Peptides 10:797–803. 
125.  Essah PA, Levy JR, Sistrun SN, et al (2007) Effect of macronutrient composition on 
postprandial peptide YY levels. J Clin Endocrinol Metab 92:4052–4055.  
126.  Psichas A, Sleeth ML, Murphy KG, et al (2015) The short chain fatty acid propionate 
stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents. Int J Obes 
(Lond) 39:424–9.  
127.  Cherbut C, Ferrier L, Roze C, et al (1998) Short-chain fatty acids modify colonic motility 
through nerves and polypeptide YY release in the rat. Am J Physiol 275:G1415–22.  
128.  Steinert RE, Beglinger C (2011) Nutrient sensing in the gut : interactions between 
chemosensory cells , visceral afferents and the secretion of satiation peptides. Physiol 
Behav 105:62–70.  
129.  Gerspach AC, Steinert RE, Schönenberger L, et al (2011) The role of the gut sweet taste 
receptor in regulating GLP-1, PYY, and CCK release in humans. Am J Physiol Endocrinol 
Metab 301:E317–25. 
130.  Mace OJ, Schindler M, Patel S (2012) The regulation of K- and L-cell activity by GLUT2 
and the calcium-sensing receptor CasR in rat small intestine. J Physiol 590:2917–36.  
131.  Gerald C, Walker MW, Criscione L, et al (1996) A receptor subtype involved in 
neuropeptide-Y-induced food intake. Nature 382:168–171.  
132.  Boey D, Lin S, Karl T, et al (2006) Peptide YY ablation in mice leads to the development 
of hyperinsulinaemia and obesity. Diabetologia 49:1360–1370.  
INTRODUCTION 
 
56 
 
133.  Chandarana K, Gelegen C, Irvine EE, et al (2013) Peripheral activation of the Y2-receptor 
promotes secretion of GLP-1 and improves glucose tolerance. Mol Metab 2:142–152.  
134.  Chelikani PK, Haver AC, Reidelberger RD (2004) Comparison of the inhibitory effects of 
PYY ( 3-36 ) and PYY ( 1-36 ) on gastric emptying in rats. Am J Physiol Regul Integr 
Comp Physiol 68105:1064–1070.  
135.  Halatchev IG, Cone RD (2005) Peripheral administration of PYY3-36 produces 
conditioned taste aversion in mice. Cell Metab 1:159–168.  
136.  Koda S, Date Y, Murakami N, et al (2005) The role of the vagal nerve in peripheral PYY 3-
36-induced feeding reduction in rats. Endocrinology 146:2369–2375.  
137.  Sakata I, Nakamura K, Yamazaki M, et al (2002) Ghrelin-producing cells exist as two 
types of cells, closed- and opened-type cells, in the rat gastrointestinal tract. Peptides 
23:531–536. 
138.  Takahashi T, Ida T, Sato T, et al (2009) Production of n-octanoyl-modified ghrelin in 
cultured cells requires prohormone processing protease and ghrelin o-acyltransferase, 
as well as n-octanoic acid. J Biochem 146:675–682. 
139.  Kojima M, Kangawa K (2005) Ghrelin : Structure and Function. Physiol Rev 85:495–522.. 
140.  Banks WA (2002) Extent and Direction of Ghrelin Transport Across the Blood-Brain 
Barrier Is Determined by Its Unique Primary Structure. J Pharmacol Exp Ther 302:822–
827.  
141.  Zhao T, Sakata I, Li RL, et al (2010) Ghrelin secretion stimulated by {beta}1-adrenergic 
receptors in cultured ghrelinoma cells and in fasted mice. Proc Natl Acad Sci U S A 
107:15868–73.  
142.  Laermans J, Vancleef L, Tack J, Depoortere I (2015) Role of the clock gene Bmal1 and the 
gastric ghrelin-secreting cell in the circadian regulation of the ghrelin-GOAT system. Nat 
Publ Gr 1–10.  
143.  Engelstoft MS, Park W, Sakata I, et al (2013) Seven transmembrane G protein-coupled 
receptor repertoire of gastric ghrelin cells. Mol Metab 2:376–392.  
144.  Lippl F, Kircher F, Erdmann J, et al (2004) Effect of GIP, GLP-1, insulin and gastrin on 
ghrelin release in the isolated rat stomach. Regul Pept 119:93–98.  
145.  Steensels S, Vancleef L, Depoortere I (2016) The sweetener-sensing mechanisms of the 
ghrelin cell. Nutrients.  
146.  Tschöp M, Smiley DL, Heiman ML (2000) Ghrelin induces adiposity in rodents. Nature 
407:908–913.  
147.  Cowley MA, Smith RG, Diano S, et al (2003) The distribution and mechanism of action of 
ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy 
homeostasis. Neuron 37:649–661.  
INTRODUCTION 
 
57 
 
148.  Masuda Y, Tanaka T, Inomata N, et al (2000) Ghrelin Stimulates Gastric Acid Secretion 
and Motility in Rats. Biochem Biophys Res Commun 276:905–908.  
149.  Qin J, Li R, Raes J, et al (2010) A human gut microbial gene catalog established by 
metagenomic sequencing. Nature 464:59–65. 
150.  Neish AS (2009) Microbes in Gastrointestinal Health and Disease. Gastroenterology 
136:65–80.  
151.  Musso G, Gambino R, Cassader M (2010) Obesity, diabetes, and gut microbiota: The 
hygiene hypothesis expanded? Diabetes Care 33:2277–2284.  
152.  Rajilić-Stojanović M (2013) Function of the microbiota. Best Pract Res Clin 
Gastroenterol 27:5–16.  
153.  Everard A, Sc M, Cani PD (2013) Diabetes, obesity and gut microbiota. Best Pract Res 
Clin Gastroenterol 27:73–83.  
154.  Cani PD, Delzenne NM (2009) The role of the gut microbiota in energy metabolism and 
metabolic disease. CurrPharmDes 15:1546–1558. 
155.  Round JL, Mazmanian SK (2009) The gut microbiome shapes intestinal immune 
responses during health and disease. Nat Rev Immunol 9:313–323. 
156.  Leblanc JG, Milani C, Giori GS De, et al (2013) Bacteria as vitamin suppliers to their host : 
a gut microbiota perspective. Curr Opin Biotechnol 24:160–168.  
157.  Clemente JC, Ursell LK, Wegener Parfrey L, Knight R (2016) the impact of the Gut 
Microbiota on Human Health: An Integrative View. Cell 148:1258–1270.  
158.  Biagi E, Nylund L, Candela M, et al (2010) Through ageing, and beyond: Gut microbiota 
and inflammatory status in seniors and centenarians. PLoS One.  
159.  Kau AL, Ahern PP, Griffin NW, et al (2012) Human nutrition, the gut microbiome, and 
immune system: envisioning the future. Nature 474:327–336.  
160.  Bergman EN (1990) Energy contributions of volatile fatty acids from the 
gastrointestinal tract in various species. Physiol Rev 70:567–590. 
161.  Tazoe H, Otomo Y, Kajir I, et al (2008) Role of short-chain fatty acids receptors, GPR41 
and GPR43 on colonic functions. In: J. Physiol. Pharmacol. pp 117–133 
162.  Tolhurst G, Reimann F, Gribble FM (2009) Nutritional regulation of glucagon-like 
peptide-1 secretion. J Physiol 587:27–32.  
163.  Samuel BS, Shaito A, Motoike T, et al (2008) Effects of the gut microbiota on host 
adiposity are modulated by the short-chain fatty-acid binding G protein-coupled 
receptor, Gpr41. Proc Natl Acad Sci U S A 105:16767–16772.  
164.  Cani PD, Hoste S, Guiot Y, Delzenne NM (2007) Dietary non-digestible carbohydrates 
promote L-cell differentiation in the proximal colon of rats. Br J Nutr 98:32–37.  
INTRODUCTION 
 
58 
 
165.  Everard A, Belzer C, Geurts L, et al (2013) Cross-talk between Akkermansia muciniphila 
and intestinal epithelium controls diet-induced obesity. Proc Nati Acad Sci USA 
110:9066–9071.  
166.  Greiner T, Bäckhed F (2011) Effects of the gut microbiota on obesity and glucose 
homeostasis. Trends Endocrinol Metab 22:117–123.  
167.  Turnbaugh PJ, Ley RE, Mahowald MA, et al (2006) An obesity-associated gut 
microbiome with increased capacity for energy harvest. Nature 444:1027–31 
168.  Backhed F (2004) The gut microbiota as an environmental factor that regulates fat 
storage. Proc Natl Acad Sci USA 101:15718–15723. 
169.  De Vadder F, Kovatcheva-Datchary P, Goncalves D, et al (2014) Microbiota-generated 
metabolites promote metabolic benefits via gut-brain neural circuits. Cell 156:84–96.  
170.  Cani PD, Amar J, Iglesias MA, et al (2007) Metabolic Endotoxemia Initiates Obesity and 
Insulin Resistence. Diabetes 56:1761–1772.  
171.  Grundy SM (2008) Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 
28:629–636.  
172.  Samuel VT, Petersen KF, Shulman GI (2010) Lipid-induced insulin resistance: 
unravelling the mechanism. Lancet 375:2267–2277.  
173.  Henriksen EJ (2010) Dysregulation of glycogen synthase kinase-3 in skeletal muscle and 
the etiology of insulin resistance and type 2 diabetes. Curr Diabetes Rev 6:285–293.  
174.  Murphy KG, Bloom SR (2006) Gut hormones and the regulation of energy homeostasis. 
Nature 444:854–859.  
175.  Karra E, Batterham RL (2010) The role of gut hormones in the regulation of body weight 
and energy homeostasis. Mol Cell Endocrinol 316:120–128.  
176.  Shaw JE, Sicree RA, Zimmet PZ (2010) Global estimates of the prevalence of diabetes for 
2010 and 2030. Diabetes Res Clin Pract 87:4–14.  
177.  Nauck MA (2011) Incretin-based therapies for type 2 diabetes mellitus: properties, 
functions, and clinical implications. Am J Med 124:S3–18.  
178.  Mao J, Hu X, Xiao Y, et al (2013) Overnutrition stimulates intestinal epithelium 
proliferation through ??-catenin signaling in obese mice. Diabetes 62:3736–3746.  
179.  Duca FA, Sakar Y, Covasa M (2013) Combination of obesity and high-Fat feeding 
diminishes sensitivity to GLP-1R agonist exendin-4. Diabetes 62:2410–2415.  
180.  Sakar Y, Duca FA, Langelier B, et al (2014) Impact of high-fat feeding on basic helix – 
loop – helix transcription factors controlling enteroendocrine cell differentiation This 
article has been corrected since online publication and a corrigendum appears in this 
issue. Int J Obes 38:1440–1448.  
INTRODUCTION 
 
59 
 
181.  Kappe C, Zhang Q, Nyström T, Sjöholm A (2014) Effects of high-fat diet and the anti-
diabetic drug metformin on circulating GLP-1 and the relative number of intestinal L-
cells. Diabetol Metab Syndr 6:70.  
182.  Aranias T, Grosfeld A, Poitou C, et al (2015) Lipid-rich diet enhances L-cell density in 
obese subjects and in mice through improved L-cell differentiation. J Nutr Sci 4:e22.  
183.  Everard A, Lazarevic V, Derrien M, et al (2011) Responses of gut microbiota and glucose 
and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant 
mice. Diabetes 60:2775–2786.  
184.  Petersen N, Reimann F, Bartfeld S, et al (2014) Generation of l cells in mouse and human 
small intestine organoids. Diabetes 63:410–420. 
185.  Brahe LK, Le Chatelier E, Prifti E, et al (2015) Specific gut microbiota features and 
metabolic markers in postmenopausal women with obesity. Nutr Diabetes 5:e159.  
186.  Vijay-Kumar M, Aitken J (2010) Metabolic Syndrome and Altered Gut Microbiota in Mice 
Lacking Toll-Like Receptor 5. Science (80- ) 344:228–231. 
187.  Larsen N, Vogensen FK, Van Den Berg FWJ, et al (2010) Gut microbiota in human adults 
with type 2 diabetes differs from non-diabetic adults. PLoS One.  
188.  Turnbaugh PJ, B??ckhed F, Fulton L, Gordon JI (2008) Diet-Induced Obesity Is Linked to 
Marked but Reversible Alterations in the Mouse Distal Gut Microbiome. Cell Host 
Microbe 3:213–223.  
189.  Ley RE, Backhed F, Turnbaugh P, et al (2005) Obesity alters gut microbial ecology. Proc 
Natl Acad Sci 102:11070–11075. 
190.  Ley R, Turnbaugh P, Klein S, Gordon J (2006) Microbial ecology: human gut microbes 
associated with obesity. Nature 444:1022–3. 
191.  Armougom F, Henry M, Vialettes B, et al (2009) Monitoring bacterial community of 
human gut microbiota reveals an increase in Lactobacillus in obese patients and 
Methanogens in anorexic patients. PLoS One 4:1–8.  
192.  Collado MC, Isolauri E, Laitinen K, Salminen S (2008) Distinct composition of gut 
microbiota during pregnancy in overweight and normal-weight women. Am J Clin Nutr 
88:894–899.  
193.  Furet J, Kong L, Tap J, et al (2010) Differential Adaptation of Human Gut Microbiota to 
bariatric surgery-induced weight loss. Diabetes 59:3049–3057. 
194.  Greenfield JR, Farooqi IS, Keogh JM, et al (2009) Oral glutamine increases circulating 
glucagon-like peptide 1 , glucagon , and insulin concentrations in lean , obese , and type 
2 diabetic subjects 1 – 4. Am J Clin Nutr 1:106–113.  
195.  Samocha-Bonet D, Wong O, Synnott EL, et al (2011) Glutamine reduces postprandial 
glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes 
patients. J Nutr 141:1233–1238.  
INTRODUCTION 
 
60 
 
196.  González-Abuín N, Martínez-Micaelo N, Margalef M, et al (2014) A grape seed extract 
increases active glucagon-like peptide-1 levels after an oral glucose load in rats. Food 
Funct 2357–2364. 
197.  Geraedts MCP, Troost FJ, Fischer MAJG, et al (2011) Direct induction of CCK and GLP-1 
release from murine endocrine cells by intact dietary proteins. Mol Nutr Food Res 
55:476–484.  
198.  Delzenne NM, Neyrinck AM, Bäckhed F, Cani PD (2011) Targeting gut microbiota in 
obesity : effects of prebiotics and probiotics. Nat Publ Gr 7:639–646.  
199.  Del Rio D, Rodriguez-Mateos A, Spencer JPE, et al (2013) Dietary (Poly)phenolics in 
Human Health: Structures, Bioavailability, and Evidence of Protective Effects Against 
Chronic Diseases. Antioxid Redox Signal 18:1818–92. 
200.  Beecher GR (2009) Phytonutrients’ Role in Metabolism: Effects on Resistance to 
Degenerative Processes. Nutr Rev 57:3–6. 
201.  Bladé C, Arola L, Salvadó MJ (2010) Hypolipidemic effects of proanthocyanidins and 
their underlying biochemical and molecular mechanisms. Mol Nutr Food Res 54:37–59. 
202.  Aherne SA, Brien NMO (2002) Dietary Flavonols : Chemistry , Food Content , and 
Metabolism. Nutrition 18:75–81. 
203.  Nishiumi S, Miyamoto S, Kawabata K, et al (2011) Dietary flavonoids as cancer-
preventive and therapeutic biofactors. Front Biosci (Schol Ed) 3:1332–62. 
204.  Hackman RM, Polagruto JA, Zhu QY, et al (2008) Flavanols: Digestion, absorption and 
bioactivity. Phytochem Rev 7:195–208.  
205.  Bladé C, Aragonès G, Arola-Arnal A, et al (2016) Proanthocyanidins in health and 
disease. BioFactors 42:5–12.  
206.  Zanotti I, Dall’Asta M, Mena P, et al (2015) Atheroprotective effects of (poly)phenols: a 
focus on cell cholesterol metabolism. Food Funct 6:13–31.  
207.  Starp C, Alteheld B, Stehle P (2006) Characteristics of (+)-catechin and (-)-epicatechin 
transport across pig intestinal brush border membranes. Ann Nutr Metab 50:59–65.  
208.  Monagas M, Urpi-Sarda M, Sánchez-Patán F, et al (2010) Insights into the metabolism 
and microbial biotransformation of dietary flavan-3-ols and the bioactivity of their 
metabolites. Food Funct 1:233–253.  
209.  Clifford MN (2004) Diet-derived phenols in plasma and tissues and their implications 
for health. Planta Med 70:1103–1114.  
210.  Margalef M, Pons Z, Isabel F (2015) Plasma kinetics and microbial biotransformation of 
grape seed flavanols in rats. J Funct Foods 12:478–488.  
211.  Selma M V., Espín JC, Tomás-Barberán FA (2009) Interaction between phenolics and gut 
microbiota: Role in human health. J Agric Food Chem 57:6485–6501.  
INTRODUCTION 
 
61 
 
212.  Margalef Jornet M (2015) External and internal factors affecting the metabolism, 
bioavailability, tissue distribution, and bioactivity of grape seed flavanols.  
213.  Llópiz N, Puiggròs F, Céspedes E, et al (2004) Antigenotoxic effect of grape seed 
procyanidin extract in Fao cells submitted to oxidative stress. J Agric Food Chem 
52:1083–1087.  
214.  Friedman M (2007) Overview of antibacterial, antitoxin, antiviral, and antifungal 
activities of tea flavonoids and teas. Mol Nutr Food Res 51:116–134.  
215.  PUIGGRòS F, LLóPIZ N, ARDÉVOL A, et al (2005) Grape seed procyanidins prevent 
oxidative injury by modulatin the expression of antioxidant enzyme systems. J Agric 
Food Chem 2005:6080–6086. 
216.  Gil-Cardoso K, Ginés I, Pinent M, et al (2017) A cafeteria diet triggers intestinal 
inflammation and oxidative stress in obese rats. Br J Nutr 117:218–229.  
217.  Gil-Cardoso K, Ginés I, Pinent M, et al (2016) Effects of flavonoids on intestinal 
inflammation, barrier integrity and changes in gut microbiota during diet-induced 
obesity. Nutr Res Rev 29:1–15.  
218.  Faria A, Calhau C, De Freitas V, Mateus N (2006) Procyanidins as antioxidants and tumor 
cell growth modulators. J Agric Food Chem 54:2392–2397.  
219.  Mantena SK, Baliga MS, Katiyar SK (2006) Grape seed proanthocyanidins induce 
apoptosis and inhibit metastasis of highly metastatic breast carcinoma cells. 
Carcinogenesis 27:1682–1691. 
220.  Quiñones M, Guerrero L, Suarez M, et al (2013) Low-molecular procyanidin rich grape 
seed extract exerts antihypertensive effect in males spontaneously hypertensive rats. 
Food Res Int 51:587–595.  
221.  Guerrero L, Margalef M, Pons Z, et al (2013) Serum metabolites of proanthocyanidin-
administered rats decrease lipid synthesis in HepG2 cells. J Nutr Biochem 24:2092–
2099. 
222.  Pinent M, Cedó L, Montagut G, et al (2012) Procyanidins Improve some Disrupted 
Glucose Homoeostatic Situations: An Analysis of Doses and Treatments According to 
Different Animal Models. Crit Rev Food Sci Nutr 52:569–584.  
223.  González-Abuín N, Pinent M, Casanova-Martí À, et al (2015) Procyanidins and their 
healthy protective effects against type 2 diabetes. Curr Med Chem 22:39–50.  
224.  Pinent M, Blay M, Serrano J, Ardevol A (2017) Effects of flavanols on the 
enteroendocrine system: Repercussions on food intake. Crit Rev Food Sci Nutr 57:326–
334.  
225.  Matvienko OA, Alekel DL, Genschel U, et al (2011) Appetitive Hormones, but Not 
Isoflavone Tablets, Influence Overall and Central Adiposity in Healthy Postmenopausal 
Women. Menopause 17:594–601.  
INTRODUCTION 
 
62 
 
226.  Weickert MO, Reimann M, Otto B, et al (2006) Soy isoflavones increase preprandial 
peptide YY (PYY), but have no effect on ghrelin and body weight in healthy 
postmenopausal women. J Negat Results Biomed 5:11. 
227.  Nikander E, Tiitinen A, Laitinen K, et al (2004) Effects of isolated isoflavonoids on lipids, 
lipoproteins, insulin sensitivity, and ghrelin in postmenopausal women. J Clin 
Endocrinol Metab 89:3567–3572. 
228.  Zhang Y, Na X, Zhang Y, et al (2009) Isoflavone reduces body weight by decreasing food 
intake in ovariectomized rats. Ann Nutr Metab 54:163–170.  
229.  Ryökkynen A, Kukkonen JVK, Nieminen P (2006) Effects of dietary genistein on mouse 
reproduction, postnatal development and weight-regulation. Anim Reprod Sci 93:337–
348.  
230.  Raasmaja A, Lecklin A, Ming X, et al (2013) A water-alcohol extract of Citrus grandis 
whole fruits has beneficial metabolic effects in the obese Zucker rats fed with high fat / 
high cholesterol diet. Food Chem 138:1392–1399.  
231.  Hsu CH, Liao Y, Lin S, et al (2011) Does supplementation with green tea extract improve 
acne in post-adolescent women? A randomized, double-blind, and placebo-controlled 
clinical trial. Complement Ther Med 16:157–163. 
232.  Hsu C-H, Tsai T-H, Kao Y-H, et al (2008) Effect of green tea extract on obese women: A 
randomized, double-blind, placebo-controlled clinical trial. Clin Nutr 27:363–370. 
233.  Dostal AM, Samavat H, Espejo L, et al (2016) Green Tea Extract and Catechol- O -
Methyltransferase Genotype Modify Fasting Serum Insulin and Plasma Adiponectin 
Concentrations in a Randomized Controlled Trial of Overweight and Obese 
Postmenopausal Women 1 – 4. J Nutr Dis 1–8. 
234.  Chen I-J, Liu C-Y, Chiu J-P, Hsu C-H (2016) Therapeutic effect of high-dose green tea 
extract on weight reduction: A randomized, double-blind, placebo-controlled clinical 
trial. Clin Nutr 35:592–599.  
235.  Hy K, Park M, Kim K, et al (2013) Hesperetin Stimulates Cholecystokinin Secretion in 
Enteroendocrine STC-1 Cells. Biomol Ther 21:121–125.  
236.  Park M, Kim K, Lee YM, et al (2014) Naringenin stimulates cholecystokinin secretion in 
STC-1 cells. Nutr Res Pract 8:146–150.  
237.  Al Shukor N, Ravallec R, Van Camp J, et al (2016) Flavonoids stimulate cholecystokinin 
peptide secretion from the enteroendocrine STC-1 cells. Fitoterapia 113:128–131.  
238.  Stefoska-Needham A, Beck EJ, Johnson SK, et al (2016) Flaked sorghum biscuits increase 
postprandial GLP-1 and GIP levels and extend subjective satiety in healthy subjects. Mol 
Nutr Food Res 60:1118–1128.  
239.  Hoggard N, Cruickshank M, Moar K, et al (2013) A single supplement of a standardised 
bilberry (Vaccinium myrtillus L.) extract (36 % wet weight anthocyanins) modifies 
glycaemic response in individuals with type 2 diabetes controlled by diet and lifestyle. J 
Nutr Sci 2:e22, 9 pages, doi:10.1017/jns.2013.1.  
INTRODUCTION 
 
63 
 
240.  Kwon E-Y, Lee J, Kim Y, et al (2017) Seabuckthorn Leaves Extract and Flavonoid 
Glycosides Extract from Seabuckthorn Leaves Ameliorates Adiposity, Hepatic Steatosis, 
Insulin Resistance, and Inflammation in Diet-Induced Obesity. Nutrients 9:569.  
241.  Liu C, Huang C-J, Huang L, et al (2014) Effects of green tea extract on insulin resistance 
and glucagon-like peptide 1 in patients with type 2 diabetes and lipid abnormalities: a 
randomized, double-blinded, and placebo-controlled trial. PLoS One 9:e91163.  
242.  Törrönen R, Sarkkinen E, Niskanen T, et al (2012) Postprandial glucose, insulin and 
glucagon-like peptide 1 responses to sucrose ingested with berries in healthy subjects. 
Br J Nutr 107:1445–51.  
243.  Phuwamongkolwiwat P, Hira T, Hara H (2014) A nondigestible saccharide, 
fructooligosaccharide, increases the promotive effect of a flavonoid, ??-glucosyl-
isoquercitrin, on glucagon-like peptide 1 (GLP-1) secretion in rat intestine and 
enteroendocrine cells. Mol Nutr Food Res 58:1581–1584. 
244.  Yamashita Y, Okabe M, Natsume M, Ashida H (2013) Cinnamtannin A2, a tetrameric 
procyanidin, increases GLP-1 and insulin secretion in mice. Biosci Biotechnol Biochem 
77:888–891. 
245.  Yu Y, Liu L, Wang X, et al (2010) Modulation of glucagon-like peptide-1 release by 
berberine: In vivo and in vitro studies. Biochem Pharmacol 79:1000–1006. 
246.  Lu SS, Yu YL, Zhu HJ, et al (2009) Berberine promotes glucagon-like peptide-1 (7-36) 
amide secretion in streptozotocin-induced diabetic rats. J Endocrinol 200:159–165. 
247.  Kwon DY, Hong SM, Ahn IS, et al (2011) Isoflavonoids and peptides from meju, long-
term fermented soybeans, increase insulin sensitivity and exert insulinotropic effects in 
vitro. Nutrition 27:244–252. 
248.  Park S, Ahn IS, Kim JH, et al (2010) Glyceollins, one of the phytoalexins derived from 
soybeans under fungal stress, enhance insulin sensitivity and exert lnsulinotropic 
actions. J Agric Food Chem 58:1551–1557. 
249.  González-Abuín N, Martínez-Micaelo N, Blay M, et al (2014) Grape-seed procyanidins 
modulate cellular membrane potential and nutrient-induced GLP-1 secretion in STC-1 
cells. Am J Physiol Cell Physiol 306:C485–92. 
250.  Kurogi M, Miyashita M, Emoto Y, et al (2012) Green tea polyphenol epigallocatechin 
gallate activates trpa1 in an intestinal enteroendocrine cell Line, STC-1. Chem Senses 
37:167–177. 
251.  Roland WSU, Van Buren L, Gruppen H, et al (2013) Bitter taste receptor activation by 
flavonoids and isoflavonoids: Modeled structural requirements for activation of 
hTAS2R14 and hTAS2R39. J Agric Food Chem 61:10454–10466. 
252.  Narukawa M, Noga C, Ueno Y, et al (2011) Evaluation of the bitterness of green tea 
catechins by a cell-based assay with the human bitter taste receptor hTAS2R39. 
Biochem Biophys Res Commun 405:620–625.  
INTRODUCTION 
 
64 
 
253.  Li J, Xu J, Hou R, et al (2017) Qing-Hua Granule induces GLP-1 secretion via bitter taste 
receptor in db / db mice. Biomed Pharmacother 89:10–17. doi: 
10.1016/j.biopha.2017.01.168 
254.  González-Abuín N, Martínez-Micaelo N, Blay M, et al (2012) Grape seed-derived 
procyanidins decrease dipeptidyl-peptidase 4 activity and expression. In: J. Agric. Food 
Chem. pp 9055–9061 
255.  Ryan CM, Khoo W, Stewart AC, et al (2017) Flavanol concentrations do not predict 
dipeptidyl peptidase-IV inhibitory activities of four cocoas with different processing 
histories. Food Funct 8:746–756. doi: 10.1039/C6FO01730D 
256.  González-Abuín N, Martínez-Micaelo N, Blay M, et al (2014) Grape-seed procyanidins 
prevent the cafeteria-diet-induced decrease of glucagon-like peptide-1 production. J 
Agric Food Chem 62:1066–1072. doi: 10.1021/jf405239p 
257.  Yang G, Xue Y, Zhang H, et al (2015) Favourable effects of grape seed extract on 
intestinal epithelial differentiation and barrier function in IL10-deficient mice. Br J Nutr 
1–9. doi: 10.1017/S0007114515001415 
258.  Sagara Y, Vanhnasy J, Maher P (2004) Induction of PC12 cell differentiation by 
flavonoids is dependent upon extracellular signal-regulated kinase activation. J 
Neurochem 90:1144–1155. doi: 10.1111/j.1471-4159.2004.02563.x 
259.  Xu SL, Choi RCY, Zhu KY, et al (2012) Isorhamnetin, a flavonol aglycone from Ginkgo 
biloba L., induces neuronal differentiation of cultured PC12 cells: Potentiating the effect 
of nerve growth factor. Evidence-based Complement Altern Med. doi: 
10.1155/2012/278273 
260.  Jhun JY, Moon SJ, Yoon BY, et al (2013) Grape seed proanthocyanidin extract-mediated 
regulation of STAT3 proteins contributes to Treg differentiation and attenuates 
inflammation in a murine model of obesity-associated arthritis. PLoS One. 
261.  Pinent M, Bladé MC, Salvadó MJ, et al (2005) Grape-seed derived procyanidins interfere 
with adipogenesis of 3T3-L1 cells at the onset of differentiation. Int J Obes (Lond) 
29:934–941. 
262.  Chen KM, Ge BF, Ma HP, et al (2005) Icariin, a flavonoid from the herb Epimedium 
enhances the osteogenic differentiation of rat primary bone marrow stromal cells. 
Pharmazie 60:939–942. 
263.  Chen KM, Ge BF, Ma HP, Zheng RL (2004) The serum of rats administered flavonoid 
extract from Epimedium sagittatum but not the extract itself enhances the development 
of rat calvarial osteoblast-like cells in vitro. Pharmazie 59:61–64. 
264.  Cani PD, Everard A, Duparc T (2013) Gut microbiota, enteroendocrine functions and 
metabolism. Curr Opin Pharmacol 13:935–940. 
265.  Geurts L, Neyrinck AM, Delzenne NM, et al (2014) Gut microbiota controls adipose 
tissue expansion, gut barrier and glucose metabolism: Novel insights into molecular 
targets and interventions using prebiotics. Benef Microbes 5:3–17.  
INTRODUCTION 
 
65 
 
266.  Zhang C, Zhang M, Wang S, et al (2009) Interactions between gut microbiota, host 
genetics and diet relevant to development of metabolic syndromes in mice. ISME J 
4:232–241.  
267.  Marchesi JR, Adams DH, Fava F, et al (2015) The gut microbiota and host health: a new 
clinical frontier. Gut 1–10.  
268.  Cueva C, Gil-Sánchez I, Ayuda-Durán B, et al (2017) An Integrated View of the Effects of 
Wine Polyphenols and Their Relevant Metabolites on Gut and Host Health. Molecules 
22:99.  
269.  Fernandes I, Pérez-Gregorio R, Soares S, et al (2017) Wine Flavonoids in Health and 
Disease Prevention. Molecules 22:292.  
270.  Strat KM, Rowley TJ, Smithson AT, et al (2016) Mechanisms by which cocoa flavanols 
improve metabolic syndrome and related disorders ☆. J Nutr Biochem 35:1–21.  
271.  Neyrinck AM, Van Hée VF, Bindels LB, et al (2013) Polyphenol-rich extract of 
pomegranate peel alleviates tissue inflammation and hypercholesterolaemia in high-fat 
diet-induced obese mice: potential implication of the gut microbiota. Br J Nutr 109:802–
9.  
272.  Ankolekar C, Johnson D, Pinto M da S, et al (2011) Inhibitory Potential of Tea 
Polyphenolics and Influence of Extraction Time Against Helicobacter pylori and Lack of 
Inhibition of Beneficial Lactic Acid Bacteria. J Med Food 14:1321–1329. 
273.  Jung-Sook S, Ha-Sook C (2007) Antibacterial Activities of Phenolic Components from 
Camellia sinensis L . on Pathogenic Microorganisms. J Food Sci Nutr 12:135–140. 
274.  Nakayama M, Shigemune N, Tsugukuni T, et al (2012) Mechanism of the combined anti-
bacterial effect of green tea extract and NaCl against Staphylococcus aureus and 
Escherichia coli O157:H7. Food Control 25:225–232. 
275.  Kohda C, Yanagawa Y, Shimamura T (2008) Epigallocatechin gallate inhibits 
intracellular survival of Listeria monocytogenes in macrophages. Biochem Biophys Res 
Commun 365:310–315. 
276.  Si W, Gong J, Tsao R, et al (2006) Bioassay-guided purification and identification of 
antimicrobial components in Chinese green tea extract. J Chromatogr A 1125:204–210.  
277.  Bancirova M (2010) Comparison of the antioxidant capacity and the antimicrobial 
activity of black and green tea. Food Res Int 43:1379–1382. 
278.  Duda-Chodak A (2012) The inhibitory effect of polyphenols on human gut microbiota. J 
Physiol Pharmacolgy Pharmacolgy 63:497–503. 
279.  Tzounis X (2008) Flavanol monomer-induced changes to the human faecal microflora. 
Br J Nutr 99:782–792. 
280.  Lee HC, Jenner AM, Low CS, Lee YK (2006) Effect of tea phenolics and their aromatic 
fecal bacterial metabolites on intestinal microbiota. Res Microbiol 157:876–884. 
INTRODUCTION 
 
66 
 
281.  Bustos I, Herna B, Pela C, et al (2012) Effect of Flavan-3-ols on the Adhesion of Potential 
Probiotic Lactobacilli to Intestinal Cells. J Agric Food Chem 60:9082–9088. 
282.  Parkar SG, Stevenson DE, Skinner MA (2008) The potential influence of fruit 
polyphenols on colonic microflora and human gut health. Int J Food Microbiol 124:295–
298. 
283.  Queipo-Ortuño MI, Boto-Ordóñez M, Murri M, et al (2012) Influence of red wine 
polyphenols on the gut microbiota ecology. Am J Clin Nutr 95:1323–1334. 
284.  Tzounis X, Rodriguez-Mateos A, Vulevic J, et al (2011) Prebiotic evaluation of cocoa-
derived flavanols in healthy humans by using a randomized, controlled, double-blind, 
crossover intervention study. Am J Clin Nutr 93:62–72. 
285.  Clavel T, Fallani M, Lepage P, et al (2005) Isoflavones and functional foods alter the 
dominant intestinal microbiota in postmenopausal women. J Nutr 135:2786–92. 
286.  Masumoto S, Terao A, Yamamoto Y, et al (2016) Non-absorbable apple procyanidins 
prevent obesity associated with gut microbial and metabolomic changes. Sci Rep 
6:31208. 
287.  Anhê FF, Roy D, Pilon G, et al (2015) A polyphenol-rich cranberry extract protects from 
diet-induced obesity, insulin resistance and intestinal inflammation in association with 
increased Akkermansia spp. population in the gut microbiota of mice. Gut 64:872–83.  
288.  Axling U, Olsson C, Xu J, et al (2012) Green tea powder and Lactobacillus plantarum 
affect gut microbiota, lipid metabolism and inflammation in high-fat fed C57BL/6J mice. 
Nutr Metab (Lond) 9:105. 
289.  Roopchand DE, Carmody RN, Kuhn P, et al (2015) Dietary polyphenols promote growth 
of the gut bacterium akkermansia muciniphila and attenuate high-fat diet-induced 
metabolic syndrome. Diabetes 64:2847–2858. 
290.  Liu W, Zhao S, Wang J, et al (2017) Grape seed proanthocyanidin extract ameliorates 
inflammation and adiposity by modulating gut microbiota in high-fat diet mice. Mol Nutr 
Food Res 1601082. 
291.  Etxeberria U, Arias N, Boqu?? N, et al (2015) Reshaping faecal gut microbiota 
composition by the intake of trans-resveratrol and quercetin in high-fat sucrose diet-fed 
rats. J Nutr Biochem 26:651–660. 
292.  Dolara P, Luceri C, De Filippo C, et al (2005) Red wine polyphenols influence 
carcinogenesis, intestinal microflora, oxidative damage and gene expression profiles of 
colonic mucosa in F344 rats. Mutat Res - Fundam Mol Mech Mutagen 591:237–246. 
293.  Kovatcheva-datchary P, Fellow P (2013) Nutrition , the gut microbiome and the 
metabolic syndrome. Best Pract Res Clin Gastroenterol 27:59–72.  
294.  Mine Y, Li-Chan ECY, Jiang B (2010) Biologically Active Food Proteins and Peptides in 
Health: An Overview. In: Bioact. Proteins Pept. as Funct. Foods Nutraceuticals. Wiley-
Blackwell, pp 3–11 
INTRODUCTION 
 
67 
 
295.  Udenigwe CC (2014) Bioinformatics approaches, prospects and challenges of food 
bioactive peptide research. Trends Food Sci Technol 36:137–143. 
296.  Bhat ZF, Kumar S, Bhat HF (2015) Bioactive peptides of animal origin: a review. J Food 
Sci Technol 52:5377–5392. 
297.  Suleria HAR, Gobe G, Masci P, Osborne SA (2016) Marine bioactive compounds and 
health promoting perspectives; innovation pathways for drug discovery. Trends Food 
Sci Technol 50:44–55. 
298.  Hsieh CH, Wang TY, Hung CC, et al (2015) Improvement of glycemic control in 
streptozotocin-induced diabetic rats by Atlantic salmon skin gelatin hydrolysate as the 
dipeptidyl-peptidase IV inhibitor. Food Funct 6:1887–1892. 
299.  Huang SL, Hung CC, Jao CL, et al (2014) Porcine skin gelatin hydrolysate as a dipeptidyl 
peptidase IV inhibitor improves glycemic control in streptozotocin-induced diabetic 
rats. J Funct Foods 11:235–242. 
300.  Wang TY, Hsieh CH, Hung CC, et al (2015) Fish skin gelatin hydrolysates as dipeptidyl 
peptidase IV inhibitors and glucagon-like peptide-1 stimulators improve glycaemic 
control in diabetic rats: A comparison between warm- and cold-water fish. J Funct Foods 
19:330-340. 
301.  Hsieh CC, Hernández-Ledesma B, Fernández-Tomé S, et al (2015) Milk proteins, 
peptides, and oligosaccharides: Effects against the 21st century disorders. Biomed Res 
Int. 
302.  Nongonierma AB, Fitzgerald RJ (2012) Biofunctional properties of 
caseinophosphopeptides in the Oral Cavity. Caries Res 46:234–267. 
303.  Udenigwe CC, Aluko RE (2012) Food protein-derived bioactive peptides: Production, 
processing, and potential health benefits. J Food Sci 
304.  Hanke AT, Ottens M (2014) Purifying biopharmaceuticals : knowledge-based 
chromatographic process development. Trends Biotechnol 32:210–220.  
305.  Li-Chan ECY (2015) Bioactive peptides and protein hydrolysates: Research trends and 
challenges for application as nutraceuticals and functional food ingredients. Curr Opin 
Food Sci 1:28–37. 
306.  Norris R, Casey F, Fitzgerald RJ, et al (2012) Predictive modelling of angiotensin 
converting enzyme inhibitory dipeptides. Food Chem 133:1349–1354. 
307.  Nongonierma AB, Fitzgerald RJ (2014) An in silico model to predict the potential of 
dietary proteins as sources of dipeptidyl peptidase IV ( DPP-IV ) inhibitory peptides. 
FOOD Chem 165:489–498. 
308.  Velarde-Salcedo AJ, Barrera-Pacheco A, Lara-González S, et al (2013) In vitro inhibition 
of dipeptidyl peptidase IV by peptides derived from the hydrolysis of amaranth 
(Amaranthus hypochondriacus L.) proteins. Food Chem 136:758–764. 
INTRODUCTION 
 
68 
 
309.  Zhang T, Nie S, Liu B, et al (2015) Activity prediction and molecular mechanism of 
bovine blood derived angiotensin I-converting enzyme inhibitory peptides. PLoS One 
10:1–13. 
310.  Mooney C, Haslam NJ, Pollastri G, Shields DC (2012) Towards the Improved Discovery 
and Design of Functional Peptides: Common Features of Diverse Classes Permit 
Generalized Prediction of Bioactivity. PLoS One. 
311.  Carrasco-Castilla J, Hernández-Álvarez AJ, Jiménez-Martínez C, et al (2012) Use of 
Proteomics and Peptidomics Methods in Food Bioactive Peptide Science and 
Engineering. Food Eng Rev 4:224–243. 
312.  Majumder K, Jianping W (2009) Angiotensin I converting enzyme inhibitory peptides 
from stimulated in vitro gastrointestinal digestion of cooked eggs. J Agric Food Chem 
57:471–477. 
313.  Nongonierma AB, FitzGerald RJ (2016) Strategies for the discovery and identification of 
food protein-derived biologically active peptides. Trends Food Sci Technol. 
314.  Lacroix IME, Li-Chan ECY (2014) Overview of food products and dietary constituents 
with antidiabetic properties and their putative mechanisms of action: A natural 
approach to complement pharmacotherapy in the management of diabetes. Mol Nutr 
Food Res 58:61–78. 
315.  Murray BA, FitzGerald RJ (2007) Angiotensin converting enzyme inhibitory peptides 
derived from food proteins: biochemistry, bioactivity and production. Curr Pharm Des 
13:773–91. 
316.  Diakogiannaki E, Pais R, Tolhurst G, et al (2013) Oligopeptides stimulate glucagon-like 
peptide-1 secretion in mice through proton-coupled uptake and the calcium-sensing 
receptor. Diabetologia 56:2688–2696. 
317.  Ishikawa Y, Hira T, Inoue D, et al (2015) Rice protein hydrolysates stimulate GLP-1 
secretion, reduce GLP-1 degradation, and lower the glycemic response in rats. Food 
Funct 6:2525–34.  
318.  Lacroix IME, Li-Chan ECY (2013) Inhibition of dipeptidyl peptidase (DPP)-IV and α-
glucosidase activities by pepsin-treated whey proteins. J Agric Food Chem 61:7500–
7506. 
319.  Silveira ST, Martínez-maqueda D, Recio I, Hernández-ledesma B (2013) Dipeptidyl 
peptidase-IV inhibitory peptides generated by tryptic hydrolysis of a whey protein 
concentrate rich in b -lactoglobulin. Food Chem 141:1072–1077. 
320.  Nongonierma AB, FitzGerald RJ (2013) Dipeptidyl peptidase IV inhibitory properties of 
a whey protein hydrolysate: Influence of fractionation, stability to simulated 
gastrointestinal digestion and food-drug interaction. Int Dairy J 32:33–39. 
321.  Konrad B, Anna D, Marek S, et al (2014) The evaluation of dipeptidyl peptidase (DPP)-
IV, α-glucosidase and angiotensin converting enzyme (ACE) inhibitory activities of whey 
proteins hydrolyzed with serine protease isolated from asian pumpkin (Cucurbita 
ficifolia). Int J Pept Res Ther 20:483–491. 
INTRODUCTION 
 
69 
 
322.  Boots J-WP protein hydrolysate enriched in peptides inhibiting DPP-IV and their use. 
(patent: US 2013/0090674 A1)  
323.  Connolly A, Piggott CO, FitzGerald RJ (2014) In vitro α-glucosidase, angiotensin 
converting enzyme and dipeptidyl peptidase-IV inhibitory properties of brewers’ spent 
grain protein hydrolysates. Food Res Int 56:100–107. 
324.  Lacroix IME, Li-Chan ECY (2012) Dipeptidyl peptidase-IV inhibitory activity of dairy 
protein hydrolysates. Int Dairy J 25:97–102. 
325.  Mojica L, Chen K, de Mejía EG (2015) Impact of Commercial Precooking of Common 
Bean (Phaseolus vulgaris) on the Generation of Peptides, After Pepsin-Pancreatin 
Hydrolysis, Capable to Inhibit Dipeptidyl Peptidase-IV. J Food Sci 80:H188–H198.  
326.  Van amerongen A, Beelen-Thomissen MJC, Van Zeeland-Wolbers LAM, et al egg protein 
hydrlysates. (patent: WO 2009/128713 A1).  
327.  Sila A, Martinez-Alvarez O, Haddar A, et al (2015) Recovery, viscoelastic and functional 
properties of Barbel skin gelatine: Investigation of anti-DPP-IV and anti-prolyl 
endopeptidase activities of generated gelatine polypeptides. Food Chem 168:478–486.  
328.  Nongonierma AB, Fitzgerald RJ (2014) Susceptibility of milk protein-derived peptides to 
dipeptidyl peptidase IV ( DPP-IV ) hydrolysis. Food Chem 145:845–852. 
329.  Zhang Y, Chen R, Zuo F, et al (2016) Comparison of dipeptidyl peptidase IV-inhibitory 
activity of peptides from bovine and caprine milk casein by in silico and in vitro 
analyses. Int Dairy J 53:37–44. 
330.  Lan VTT, Ito K, Ohno M, et al (2015) Analyzing a dipeptide library to identify human 
dipeptidyl peptidase IV inhibitor. Food Chem 175:66–73. 
331.  Lacroix IME, Li-Chan ECY (2014) Isolation and characterization of peptides with 
dipeptidyl peptidase-IV inhibitory activity from pepsin-treated bovine whey proteins. 
Peptides 54:39–48. 
332.  Lambeir A, Durinx C, Scharpé S, De Meester I (2003) Dipeptidyl-peptidase IV from bench 
to bedside: an update on structural properties, functions, and clinical aspects of the 
enzyme DPP IV. Crit Rev Clin Lab Sci 40:209–294 
333.  Tominaga Y, Yokota S, Tanaka H, et al (2012) Dipeptidyl peptidase-4 inhibitor. (patent: 
US 20120189611 A1).  
334.  Uchida M, Ohshiba Y, Mogami O (2011) Novel dipeptidyl peptidase-4-inhibiting peptide 
derived from β-lactoglobulin. J Pharmacol Sci 117:63–6. 
335.  Uenishi H, Kabuki T, Seto Y, et al (2012) Isolation and identification of casein-derived 
dipeptidyl-peptidase 4 (DPP-4)-inhibitory peptide LPQNIPPL from gouda-type cheese 
and its effect on plasma glucose in rats. Int Dairy J 22:24–30. 
INTRODUCTION 
 
70 
 
336.  Wang Y, Landheer S, van Gilst WH, et al (2012) Attenuation of Renovascular Damage in 
Zucker Diabetic Fatty Rat by NWT-03, an Egg Protein Hydrolysate with ACE- and DPP4-
Inhibitory Activity. PLoS One 7:e46781. 
337.  Mochida T, Hira T, Hara H (2010) The corn protein, zein hydrolysate, administered into 
the ileum attenuates hyperglycemia via its dual action on glucagon-like peptide-1 
secretion and dipeptidyl peptidase-IV activity in rats. Endocrinology 151:3095–3104.  
338.  De Souza Rocha T, Hernandez LMR, Chang YK, de Mejía EG (2014) Impact of 
germination and enzymatic hydrolysis of cowpea bean (Vigna unguiculata) on the 
generation of peptides capable of inhibiting dipeptidyl peptidase IV. Food Res Int 
64:799–809. 
339.  Caron J, Cudennec B, Domenger D, et al (2016) Simulated GI digestion of dietary protein: 
Release of new bioactive peptides involved in gut hormone secretion. Food Res Int 
89:382–390. 
340.  Caron J, Domenger D, Belguesmia Y, et al (2016) Protein digestion and energy 
homeostasis: How generated peptides may impact intestinal hormones? Food Res Int 
88:310–318. 
341.  Nongonierma AB, FitzGerald RJ (2013) Inhibition of dipeptidyl peptidase IV (DPP-IV) by 
proline containing casein-derived peptides. J Funct Foods 5:1909–1917. doi: 
10.1016/j.jff.2013.09.012 
342.  Nongonierma AB, Mazzocchi C, Paolella S, FitzGerald RJ (2017) Release of dipeptidyl 
peptidase IV (DPP-IV) inhibitory peptides from milk protein isolate (MPI) during 
enzymatic hydrolysis. Food Res Int 94:79–89. 
343.  Nongonierma AB, Fitzgerald RJ (2016) Structure activity relationship modelling of milk 
protein-derived peptides with dipeptidyl peptidase IV ( DPP-IV ) inhibitory activity. 
Peptides 79:1–7. 
344.  Zhang Y, Chen R, Ma H, Chen S (2015) Isolation and Identification of Dipeptidyl 
Peptidase IV-Inhibitory Peptides from Trypsin/Chymotrypsin-Treated Goat Milk Casein 
Hydrolysates by 2D-TLC and LC-MS/MS. J Agric Food Chem 63:8819–8828. 
345.  Tulipano G, Faggi L, Nardone A, et al (2015) Characterisation of the potential of beta-
lactoglobulin and alpha-lactalbumin as sources of bioactive peptides affecting incretin 
function: In silico and in vitro comparative studies. Int Dairy J 48:66–72. 
346.  Nongonierma AB, Fitzgerald RJ (2013) Dipeptidyl peptidase IV inhibitory and 
antioxidative properties of milk protein-derived dipeptides and hydrolysates. Peptides 
39:157–163. 
347.  Lafarga T, Aluko RE, Rai DK, et al (2016) Identification of bioactive peptides from a 
papain hydrolysate of bovine serum albumin and assessment of an antihypertensive 
effect in spontaneously hypertensive rats. Food Res Int 81:91–99. 
348.  Lacroix IME, Meng G, Cheung IWY, Li-chan ECY (2016) Do whey protein-derived 
peptides have dual dipeptidyl-peptidase IV and angiotensin I-converting enzyme 
inhibitory activities ? J Funct Foods 21:87–96. 
INTRODUCTION 
 
71 
 
349.  Power-Grant O, Bruen C, Brennan L, et al (2015) In vitro bioactive properties of intact 
and enzymatically hydrolysed whey protein: targeting the enteroinsular axis. Food 
Funct 6:972–980. doi: 10.1039/C4FO00983E 
350.  Le Maux S, Nongonierma AB, Barre C, Fitzgerald RJ (2016) Enzymatic generation of 
whey protein hydrolysates under pH-controlled and non pH-controlled conditions: 
Impact on physicochemical and bioactive properties. Food Chem 199:246–251. doi: 
10.1016/j.foodchem.2015.12.021 
351.  Cudennec B, Balti R, Ravallec R, et al (2015) In vitro evidence for gut hormone 
stimulation release and dipeptidyl-peptidase IV inhibitory activity of protein 
hydrolysate obtained from cuttlefish (Sepia officinalis) viscera. Food Res Int 78:238–
245. doi: 10.1016/j.foodres.2015.10.003 
352.  Nongonierma AB, FitzGerald RJ (2015) Investigation of the Potential of Hemp, Pea, Rice 
and Soy Protein Hydrolysates as a Source of Dipeptidyl Peptidase IV (DPP-IV) Inhibitory 
Peptides. Food Dig 6:19–29. doi: 10.1007/s13228-015-0039-2 
353.  Harnedy PA, O’Keeffe MB, Fitzgerald RJ (2015) Purification and identification of 
dipeptidyl peptidase (DPP) IV inhibitory peptides from the macroalga Palmaria palmata. 
Food Chem 172:400–406. doi: 10.1016/j.foodchem.2014.09.083 
354.  Nongonierma AB, Le Maux S, Dubrulle C, et al (2015) Quinoa (Chenopodium quinoa 
Willd.) protein hydrolysates with in vitro dipeptidyl peptidase IV (DPP-IV) inhibitory 
and antioxidant properties. J Cereal Sci 65:112–118. doi: 10.1016/j.jcs.2015.07.004 
355.  Hatanaka T, Inoue Y, Arima J, et al (2012) Production of dipeptidyl peptidase IV 
inhibitory peptides from defatted rice bran. Food Chem 134:797–802. doi: 
10.1016/j.foodchem.2012.02.183 
356.  Guo L, Harnedy PA, Zhang L, et al (2015) In vitro assessment of the multifunctional 
bioactive potential of Alaska pollock skin collagen following simulated gastrointestinal 
digestion. J Sci Food Agric 95:1514–1520. doi: 10.1002/jsfa.6854 
357.  Li-Chan ECY, Hunag SL, Jao CL, et al (2012) Peptides derived from Atlantic salmon skin 
gelatin as dipeptidyl-peptidase IV inhibitors. J Agric Food Chem 60:973–978. doi: 
10.1021/jf204720q 
358.  Jin Y, Yan J, Yu Y, Qi Y (2015) Screening and identification of DPP-IV inhibitory peptides 
from deer skin hydrolysates by an integrated approach of LC – MS / MS and in silico 
analysis. J Funct Foods 18:344–357. doi: 10.1016/j.jff.2015.07.015 
359.  Hatanaka T, Kawakami K, Uraji M (2014) Inhibitory effect of collagen-derived 
tripeptides on dipeptidylpeptidase-IV activity. J Enzyme Inhib Med Chem 6366:1–6. doi: 
10.3109/14756366.2013.858143 
360.  Hsu K, Tung Y (2013) Dipeptidyl Peptidase-IV Inhibitory Activity of Peptides in Porcine 
Skin Gelatin Hydrolysates. Bioact Food Pept Heal Dis 205–218. doi: 
http://dx.doi.org/10.5772/51264 
361.  Gallego M, Aristoy MC, Toldrá F (2014) Dipeptidyl peptidase IV inhibitory peptides 
generated in Spanish dry-cured ham. Meat Sci 96:757–761. 
INTRODUCTION 
 
72 
 
362.  Huang S, Jao C, Ho K, Hsu K (2012) Peptides Dipeptidyl-peptidase IV inhibitory activity 
of peptides derived from tuna cooking juice hydrolysates. Peptides 35:114–121. 
363.  Pais R, Gribble FM, Reimann F (2016) Signalling pathways involved in the detection of 
peptones by murine small intestinal enteroendocrine L-cells. Peptides 77:9–15. doi: 
10.1016/j.peptides.2015.07.019 
364.  Reimer RA (2006) Meat hydrolysate and essential amino acid-induced glucagon-like 
peptide-1 secretion, in the human NCI-H716 enteroendocrine cell line, is regulated by 
extracellular signal-regulated kinase1/2 and p38 mitogen-activated protein kinases. J 
Endocrinol 191:159–170. 
365.  Gillespie AL, Calderwood D, Hobson L, Green BD (2015) Whey proteins have beneficial 
effects on intestinal enteroendocrine cells stimulating cell growth and increasing the 
production and secretion of incretin hormones. Food Chem 189:120–128. 
366.  Gillespie AL, Green BD (2016) The bioactive effects of casein proteins on 
enteroendocrine cell health, proliferation and incretin hormone secretion. Food Chem 
211:148–159. 
367.  Kato M, Nakanishi T, Tani T, Tsuda T (2017) Low-molecular fraction of wheat protein 
hydrolysate stimulates glucagon-like peptide-1 secretion in an enteroendocrine L cell 
line and improves glucose tolerance in rats. Nutr Res 37:37–45. 
368.  Hall WL, Millward DJ, Long SJ, Morgan LM (2003) Casein and whey exert different 
effects on plasma amino acid profiles, gastrointestinal hormone secretion and appetite. 
Br J Nutr 89:239–248. 
369.  Overduin J, Guérin-Deremaux L, Wils D, Lambers TT (2015) NUTRALYS pea protein: 
Characterization of in vitro gastric digestion and in vivo gastrointestinal peptide 
responses relevant to satiety. Food Nutr Res 59:1–9. 
370.  Wellendorph P, Bräuner-Osborne H (2009) Molecular basis for amino acid sensing by 
family C G-protein-coupled receptors. Br J Pharmacol 156:869–884. 
371.  Oya M, Kitaguchi T, Pais R, et al (2013) The G protein-coupled receptor family C group 6 
subtype a (GPRC6A) receptor is involved in amino acid-induced glucagon-like peptide-1 
secretion from GLUTag cells. J Biol Chem 288:4513–4521. 
372.  Reimann F, Williams L, Da Silva Xavier G, et al (2004) Glutamine potently stimulates 
glucagon-like peptide-1 secretion from GLUTag cells. Diabetologia 47:1592–1601. 
373.  Tolhurst G, Zheng Y, Parker HE, et al (2011) Glutamine triggers and potentiates 
glucagon-like peptide-1 secretion by raising cytosolic Ca2+and cAMP. Endocrinology 
152:405–413. 
374.  Young SH, Rey O, Sternini C, Rozengurt E (2010) Amino acid sensing by enteroendocrine 
STC-1 cells: role of the Na+-coupled neutral amino acid transporter 2. Am J Physiol Cell 
Physiol 298:1401–1413. 
INTRODUCTION 
 
73 
 
375.  Gevrey JC, Malapel M, Philippe J, et al (2004) Protein hydrolysates stimulate 
proglucagon gene transcription in intestinal endocrine cells via two elements related to 
cyclic AMP response element. Diabetologia 47:926–936.  
376.   Lacroix IME, Li-Chan ECY (2016) Food-derived dipeptidyl-peptidase IV inhibitors as a 
potential approach for glycemic regulation - Current knowledge and future research 
considerations. Trends Food Sci Technol 54:1–16. 
  
 
  
 
 
 
 
 
II. HYPOTHESIS AND 
OBJECTIVES 
 
 
 
 
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HYPOTHESIS AND OBJECTIVES 
 
 
77 
 
Hypothesis and objectives 
The gastrointestinal tract represents the physical interface between the external 
environment and the circulation. Consequently, it is the first interaction between 
dietary components and the host. The interactions of dietary components with 
receptors and transporters located on the enteroendocrine cells of the intestinal tract 
can induce the secretion of hormones, which are profoundly involved in the control of 
metabolism, especially in the control of satiety and glucose homeostasis. Therefore, 
identifying natural bioactive compounds and the mechanism by which these modulate 
the secretion of hormones from entereoendocrine cells could lead to the development 
therapeutic agents for the treatment of obesity and glucose homeostasis disorders. 
Flavanols and phenolic acids are considered the most abundant phenolic compounds 
in the human diet due to their wide distribution in plants and fruits. Their 
consumption has been associated with beneficial effects in health, and it has been 
reported to target different tissues of the body. Previous studies performed in our 
research group reported that grape seed proanthocyanidin extract (GSPE) induces 
changes at intestinal level, specifically modulating production and cleavage of the 
anorectic gut hormone glucagon like peptide 1 (GLP-1). These results were linked with 
glucose homeostasis improvements and thereby indicated that the enteroendocrine 
system could be an important GSPE target. Therefore, due to its role in body metabolic 
homeostasis, understanding the potential mechanisms by which GSPE modulates the 
enteroendocine system is important. Actually, as above mentioned, the 
enteroendocrine system is not only important in regulation of glucose homeostasis but 
also in the control of food intake. This thesis has been performed in parallel to another 
one in which the influence of GSPE on food intake has been studied.  
While the beneficial effects of food phenolic compounds have been largely studied, 
bioactive peptides (BPs) are still a novel field of research. BPs encrypted within dietary 
protein sequence have been associated to health promoting effects. Different methods 
have been described to obtain the BPs, which may act upon different parts of the body. 
Therefore, dietary protein hydrolyzates are a promising source of potential BPs that 
might interact with the enteroendocrine system at the gastrointestinal level. However 
few studies have described an effect of BPs on GLP-1 secretion or on the enzyme 
responsible for GLP-1 inactivation, DPP-IV. Furthermore, very few in vivo studies 
associated the administration of BPs with glucose homeostasis improvement. 
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On the basis of the information described above, we hypothesized that bioactive 
natural compounds might act at different intestinal levels to modulate the 
amount of the main active enterohormones related to satiety and glucose 
homeostasis. Therefore, the main objective of thesis is to elucidate whether bioactive 
natural compounds, particularly GSPE and bioactive peptides derived from chicken 
feet, can modulate the levels of the main enterohormones by modulating different 
intestinal mechanisms.  
The specific objectives proposed to fulfill the established hypothesis were: 
1. To determine whether grape-seed proanthocyanidin extract directly affects 
the release of the main enterohormones. 
Previous results reported that an acute dose of GSPE modulates GLP-1 plasma levels in 
vivo. One potential mechanism by which GSPE could exert this effect, in addition to the 
previously shown DPP-IV inhibition, is the direct activation of GLP-1 secretion. Hence, 
we aimed to elucidate if GSPE is able to directly stimulate the release of intestinal GLP-
1, and if such action is extended to other enterohormones. 
2. To study whether grape-seed proanthocyanidin extract affects intestinal 
differentiation.  
Previous results showed that chronic treatment of GSPE counteract the down-
regulation of Chga, GLP-1 and PYY gene expression induced by a cafeteria diet, 
suggesting that one possible mechanism by which GSPE could act in chronic treatment 
is the promotion of enteroendocrine cell differentiation. Therefore, we aimed to 
discover whether GSPE modulates enteroendocrine cell differentiation. 
3. To study whether grape-seed proanthocyanidin extract modulates the gut 
microbiota and if such modulation influences the enteroendocrine system.  
In the last few years, the composition of the gut microbiota and its modulation has 
become of growing interest due to its influence on host metabolism. Several studies 
reported that other extracts rich in phenolic compounds are able to modulate the 
composition of the gut microbiota, although none of them evaluated the crosstalk 
between such modulation and the enteroendocrine system. Therefore, we aimed to 
explore whether GSPE alters gut microbiota composition and whether such 
modulation might be linked to the modulation of the enteroendocrine system. 
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4. To evaluate whether bioactive peptides derived from chicken feet modulate 
the incretin system through affecting GLP-1 cleavage and secretion.  
Previous results showed that GSPE improved glucose homeostasis, in part, through 
modulating GLP-1 levels. In order to discover new bioactive compounds that could also 
exert their effects by modulating the incretin system at the intestinal level, we 
screened protein hydrolysates derived from chicken feet. We searched for bioactive 
peptides that influence the incretin system, specifically GLP-1, through different 
mechanisms, and therefore, ameliorate glucose homeostasis.  
 
 
The research work carried out in this Ph.D. has been supported by grants [AGL2014-
55347-R] from the Ministerio de Educación y Ciencia of the Spanish Government. This 
thesis was performed in the MoBioFood Research Group of the Universitat Rovira i Virgili 
with a pre-doctoral grant from the Universitat Rovira i Virgili. An international phase 
was completed in Department of Medicine, Division of Diabetes, Endocrinology and 
Metabolism of the Imperial College London (UK). 
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Hipòtesi i objectius 
La primera interacció entre els components de la dieta i l’hoste la confereix el tracte 
gastrointestinal, el qual representa la interfície física entre l’ambient extern i la 
circulació. Les interaccions dels components de la dieta amb els receptors i els 
transportadors localitzats en les cèl·lules entreoendocrines del tracte intestinal poden 
induir la secreció d’hormones, les quals estan profundament involucrades amb el 
control del metabolisme, especialment en el control de la sacietat i de la homeòstasi de 
glucosa. Per tant, identificar components bioactius alimentaris i els mecanismes pels 
quals aquests modulen la secreció d’hormones produïdes per les cèl·lules 
entreoendocrines podria derivar en el desenvolupament d’agents terapèutics per al 
tractament de l’obesitat i dels trastorns de l’homeòstasi de la glucosa. 
Flavanols i àcids fenòlics són considerats els compostos fenòlics més abundants en la 
dieta humana a causa de la seva àmplia distribució en plantes i fruites. La seva 
composició s’ha associat amb efectes beneficiosos per a la salut, sent diferents teixits 
del cos objectiu d’aquests efectes. Estudis previs fets en el nostre grup de recerca van 
mostrar que l’extracte de proantocianidines de pinyol de raïm (GSPE) indueix canvis a 
nivell intestinal, específicament modulant la producció i la escissió de la hormona 
intestinal anorètica, pèptid similar al glucagó tipus 1 (GLP-1). Aquests resultats es van 
relacionar amb millores en la homeòstasi de la glucosa i conseqüentment van indicar 
que el sistema entreoendocrí pot ser un objectiu d’acció estratègic per GSPE. Per tant, a 
causa del seu rol en la homeòstasi del metabolisme de l’organisme, és rellevant 
entendre els potencials mecanismes pels quals GSPE modula el sistema enteroendocrí. 
A més a més, tal com s’ha mencionat anteriorment, el sistema enteroendocrí no 
solament és important en la regulació de l’homeòstasi de la glucosa, sinó que també en 
el control de la ingesta. Aquesta tesi doctoral s’ha realitzat paral·lelament amb una 
altra en la que s’ha avaluat la influència del GSPE sobre la ingesta. 
Hi ha força estudis que han investigat els efectes beneficiosos dels compostos fenòlics 
alimentaris, en front això, els pèptids bioactius (BPs) són un camp innovador de 
recerca. Els BPs encriptats dins de les seqüències de proteïnes dietètiques s’han 
associat en efectes promotors de la salut. S’han descrit diferents mètodes per obtenir 
aquests BPs, els quals poden actuar sobre diferents parts de l’organisme. Els 
hidrolitzats de proteïnes dietètiques són per tant una font prometedora de potencials 
BPs els quals poden interactuar amb el sistema enteroendocrí a nivell intestinal. Tot i 
que pocs estudis han descrit l’efecte dels BPs sobre la secreció de GLP-1 o sobre 
l’enzim responsable de la inactivació de GLP-1. D’altra banda, molts pocs estudis in vivo 
han associat l’administració dels BPs  amb la millora de la homeòstasi de la glucosa.  
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D’acord amb l’explicat anteriorment, es va hipotetitzar que els compostos naturals 
bioactius poden actuar a diferents nivells intestinals modulant les quantitats de 
les principals enterohormones actives relacionades en la sacietat i en la 
homeòstasi de la glucosa. Així doncs, el principal objectiu d’aquesta tesi doctoral es 
determinar si els compostos naturals bioactius, particularment GSPE i els pèptids 
bioactius procedents de pota de pollastre, poden modular els nivells de les principals 
enterhormones mitjançant la modulació de diferents mecanismes intestinals. 
Els objectius específics proposats per resoldre la hipòtesi establerta són: 
1. Determinar si l’extracte de proantocianidines de pinyol de raïm afecta 
directament la secreció de les principals enterohormones. 
Resultats previs van descriure que una dosi aguda de GSPE modula els nivells 
plasmàtics de GLP-1 in vivo. Un mecanisme pel qual GSPE podria exercir aquest efecte, 
a més a més de la inhibició de DPP-IV que s’ha descrit anteriorment, és la directa 
activació de la secreció de GLP-1. Per tant, es va voler determinar si GSPE és capaç 
d’estimular directament la secreció de GLP-1 intestinal, i si aquesta acció s’estén a 
altres enterohormones.  
2. Estudiar si l’extracte de proantocianidines de pinyol de raïm afecta a la 
diferenciació intestinal. 
En estudis previs es van observar que els tractaments crònics de GSPE contrarestaven 
la disminució de l’expressió gènica de ChgA, GLP-1 i PYY induïda per una dieta de 
cafeteria, suggerint que un possible mecanisme pel qual GSPE podria actuar en els 
tractaments crònics és la promoció de la diferenciació de les cèl·lules 
enteroendocrines. A partir d’aquests resultats, es va voler descobrir si GSPE modifica 
la diferenciació de les cèl·lules enteroendocrines. 
3. Estudiar si l’extracte de proantocianidines de pinyol de raïm modifica la biota 
intestinal i si aquesta modulació influeix el sistema enteroendocrí. 
En els darrers anys, ha augmentat l’interès sobre la composició de la biota intestinal i 
la seva modulació degut a la seva influència en el metabolisme de l’hoste. Alguns 
estudis han descrit que altres extractes rics en compostos fenòlics tenen la capacitat de 
modular la composició de la biota intestinal, encara que cap d’aquests van avaluar la 
interferència entre aquesta modulació i el sistema enteroendocrí. Partint d’aquesta 
base, es va voler explorar si GSPE modifica la composició de la  biota intestinal i si 
aquesta modulació pot estar relacionada amb la modulació del sistema enteroendocrí. 
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4. Avaluar si els pèptids bioactius procedents de pota de pollastre modulen el 
sistema d’incretines afectant la secreció i escissió de GLP-1. 
Resultats previs van descriure que GSPE millora la homeòstasi de glucosa, en part, per 
mitjà de la modulació dels nivells de GLP-1. Per descobrir nous compostos bioactius els 
quals puguin també exercir els seus efectes mitjançant la modulació dels sistema 
d’incretines a nivell intestinal, es van examinar hidrolitzats proteics procedents de 
pota de pollastre. Es van buscar pèptids bioactius que influeixin  a l’hormona incretina 
GLP-1, mitjançant diferents mecanismes, i conseqüentment, que millorin la homeòstasi 
de la glucosa. 
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PREFACE 
In the first manuscript, we focused on studying the acute effect of grape-seed 
proanthocyanidin extract (GSPE) on the main enterohormones secretion (objective 
1).  
An ex vivo model was employed to elucidate if GSPE directly acts on 
enteroendocrine cells modulating the secretion of enterohormones. The ex vivo 
model enables us to study the specific hormone secretion patterns of different 
subtypes of enteroendocrine cells distributed along of the gastrointestinal tract. 
Moreover, to simulate the in vivo conditions, the intact extract was employed to 
treat upper-intestine sections, while GSPE metabolites obtained from caecum 
extraction after GSPE administration were employed to treat colon segments. 
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ABSTRACT  
Background: Intestinal enteroendocrine cells respond to food components by 
secreting an array of hormones that regulate several functions. We have previously 
shown that grape seed proanthocyanidins (GSPE) modulate plasma GLP-1 levels.  
Objective: This study aimed to deepen on the knowledge of the mechanisms used by 
GSPE to increase GLP-1, and extend it to its role at modulation of other 
enterohormones.  
Design: We used an ex vivo system to test direct modulation of enterohormones; STC-1 
cells to test pure phenolic compounds; and rats to test the effects in vivo at different 
gastrointestinal segments.  
Results: Our results show that GSPE compounds act at several locations along the 
gastrointestinal tract modulating enterohormone secretion depending on the feeding 
condition. GSPE directly promotes GLP-1 secretion in the ileum, while 
unabsorbed/metabolized forms do so in the colon. Such stimulation requires the 
presence of glucose. GSPE enhanced GIP and reduced CCK secretion, and gallic acid 
could be partly responsible for this effect.  
Conclusions: the activity of GSPE modulating enterohormone secretion along the 
gastrointestinal tract may help to explain its effects at regulation of food intake and 
glucose homeostasis. We show that GSPE acts through several mechanisms; 
compounds found in GSPE and their metabolites act as GLP-1 secretagogues in ileum 
and colon, respectively. In vivo GLP-1 secretion might also be mediated by indirect 
pathways involving modulation of other enterohormones that in turn regulate GLP-1 
release, such as enhancing GIP and reducing CCK secretion in the duodenum. 
Keywords: Phenolic compounds, ileum, colon, enterohormone, GLP-1 
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INTRODUCTION  
The intestinal endocrine cells are the largest organ in the human body. They are 
responsible for the secretion of enterohormones such as glucagon-like peptide-1 –
(GLP-1) and glucose-dependent insulinotropic peptide (GIP) (together called the 
incretins), peptide tyrosine tyrosine (PYY), cholecystokinin (CCK), and ghrelin, which 
are involved in the modulation of food intake, digestion, insulin secretion and 
metabolism. New functions for these hormones are still being studied. The modulation 
of intestinal enterohormone pathways has attracted increasing interest in the fight 
against wide spread pathologies such as obesity and type 2 diabetes. Incretin-based 
therapies have been established for type 2 diabetes and involve the use of GLP-1 
analogues to increase GLP-1 receptor agonist concentrations in the pharmacological 
range and dipeptidyl peptidase-4 (DPP-4) inhibitors to prevent the degradation of 
endogenous GLP-1 and GIP, which are both substrates for the DPP-4 enzyme, elevating 
their plasma levels (1). The most effective way to increase enterohormones, especially 
GLP-1 and PYY, is the bariatric bypass known as Roux-en-Y, which is used to treat 
obesity and also leads to normalization of glucose homeostasis in diabetic patients. 
GLP-1 secretagogues are therefore in the spotlight as promising therapies against type 
2 diabetes and for weight management. 
Although studies are being carried out on pharmacological compounds, there are also 
natural products with capabilities to enhance enterohormone levels, and these could 
be used as a complementary therapy or in the area of functional foods. They have been 
reviewed, and more recently (2,3). Even for these types of product, a complete 
description of their mechanisms of action is compulsory if their use is to be 
recommended for a target population. In this regard, grape seed proanthocyanidin 
extract (GSPE) has been shown to modulate glucose homeostasis and food intake, and 
this in part is mediated through increases in plasma GLP-1 levels (4,5). GSPE has DPP4 
inhibitory properties, but its effects on GLP-1 secretion need further analysis. In vivo 
studies revealed that increases in plasma GLP-1 levels are only observed after a 
glucose or meal load, which raises the question of whether GSPE compounds might 
directly stimulate secretion or modulate the interaction of nutrients with the 
enteroendocrine cells, for instance making it possible for them to reach more distal 
parts of the intestine. It has been suggested that the monomeric flavanols found in 
GSPE bind and activate bitter taste receptors, which, in turn, are regarded as 
interesting targets to modulate enterohormone secretion.  
In this study we aim to deepen on the knowledge of the mechanisms used by GSPE to 
increase GLP-1 levels, and to determine whether it also modulate other 
enterohormones. 
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MATERIALS AND METHODS 
Materials 
GSPE was obtained from Les Dérivés Résiniques et Terpéniques (Dax, France). The 
same batch (#124029) was used in all the studies. According to the manufacturer, the 
extract contains monomeric (21.3 %), dimeric (17.4 %), trimeric (16.3 %), tetrameric 
(13.3 %) and oligomeric (5–13 U; 31.7 %) proanthocyanidins. The small molecules 
were previously characterized by liquid chromatography-tandem mass spectrometry 
(6). A detailed phenolic composition of this GPSE is included in Supplemental Table 1. 
(-)-Epicatechin (EC) and gallic acid (GA) were obtained from Sigma (St. Louis, USA). (-)-
Epicatechin gallate (ECg) and procyanidin dimer B2 (B2) were obtained from 
Extrasynthese (Genay, France). The procyanidin dimer B2-gallate (B2g) was obtained 
from TransMTT (Gieβen, Germany). For all the studies, stocks were prepared in 
dimethylsulfoxide (DMSO) and further diluted in the specific buffer required for each 
experiment. 
Cell culture STC-1  
The STC-1 clonal cell line was accepted as a generous gift from Dr. B. Wice 
(Washington University of St. Louis) with the permission of Dr. D. Hanahan (University 
of California, San Francisco, CA). This enteroendocrine cell line was derived from a 
double-transgenic mouse tumor (7) and cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) with GlutaMAX containing 4.5 g/l D-glucose, without sodium 
pyruvate (Thermo Fisher Scientific, Madrid, Spain), supplemented with 17.5% foetal 
bovine serum, 100 U/ml penicillin, and 100 mg/l streptomycin (BioWhittaker, 
Barcelona, Spain), and incubated in a 5% CO2-humidified atmosphere at 37 °C. Cells 
were used between passage numbers 30-50. 
Cellular membrane potential of STC-1 
To evaluate membrane potential, STC-1 cells were seeded in a 96-well culture plate at 
a density of 70,000 cells/well for 2 days until they reached 80-90% confluence. The 
cellular membrane potential (ΔΨcell) was determined in accordance with the method 
described by Gonzalez-Aubin et al. (8). Briefly, the ΔΨcell was evaluated using 
fluorescent probe DIBAC4 diluted in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES) with 10 mM glucose, which was monitored with excitation and emission 
filters set at 493 nm and 516 nm- respectively. Labeled cells were stimulated with pure 
compounds and added to a final concentration of 1, 10, 100 and 200 μM. 
Enterohormone release from STC-1 
For secretion studies, 2.0 × 105 cells/well cells were seeded in 24-well culture plates 
for 2 days to enable 80-90% confluence to be reached. On the day of the experiment, 
the cells were washed twice with HEPES (20 mM HEPES, 140 mM NaCl, 4.5 mM KCl, 1.2 
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mM CaCl2, and 1.2 mM MgCl2 at pH 7.4). Pure phenolic compounds dissolved in HEPES 
buffer with 10 mM glucose were added to each well, using HEPES buffer 0.05% DMSO 
as vehicle. After an incubation period of 2h at 37ºC, supernatants were collected, 
centrifuged to remove remaining cells and stored at -80ºC until used to determinate 
hormone concentration.  
Enterohormone release from intestinal segments 
Rats were killed and their intestines dissected out. For hormone analysis, samples 
were collected from three different positions along the GI tract: proximal duodenum, 
distal ileum and ascending colon. The tissue was rinsed with ice-cold Hank’s balanced 
salt solution (HBSS; Thermo Fisher Scientific, Madrid, Spain) and dissected in 
segments of tissue (0.75 cm2). After a 10 min washing period, tissue segments were 
placed in prewarmed (37 ºC) Krebs buffer 0.1% DMSO containing the compounds to be 
tested with 10 mM glucose or without glucose and 0.1 mM Diprotin A (Enzo Life 
Sciences International, New York, USA)). Duodenal and ileum segments were treated 
with GSPE or GA and colonic segments were treated with phenolic metabolites from 
caecal content for 1h in a humidified incubator at 37ºC and 5% CO2. To obtain the 
phenolic metabolites, rats (n=7) were administered a GSPE dose of 500mg/kg BW by 
intragastric gavage 80 min before sacrifice and the caecal content was extracted, with 
the phenolic content of the caecum of non-treated rats being used as a control. The 
caecal mass (1 g) was dissolved in 10ml/g PBS (pH 2) and the phenolic compounds 
were extracted twice with 10ml/g ethyl acetate. The organic fraction was nitrogen-
dried overnight and reconstituted in 3ml Krebs buffer 0.1% DMSO for the treatments 
(9,10).  
Tissue viability was checked by the absence of the cytoplasmic marker lactate 
dehydrogenase (LDH) in the incubated solutions. LDH was analysed using an LDH kit 
(QCA (Tarragona, Spain)).  
Animals and experimental design. 
Two sets of female Wistar rats -weighing 180–200 g- were obtained from Harlan 
(Barcelona, Spain). The subjects were single housed at 22 °C under a 12 h light/dark 
cycle (lights on at 8 am) with access to standard chow pellets (Teklad Global Diets 
#2014, Harlan, Barcelona) and tap water ad libitum during a 1 week adaptation period. 
All procedures were approved by the Experimental Animal Ethics Committee of the 
Universitat Rovira i Virgili. 
For the acute treatment in fasting conditions, overnight fasted female rats (n=5) were 
treated with 1g/kg GSPE at the end of the dark period by an oral gavage 
administration. Vehicle (tap water)-treated rats (n=5) were used as a control group. 
The abdominal cavity was incised and the portal vein catheterized while body 
temperature was monitored. Portal blood was obtained at 60 minutes under sodium 
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pentobarbital anaesthesia before the rats were killed by exsanguinations of the aortal 
vein.   
To assess the effects of an acute dose of GSPE in feeding condition, female rats were 
treated as previously described  (11). In brief, animals were fasted from 15.00 h until 
18.00h and then treated with 1 g/kg GSPE (n=11) or vehicle (n=10) (tap water) by an 
oral gavage administration. The animals were then anaesthetized with 70 mg/kg BW 
i.p of sodium pentobarbital and the portal vein was catheterized and at 60 min after 
the dose, 5 ml mash containing 1.5 g of standard chow and 25 mg of xanthan gum as a 
stabilizer was punctured into the forestomach with an Abbocath-T 18G catheter 
(Hospira, Lake Forest, IL, USA) at a constant rate of 1 ml/min. Portal blood samples 
were obtained at 80 min from the beginning. After the 120 min procedure, the animals 
were sacrificed by exsanguination of the aortal vein.  
In both models, intestinal segments from the duodenum, jejunum, ileum and proximal 
colon were dissected, immediately frozen in liquid nitrogen and then stored at -80º C 
for further enzyme activity and gene expression analysis.  
Enterohormone and glucose quantification 
The active GLP-1 concentration from STC-1, intestinal segments and plasma samples 
was analysed with a GLP-1 3-37 amide ELISA kit (Millipore, Billerica, MA, USA). Total 
CCK from STC-1 and plasma samples were analysed with a CCK enzyme immunoassay 
(EIA) kit (Raybiotech, Norcross, GA, USA) and duodenal segments with a CCK8 
(desulfated) EIA Kit (Peninsula Laboratories, San Carlos, CA, USA). Total GIP levels 
from duodenal segments were analysed by a total GIP ELISA kit (Millipore, Billerica, 
MA, USA). PYY from intestinal segments and plasma samples were measured using a 
fluorescent immunoassay kit (Phoenix Pharmaceuticals, Burlingame, CA, USA). Glucose 
plasma levels were analysed with an enzymatic colorimetric kit (glucose oxidase-
peroxidase method; QCA, Tarragona, Spain). 
Measurement of glucose-6-phosphatase enzyme activity from liver and intestine 
Liver and intestinal mucosa activities were determined following a modified version of 
the previously described protocol (12). Tissues were homogenized in 0.1 M cacodylate 
buffer (pH 6.5) using a Qiagen Tissuelyser (Qiagen, Hilden, Germany). The suspension 
was centrifuged and the supernatant incubated in the buffer containing 10 mM 
glucose-6-phosphate at 37º for 20 min. The reaction was stopped at different times of 
point by adding 100 g/L trichloroacetic acid. Glucose-6-phosphatase (G6Pase) activity 
was determined by measuring the amount of glucose release from glucose-6-
phosphatase using a glucose oxidase/peroxidase coupling system. To assess G6Pase 
liver activity, the increase of glucose production was measured using an enzymatic 
colorimetric kit (glucose oxidase-peroxidase method; QCA, Tarragona, Spain). G6Pase 
intestinal activity was assayed following Petrolonis et al. (13), using an Amplex® Red 
Glucose/Glucose Oxidase Assay Kit (Thermo Fischer Scientific, Barcelona, Spain). Both 
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enzymatic activities were normalized with mg of protein, which was analysed with a 
BCA Protein Assay Kit (Thermo Fischer Scientific, Barcelona, Spain), using bovine 
serum albumin as standard. 
Quantitative real-time RT-PCR analysis 
Total RNA was extracted using Trizol (Thermo Fisher Scientific, Madrid, Spain) and 
trichloromethane-ethanol (Panreac, Barcelona, Spain), and purified using a Qiagen 
RNAeasy kit (Qiagen, Hilden, Germany). The complementary DNA (cDNA) was 
generated using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Waltham, USA). Quantitave polymerase chain reaction amplification 
amplification was performed using specific TaqMan probes (Applied Biosystems, 
Waltham, USA) and the relative expression of each gene was calculated against the 
control group using the 2-ΔΔCt method, with cyclophilin A (PPIA) as reference. 
Statistical analysis 
Results are presented as mean ± SEM. Data were analysed with SPSS (IBM, Chicago, 
USA). Data from intestinal segments and STC-1 hormones, gene expression, enzyme 
activity and glucose plasma levels were analysed by Student t-tests. The dose-response 
effect of pure compounds on cellular membrane potential was analysed by one-way 
ANOVA. Significance was accepted over 5%. 
RESULTS  
GSPE stimulates enterohormone secretion ex vivo  
The effects of GSPE on enterohormone secretion were tested in an ex vivo intestine 
model. Bearing in mind that the enteroendocrine cell type is specialized in expressing 
different hormones throughout the intestinal tract, GIP and CCK were studied in 
duodenal segments and GLP-1 and PYY in ileum and colon segments (14). GSPE 
showed a selective effect at stimulating enterohormone secretion, since in duodenum 
explants 0.2 mg GSPE/ml (0.17 mg phenolics/ml) increased GIP but decreased CCK 
secretion (Table 1). In ileum explants the same GSPE dose significantly increased 
secretion of GLP-1 and, to a lower extent, that of PYY (Table 1). Lower concentrations 
of GSPE were also tested and showed no stimulation of GLP-1 secretion (values 
normalized to those of controls: 1.00 ± 0.08; 1.14 ± 0.12; 1.22 ± 0.32 for control, 0.1 mg 
GSPE /ml and 0.08 mg GSPE /mL, respectively).  
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Table 1 
Increase in enterohormone concentration in the medium due to GSPE or GA treatment in 
explants from different intestinal segments. 
 Duodenum Ileum 
 GIP CCK GLP1 PYY 
GSPE (0.2 mg/mL) 3.32 ± 2.0* - 0.46 ± 0.0* 2.37 ± 0.6* 1.10  ± 0.3* 
GA (31 μg/mL) 0.16 ± 0.2 -0.53 ± 0.1* 2.17 ± 1.2 - 
Results are expressed as relative units v. control. * statistically significant differences at p≤0.05, t-student. 
In the gastrointestinal tract GSPE is partially absorbed and metabolized, so digested 
GSPE was used to evaluate the effect at colon. Proximal colonic sections were 
incubated for 1 hour with non-absorbed phenolic metabolites obtained from the caecal 
content of animals treated with GSPE and the caecal content of non-treated rats as 
control. The phenolic concentrations of treated and control colon sections were 188.44 
± 7.02 mg phenolics/l and 88.76 ± 20.64 mg phenolics/l respectively. The caecal 
content of GSPE-treated rats enhanced GLP-1 secretion and tended to increase PYY 
levels (Table 2).  
 
Since GSPE is a complex mixture of several compounds, we aimed to identify those 
mainly responsible for the modulation of enteroendocrine secretions working with 
pure flavanol compounds. Given that some of these compounds could only be obtained 
in very small amounts, we had to use STC-1 cell line which secretes GLP-1 and CCK in a 
reproducible way (15,16). The in vitro results showed an inhibition of GLP-1 and CCK 
levels by 200 μM of ECG and B2 (Fig. 1). Similarly, the same concentration of B2g 
decreased GLP-1 secretion, respectively (Fig. 1). A lower concentration showed no 
differences among monomers in the CCK secretion, while a decrease was observed 
using 1 μM of dimer B2 (Fig. 1B). The inhibition of hormone secretion by high (200 
µM) doses of compounds was in agreement with a cell membrane hyperpolarization 
found when cell membrane potential was assessed  (Fig. 1). 
Gallic acid is a non-flavanol phenolic compound found in significant amounts in grape-
seed derived extracts (Supplemental Table 1). Its effects were assayed in the ex vivo 
explants and in STC-1 cells. In ex vivo explants, 6.2 µg/ml of GA caused no significant 
Table 2 
GLP1 and PYY secretion to the medium in colon explants 
after a 1-hour treatment with digested GSPE 
 
GLP1 PYY 
Control 1.00  ± 0.0 1.00  ± 0.0 
Digested GSPE 1.34  ± 0.1* 1.32  ± 0.2# 
Results are expressed as relative units v. control. * P<0.05 v. 
control; # P<0.05 v. control, t-student. 
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effect in stimulating enterohormone secretion and, this dose is within the range of 
concentration found in 0.2 mg GSPE/ml. A dose five times higher (31 µg/ml of GA) 
significantly decreased in vitro GLP-1 secretion (values normalized to those of the 
controls: 1.00 ± 0.10 and 0.72 ± 0.07 for control and 31 µg GA /ml, respectively, 
p<0.05). In ex vivo explants this dose caused no significant effect on PYY or GLP-1 
release, but it inhibited CCK release to the medium by around 50%, similarly to GSPE 
(Table 1).  
 
 
Fig. 1.  Effects of flavonols on enterohormone secretion and cellular membrane potential in STC-1 cells. 
STC-1 cells were treated for 2 hours with 200 µM and 1 µM of different flavanols found in GSPE. GLP-1 (A) 
and CCK (B) levels were measured in the culture medium. Effects of flavanols on cellular membrane 
potential after epicatechin stimulation expressed as % F/F0 and relative Δ(F/F0) (normalized to the 
control cells) (A), where F is fluorescence at 195 s and F0 is basal fluorescence at 180 s.  The data are 
displayed as the mean ± SEM. * statistically significant differences versus controls at P < 0.05. a,b,c,d, 
statistically significant differences at P < 0.05.  
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GSPE affects colonic enterohormone gene expression depending on the feeding 
condition 
In vivo we previously found that GSPE increases portal active GLP-1 only in the 
presence of glucose in the intestine (4). We next analysed how the feeding condition 
affected GSPE action throughout the intestinal tract by comparing overnight fasted 
animals to fed animals. Table 3 shows that 1g GSPE /kg bw load in fasted animals led 
to a reduced expression of GLP-1, PYY and CCK in the colon. Conversely, the plasma 
levels of these enterohormones were not significantly changed (Supplemental Table 
2). 
In animals that after a 1-hour treatment with GSPE were administered food for 1 more 
hour, we found no differences in enterohormone gene expression. In our experimental 
conditions, there were also no differences in the gene expression of these hormones 
between the fed and the fasted control animals. As previously published, these animals 
showed a modified enterohormone plasma profile (5). We also tested the effects of 
GSPE in a cell differentiation marker previously shown as a target for GSPE, 
chromogranin (CgA). Table 3 shows that a high acute dose, independently of assay 
conditions (fed or fasted), increases gene expression.  
Table 3 
Gene expression of the enterohormones from fasted and fed rats. 
  conditions 
 
 
fasted  fed 
GLP-1 colon Ctrl 1.06 ± 0.2 1.12 ± 0.2 
 1g GSPE/Kg bw 0.53 ± 0.0* 1.07 ± 0.2 
PYY colon Ctrl 1.05 ± 0.2 1.13 ± 0.2 
 1g GSPE/Kg bw 0.40  ± 0.0* 1.32 ± 0.3 
CCK colon Ctrl 1.01  ± 0.1  1.81 ± 0.8 
 1g GSPE/Kg bw 0.36  ± 0.2* 1.09 ± 0.3 
Cga colon Ctrl 1.11  ± 0.3 1.00 ± 0.0 
 1g GSPE/Kg bw 2.76  ± 0.5* 2,94 ± 0.5* 
Results are expressed as relative units v. control. * statistically significant differences at p≤0.05, t-student 
Role of glucose in the effect of GSPE’s stimulation of GLP-1 release  
Since GSPE increases GLP-1 levels only after feeding (Supplemental Table 2) or an oral 
glucose load, we next used our ex vivo model to analyse whether glucose was required 
for the direct GSPE stimulation of GLP-1 release. The stimulation of GLP-1 secretion 
achieved by GSPE in medium containing glucose 10 mM (shown in Table 1) was not 
observed in medium without glucose or with only glucose (1.00 ± 0.1, 1.21± 0.1 and 
1.17 ± 0.1 in 0 mM glucose, 10 mM glucose and 0.2 mg of GSPE/ml with 0 mM glucose,  
respectively; data normalized by 0 mM glucose). 
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In our explant system, glucose can reach the cells either from the apical or the 
basolateral side. To estimate the possible contribution of basolateral glucose presence, 
we measured portal glucose levels in the fed and fasted animals. Fig. 2 shows that 
portal levels of glucose in overnight-fasted animals treated with GSPE were around 10 
mM, while in animals that after 1 hour of GSPE treatment were administered a food 
load, 20 min after this load glucose levels were around 8 mM (significantly different 
from the fasted animals p≤0.05). In the fed model the glucose levels of GSPE-treated 
animals did not differ from the controls, while in the fasted animals GSPE significantly 
increased portal glucose (Fig. 2).  
 
 Fig. 2.  Effects of GSPE on portal glucose. In the fasted group, portal glucose levels of O/N fasted animals 
treated with GSPE for 1 hour. In the fed group, 4 hours-fasted animals were treated with GSPE for 1 hour, 
and then administered a food load. Portal glucose levels were measured 20 minutes after this food load. * 
statistically significant differences versus controls at P < 0.05 
Finally we analysed whether GSPE modulation of portal glucose levels involved 
modulation of intestinal gluconeogenesis. To do this, G6Pase activity was measured in 
the duodenum and jejunum sections of fasted and fed animals. Table 4 shows that 
GSPE inhibits G6Pase activity. In the fasted animals GSPE inhibited around 60% of 
intestinal activity (in both measured sections), and in the fed animals this inhibition 
was stronger, reaching 80% (also in both measured sections). We also measured it in 
the liver of fed animals and found that there was no change in this enzyme’s activity 
due to GSPE treatment (1.00 ± 0.1, 1.02 ± 0.1 in control and treated animals 
respectively, data normalized by controls).  
Table 4  
Glucose-6-phospatase intestine activity from fasted and fed rats. 
  conditions 
  fasted fed  
G6Pase duodenum Ctrl 1.00 ± 0.2 1.00 ± 0.2 
1g GSPE/Kg bw 0.31 ± 0.0* 0.24 ± 0.0* 
G6Pase jejunum Ctrl 1.00 ± 0.2 1.00 ± 0.2 
1g GSPE/Kg bw 0.45 ± 0.1* 0.21 ± 0.0* 
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DISCUSSION 
We have previously shown that GSPE increases plasma active GLP-1 levels, that this is 
in part due to inhibition of DPP4 but also to increased secretion, and that this leads to 
modulation of glucose homeostasis and satiety (4,5). In this paper, we describe for the 
first time how GSPE directly modulates enteroendocrine secretions and that it does so 
differently depending on the intestinal fragment. We also go further into the possible 
mechanisms for GSPE to exert such modulation of enterohormone secretion and 
production.  
In this study we have used an ex vivo system to show that GSPE directly stimulates 
GLP-1 release in the intestine. Direct stimulation could therefore contribute to the 
previously reported increase in GLP-1 levels (4). Concerning the mechanisms, we have 
described that this direct GLP-1 release by GSPE stimulation requires glucose. 
Furthermore, glucose must be sensed on the luminal side. This agrees with acute in 
vivo results in which, to observe GSPE effects on GLP-1 secretion, either glucose or 
meal must be added (4,5). Our results suggest that the effects of GSPE are not 
secondary effects on glucose absorption and/or metabolism, but direct effects on 
enteroendocrine cells. A possible explanation for the requirement of glucose could 
involve a ‘priming’ effect by GSPE of the L-cell in preparation for the subsequent oral 
glucose-stimulated GLP-1 secretion. This ‘priming effect’ has previously been shown 
for ghrelin (17) and insulin (18). Ghrelin pretreatment of GLUTag and NCI-H716 cell 
lines stimulates GLP-1 release only in a medium containing glucose, similarly to what 
we observe in GSPE treatments. Furthermore, in vivo ghrelin induces GLP-1 release 
only when an oral glucose load is performed, which is also in concordance with our 
previous in vivo results (4). Unfortunately, these priming events are still not fully 
described at the molecular level. Light has only been shed on the requirement of the 
mitogenactivated protein kinase (MAPK) pathway and MEK-ERK1/2 (17,18), which is 
a pathway previously shown to be a target for grape seed proanthocyanidins (19).  
An unexpected increase in portal glucose levels by GSPE was observed in fasted 
animals, and we wanted to analyse the role of intestinal gluconeogenesis in this 
increase. Intestinal gluconeogenesis has been shown as a mechanism used by different 
food agents to modulate feeding behaviour (20). Our results suggest an inhibition of 
intestinal gluconeogenesis by acute GSPE treatment. The increased portal glucose may 
therefore be due to reduced glucose uptake by the liver and pancreas, since 
polyphenols have been previously shown to inhibit the glucose transporter Glut-2 
(21,22) and GSPE down-regulates the glucose transporter Glut-2 and glucokinase 
expression in liver and pancreas (23). Certainly, considering that glucose may control 
hunger sensation from the portal vein via signalling to the peripheral neural system 
(24), increasing portal glucose levels during fasting could, at least in part, contribute to 
the previously reported (5) satiating effects of GSPE. 
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GSPE is composed of several different molecules with different bioavailability (25). 
Polyphenol absorption in the small intestine is in fact relatively low (5%–10%) in 
comparison to other macronutrients or micronutrients, mainly those with monomeric 
and dimeric structures (26). The remaining  90%–95% of polyphenols, mainly the 
polymeric and oligomeric forms, pass through the large intestinal lumen and 
accumulate in a millimolar range, reaching the colon where they are subjected to 
microbial catabolism(27). As shown in rats treated with the same extract as ours, some 
final products of colonic metabolites such as 3-O-methylgallic acid and benzoic acids 
could be detected in the kidneys and liver after 2 hours (25), showing that some GSPE 
compounds, most likely polymeric forms, circulate through the GI tract and reach the 
colon. Our results show that GSPE treatment decreased CCK levels in duodenum 
segments. We had previously shown that in vivo GSPE impaired CCK release after food 
intake (5). Inhibition of CCK ex vivo is reproduced by gallic acid, a compound found in 
the extract mixture. The effects of mainly monomeric and dimeric structures of GSPE 
were also tested in STC-1 cells, and our data show an inhibition of CCK levels. This 
suggests that molecules that are well absorbed in the upper intestine could be 
responsible for this direct inhibition. We also found that this inhibition does not lead to 
a modulation of CCK basal plasma levels in fasted animals (where CCK release is not 
stimulated). Regarding GLP-1 secretion, which as previously mentioned, was increased 
by GSPE in ileum segments, our in vitro results in STC-1 cells show that GLP-1 levels 
are also decreased by a low degree of polymerization structures. Our results also show 
that metabolites of digested GSPE promote colonic GLP-1 release. In contrast to CCK 
secretion, these findings could suggest that unabsorbed polyphenols (high degree of 
polymerization) and microbiota-metabolized polyphenols of GSPE act on endocrine 
cells to promote GLP-1 secretion. In agreement with this, a previous study 
demonstrated that a tetrameric procyanidin increases GLP-1 levels in mice and is more 
effective to insulin stimulation than smaller procyanidins (28). Montagut et al. also 
demonstrated that oligomers can activate insulin signalling and stimulate glucose 
uptake (19). Our findings suggest that the absorption and bioavailability of GSPE 
polyphenols could be involved in enteroendocrine secretion, although further study is 
needed to understand procyanidin’s effects on enterohormone secretion in more 
detail. 
Another function that might be modulated by GSPE is the inhibition of G6Pase activity, 
since the levels of inhibition are the same in the different parts of the intestine where it 
has been measured (i.e. duodenum and jejunum). The inhibition of G6Pase was 
dependent on the feeding condition. We analysed two animal models that received 1h 
GSPE treatment, one sacrificed in an overnight fasting condition and the other fasted 
for 3 hours and then administered a food load in the stomach 60 min after the GSPE 
dose to determine the effect of feeding. Our results show that inhibition of G6Pase was 
much stronger in the fed animals. In addition, the feeding condition also determined 
the effects of GSPE at gene expression level. We found a down-regulation of GLP-1, PYY 
and CCK at colon level in fasted animals treated for 1 hour with GSPE. Modulation of 
Acute bioactivity of GSPE on enteroendocrine secretions 
 
101 
 
gene expression of enterohormones has been studied at the level of intestinal stem cell 
differentiation (29,30). Some studies show that the messenger RNA (mRNA) of 
enterohormones can also be acutely regulated. In rodents, refeeding after a fasting 
period (31) or feeding a specific nutrient such as palmitoleic acid (32) modulates the 
mRNA levels of enterohormones within a short time (1-2 hours). In vitro models have 
also shown acute modulation of enterohormone gene expression by hormones such as 
insulin (33,34) and nesfatin (35,36). In addition, our results show that when a food 
load was administered after the GSPE, there were no differences between GSPE and 
controls. This suggests that the effects of nutrients (either directly or mediated by 
changes in hormones) counteract the down-regulation of GSPE. It should be noted that 
the fed study was performed after a shorter (3 hours) fasting period, so we cannot be 
sure that GSPE had the same effects on gene expression as in our fasting (overnight) 
experiment. Certainly, the fasted animals where down-regulation was observed 
showed no differences in GLP-1 and CCK plasma levels. At present we do not know 
whether such down-regulation at colonic levels might influence enterohormone 
secretion or if it is involved in the previously mentioned “priming”effect. We also 
observed that a previously described target of GSPE (37), chromogranin A (CgA), was 
up-regulated in both conditions. CgA is a marker for enteroendocrine cells (38), but it 
is unlikely that such short periods of treatment would already affect the number of 
enteroendocrine cells in the colon. There is a lack of information regarding acute 
regulation of CgA expression in the intestine. However, future work will focus on the 
effects of GSPE on the differentiation of enteroendocrine cells. GSPE treatment 
produced a significant induction of other enterohormone secretion in different parts of 
the intestine. In the duodenum, GSPE directly enhances GIP secretion, which could 
contribute to in vivo GLP-1 secretion due to the enteroendocrine loop between the 
duodenal GIP and the ileal GLP-1 (39). In the ileum, GSPE also promotes PYY secretion, 
to a lesser extent than that of GLP-1, while a trend data was observed in the colon. It 
was shown that soy isoflavones enhance PYY secretion in humans (40), although there 
are few data on the effects of polyphenols on PYY secretion. Altogether, these results 
reinforce the idea that GSPE has effects throughout the gastrointestinal tract, and that 
a feeding condition modulates the effects. Further studies are needed to go into greater 
detail regarding the GSPE effects on gastrointestinal tract. 
In conclusion, the compounds of GSPE act at several points of the gastrointestinal tract 
modulating enterohormone secretion, which leads to regulation of food intake and 
glucose homeostasis. The present results suggest that compounds found in GSPE 
directly promote GLP-1 secretion in the ileum, and its metabolites do so in the colon. 
Such direct stimulation requires activation of glucose-induced GLP-1 releasing 
pathways. In vivo GLP-1 secretion may also be mediated by indirect pathways 
involving modulation of other enterohormones that, in turn, regulate GLP-1 release, 
such as enhancing GIP and reducing CCK secretion in the duodenum (the latter effect 
being mediated, at least in part, by gallic acid).  
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SUPPLEMENTARY MATERIAL  
Table 1 
Main phenolic compounds of the grape seed phenolic extract (GSPE) used in this study, adapted 
from (Margalef et al., 2015). 
 
Compound Concentration (μmol/g) 
Gallic acid 182.64 ±0.47 
Protocatechuic acid 8.69 ±0.13 
Vanillic acid 4.58 ±0.24 
(+)-Catechin 417.96 ±11.75 
(-)-Epicatechin 321.91 ±14.71 
Epicatechin gallate 47.57 ±2.44 
Epigallocatechin 0.88 ±0.10 
Epigallocatechin gallate 0.07 ±0.00 
Procyanidin dimer B1 153.50 ±5.98 
Procyanidin dimer B2 57.46 ±2.40 
Procyanidin dimer B3 209.71 ±5.89 
Gallated dimers 12.13 ±0.19 
Trimers 6.65 ±0.54 
 
 
 
 
 
Table 2. 
 Portal hormone levels 60 min after the GSPE gavage 
 
hormone Control 1g GSPE/Kg bw 
GLP-1 (pmol/L) 1.80 ± 0.33 2.72 ± 0.77 
PYY (μg/L) 0.14 ± 0.07 0.09 ± 0.04 
CCK (μg/L) 0.52 ± 0.05 0.53 ± 0.07 
No significant differences, assessed by t-test (p < 0.05) were found between control and GSPE. 
 
 
References: 
Margalef, M., Pons, Z., Iglesias-Carres, L., Bravo, F. I., Muguerza, B., & Arola-Arnal, A. 
(2015). Lack of Tissue Accumulation of Grape Seed Flavanols after Daily Long-
Term Administration in Healthy and Cafeteria-Diet Obese Rats. Journal of 
Agricultural and Food Chemistry, 63(45), 9996–10003.  
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PREFACE 
The second manuscript aimed to evaluate whether GSPE affects the enteroendocrine 
system modulating intestinal differentiation (objective 2). 
In the recent years, a three-dimensional intestinal culture model has been developed.  
In this system, single Lgr5+ stem cells generate spherical structures, so-called 
organoids, which contain all cell types of the intestinal epithelium comprising multiple 
crypts and villus structures. Therefore, organoids culture has become a powerful tool 
to study the intestinal cell differentiation because of their self-renewing capacity and 
intestinal physiological structure. 
Consequently, organoids culture was employed to elucidate the second objective, 
studying GSPE’s effect on gene expression of the main L-cell differentiation markers 
and transcription factors involves in such differentiation, as well as evaluating the 
secretion of GLP-1 and PYY in mid-term treatments.  
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PREFACE 
The third manuscript was aimed to determine the effect of grape-seed 
proanthocyanidin extract (GSPE) on the gut microbiota composition and to explore 
whether such effect might be linked to host metabolism and especially to the 
enteroendocrine system (objective 3). 
An in vivo model was employed because it enabled us to analyze the gut microbiota 
composition in physiological environment and the crosstalk between host metabolism 
and the gut microbiota profile. To reach the goal proposed, the gut microbiota 
composition of different experimental groups was evaluated, as well as different 
metabolic and physiological parameters. Moreover, correlation analysis was employed 
to compare metabolic/physiological parameters with the gut microbiota profile. 
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ABSTRACT  
Grape seed proanthocyanidin extract (GSPE) modulates several parameters involved 
in metabolic syndrome. GSPE is a mixture of compounds, some which are rapidly 
absorbed, while others remain in the lumen where they might have effects that are 
translated to the whole organism. Our aim was to decipher if the 8-day treatment of 
GSPE, previously shown to reduce food intake, induces changes in the microbiota and 
enterohormone secretion. The ratio of Firmicutes:Bacteroidetes was lower in the 
microbiota of GSPE-treated rats compared to controls, and  differences in several 
taxonomic families and genera were observed. Such modulation led to a reduction in 
cecal butyrate content. GSPE also increased plasma glucagon-like-peptide-1 (GLP-1). 
Gallic acid did not induce major changes in the microbiota profile nor in GLP-1 
secretion.  Correlations between several microbiota taxa and plasma triacylglycerol, 
adiposity, and enterohormones were observed. Modulation of microbiota may be one 
of the mechanism by which GSPE impacts metabolic health. 
 
Keywords: Proanthocyanidins, microbiota, gastrointestinal tract, enterohormone, 
GLP-1 
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INTRODUCTION  
Grape seed proanthocyanidins (GSPE) have been shown to possess several beneficial 
health properties in animals and human studies 1–4. Some of the effects could directly 
be mediated by the phenolic compounds of the extract or their metabolites, since 
derived structural components  have been found in several tissues 5 . However, other 
effects might be mediated through interactions with the gastrointestinal tract where 
they act by inhibiting enzymes 6, modulating inflammation and/or gut barrier 
properties 7, or modulating enteroendocrine secretion 8,9. The effects of flavonoids on 
gut microbiota have been recently reviewed 7; but there are few studies analyzing the 
role of proanthocyanidins on gut microbiota which could also mediate their 
physiological effects. 
Satiety-related enterohormones such as glucagon-like-peptide-1 (GLP-1), peptide YY 
(PYY), Cholecystokinin (CCK) and ghrelin are signaling molecules that could act 
through the vagus nerve to signal to the brain. GSPE acutely increases plasma GLP-1 10, 
and this has been linked to an amelioration of glucose tolerance 10 and an induction of 
satiety 11. Satiating effects have been shown to be maintained during 8 days of 
treatment with GSPE 0.5 g/kg BW in rats. Interestingly this treatment also increased 
energy expenditure, which together with reduced food intake led to a lower body 
weight gain 8. The increased satiety has been linked to ghrelin secretion modulation, 
but whether other enterohomones are regulated in this specific treatment has not been 
shown. These results point out GSPE as an interesting candidate for ameliorating 
obesity and diabetes. Some authors postulate a key role of microbiota-derived short 
chain fatty acids (SCFA) 12 on satiety-related mechanisms. In this sense, an emerging 
role for microbiota and therefore of food that modulate its composition in the control 
of metabolic homeostasis is being acknowledged. In this context polyphenols, and 
more specifically flavonoids, have been suggested to act as prebiotic components. In a 
small human study moderate red wine consumption for 4 weeks increased the phylum 
Bacteroidetes in humans, and this was correlated with a decrease in plasma 
triacylglycerol (TAG) and high density lipoprotein (HDL)-cholesterol 13. In mice, 
cranberry extract, which is rich in proanthocyanidins and flavanols, modulated gut 
microbiota by increasing the proportion of the mucin-degrading bacterium 
Akkermansia when administered to mice for 8 weeks undergoing a high-fat sucrose 
diet 14.  
 
Therefore, in the present study we explore the mechanisms that could help to explain 
GSPE effects on at the level of the gastrointestinal tract. We hypothesized that 
modulation of gut microbiota could also be a mechanism for grape seed 
proanthocyanidins to exert their effects on host metabolic health. 
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MATERIALS AND METHODS 
Materials 
GSPE was obtained from Les Dérivés Résiniques et Terpéniques (Dax, France). The 
same batch (#124029) was used in all studies. According to the manufacturer, the 
extract contains monomeric (21.3 %), dimeric (17.4 %), trimeric (16.3 %), tetrameric 
(13.3 %) and oligomeric (5–13 U; 31.7 %) proanthocyanidins. The small molecules 
were previously characterized by liquid chromatography-tandem mass spectrometry 
15. Gallic acid (GA) was obtained from Sigma (St. Louis, USA).  
Animals and experimental design. 
Female Wistar rats weighing 180–200 g were obtained from Harlan (Barcelona, Spain). 
The subjects were single housed at 22°C under a 12 h light/dark cycle (lights on at 8 
am) with access to standard chow pellets (Teklad Global Diets #2014, Harlan, 
Barcelona) and tap water ad libitum during a 1 week adaptation period. All procedures 
were approved by the Experimental Animal Ethics Committee of the Universitat Rovira 
i Virgili. 
Rats were introduced (1 week) to a daily 4 h fasting and chow was replaced in the 
dark-onset. After the adaptation, rats were daily treated during 8 days with GSPE or 
gallic acid 1 h prior to chow replacement by gavage, using tap water as vehicle. A 
control group (vehicle treated) was performed in parallel. Rats (n = 9 for each group) 
were sacrificed 80 min after the last dose. Animals were sacrificed by aortal 
exsanguination under pentobarbital anesthesia, and the heparinized and acidified 
plasma (0.1 M HCl) was stored at −80ºC. Cecal content together with intestinal 
segments from the duodenum, jejunum, ileum and proximal colon were immediately 
frozen in liquid nitrogen and then stored at -80º C for further enzyme activity and gene 
expression analysis.  
Microbiota composition analysis  
gDNA from cecal content of rats was extracted using a Fast DNA Stool Mini Kit (Qiagen) 
according to the manufacturer’s instructions with minor variations. 180-220 mg 
aliquots of cecal content were placed in sterile tubes filled with glass beads and one mL 
of Inhibitex buffer (Qiagen). Samples were homogenized in a beadbeater for 2 
successive rounds for 1 min with intermittent cooling on ice. Samples were then 
heated to 95°C for 10 min and DNA extraction was carried out according to the 
manufacturer’s standard protocol. Samples were amplified in triplicate via PCR using 
primers (S-D-Bact-0563-a-S-15 / S-D-Bact-0907-b-A-20) that target the V4-V5 variable 
regions of the 16S rDNA 16. Triplicate reactions consisted of final concentrations of 
Buffer HF (1X), dNTPs (0.11 µM), primers (0.29 µM each) and Taq Phusion High 
Fidelity (0.007 U/µL) in final volumes of 35 µL. Cycling conditions consisted of 98°C for 
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3 min, followed by 25 cycles of 95°C for 20 s, 55°C for 20 s, and 72°C for 20 s, followed 
by a final extension step of 72°C for 5 min. Each sample was tagged with a barcode to 
allow multiplexing during the sequencing process. Triplicate sample amplicons were 
combined and purified using the Illustra GFX PCR DNA and Gel Band Purification Kit 
(GE Healthcare) according to the manufacturer’s instructions and combined in 
equimolar concentrations before carrying out sequencing on a MiSeq instrument 
(Illumina).  All raw sequence data has been submitted to ENA-EMBL (Accession 
number: PRJEB21445). 
Bioinformatic processing of data was carried out using the software QIIME 17. Using 
QIIME, paired-end forward and reverse Illumina reads were joined into contigs, 
barcodes were extracted, reads were demultiplexed, and then primers were removed 
using Mothur 18. Using the UPARSE pipeline for MiSeq amplicon data 19, reads were 
clustered into OTUs, chimeras were removed and an OTU abundance table was created 
by remapping reads to representative sequences from OTUs. QIIME was then used for 
all downstream processing. All samples from the OTU abundance table were rarefied 
to the sample with the lowest number of reads and singletons were removed. 
Taxonomy was assigned to representative OTUs using UCLUST 20 against the 
Greengenes database (version 13.8) 21. 
In order to carry out alpha and beta diversity analysis, representative OTU sequences 
were aligned using PYNAST 22 against the Greengenes’ core set alignment. The 
alignment was filtered using QIIME’s default settings and a phylogenetic tree was 
constructed. Alpha diversity metrics and richness estimators (Shannon’s, Simpson’s 
reciprocal, Chao1, Simpson’s evenness, Observed OTUs) were then calculated. In order 
to examine β diversity, distance matrices (using weighted and unweighted UniFrac 
distances) and Principal Coordinates Analyses (PCoA) were performed using QIIME 
and PCoAs were visualized using the R package PhyloSeq 23. A heatplot of correlation 
analysis was constructed using heatmap2() function in the R package gplots using 
default parameters.  
Short chain fatty acid quantification   
Cecal content (~500 mg) was added to 2 ml tubes containing 900 µl QH2O and H3PO4 
(0.5% final concentration) and homogenized vigorously followed by centrifugation 
(15,000 x g, 10 min at 4°C). 350 µl of supernatant was used for the derivatization of 
SCFAs according to the methods used in Kristensen et al. 24. Derivatized SCFAs were 
analyzed using a gas chromatograph-mass spectrometer (Agilent Technologies 5977A 
MSD) with a low-resolution quadrupole analyzer and gas chromatograph (Agilent 
7890B) equipped with an apolar capillary column (30 m, 0.25 mm ID; 0.25 µm film). 
The carrier gas used was helium. A constant flow mode was used (Split 30: 1; 30 ml / 
min split flow), with an initial flow of 1 ml/min, initial temperature of 90°C for 2 min, 
5°C / min to 222°C for 5 min, followed by 20°C / min to 280°C for 2 minutes, and an 
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interphase temperature of 280°C. Three ethyl acetate washings were performed prior 
to injection of samples. 
Enterohormone and plasmatic parameters quantification 
Enterohormones were analysed using commercial ELISA kits for insulin (Mercodia, 
Uppsala, Sweden), GLP-1 7-37 amide (Millipore, Billerica, MA, USA), total CCK 
(Peninsula Laboratories, San Carlos, CA, USA), PYY (Phoenix Pharmaceuticals, 
Burlingame, CA, USA) and specific octanoyl ghrelin (Phoenix Pharmaceuticals, 
Burlingame, CA, USA). Glucose and TAG plasma levels were analysed with an 
enzymatic colorimetric kit (Glucose Oxidase-Peroxidase method from QCA, Tarragona, 
Spain). 
Measurement of DPP-IV activity. 
DPP-IV was extracted from rat intestine segments as previously described 6. Briefly, 
intestine segments were homogenized using lysis buffer (PBS containing 100 KIU/mL 
aprotinin and 1% Triton X-100). Then, the obtained samples were centrifuged at 1000 
x g at 4ºC for 10 min to eliminate the cellular debris, then centrifuged twice at 20000 x 
g at 4ºC for 10 min. Supernatants were stored at -80ºC until analysis. 
To determine DPP-IV activity, intestinal lysates were incubated with 0.2 mM - 
chromogenic substrate Gly-Pro-pNA (Bachem, Bubendorf, Switzerland) in Tris−HCl 
buffer at 37°C. The mixture was measured at 405 nm at 37°C for 30 min in a microplate 
reader. 
Quantitative real-time RT-PCR analysis. 
Total RNA was extracted using Trizol (Ambion, USA) and trichloromethane-ethanol 
(Panreac, Barcelona, Spain), and purified using a Qiagen RNAeasy kit (Qiagen, Hilden, 
Germany). The cDNA was generated using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Waltham, USA). Quantitative PCR amplification 
was performed using specific TaqMan probes (Applied Biosystems, Waltham, USA): 
Rn00563215_m1 for CCK, and Rn00562293_m1 for proglucagon. The relative 
expression of each gene was calculated against the control group using the 2-ΔΔCt 
method, with cyclophilin A, PPIA (Rn00690933_m1), as reference. 
Statistical analysis 
Morphometric, plasmatic, food intake parameters, together with enterhormone 
parameters and SCFAs are presented as mean ± SEM and were analysed with SPSS 
(IBM, Chicago, USA). These data were analysed by Student t-tests. Differences between 
means were considered significant when P<0.05.  
All statistics and data visualization for microbiota data were carried out using the R 
statistical software and related R packages or QIIME. Comparison of relative 
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abundances of each phylogenetic group between treatments was carried out for each 
phylotype (dependent variable) by Kruskal-Wallis tests followed by Wilcoxon rank 
sum tests to identify significant differences between treatments. Comparison of alpha 
diversity among dietary treatments was also performed by Kruskal-Wallis and 
Wilcoxon rank sum tests. To compare bacterial community structure, PERMANOVAs 
were carried out using the QIIME script compare_categories.py and the adonis method 
using weighted and unweighted UniFrac distance matrices. Correlation analysis was 
conducted in order to compare physiological/metabolic parameters with relative 
abundances of taxonomic groups using cor.test in R.  Significance values were 
corrected for multiple comparisons using false discovery rate (FDR) and a q-value 
<0.05 was selected as significant. 
RESULTS  
Enterohormone profile is differentially modulated by GSPE and gallic acid 
A GSPE treatment (500 mg GSPE/kg bw for 8 days), previously shown to be effective at 
inhibiting food intake in male rats 8, was reproduced in female rats in this study. To 
discriminate between the effect of GSPE versus one of its monomeric components, for 
which satiating properties have been described 25, we included a group treated with 
gallic acid at an equivalent amount to that present in the GSPE. Since we aimed to 
analyze whether there was a modulation of enterohormone secretion, we sacrificed 
the animals in a condition where anorexigenic hormone secretion is stimulated, by 
allowing the animals to eat for 20 minutes after a fasting period. At sacrifice, plasma 
levels of enterohormones were measured. GSPE-treated rats had higher active GLP-1 
and active ghrelin levels, while treatment with gallic acid did not significantly change 
such parameters (Table 1). Instead, gallic acid increased CCK levels.  
GLP-1 and CCK gene expression was assessed in the ileum and colon of the animals. 
GSPE caused a significant up-regulation of CCK gene expression in the ileum, while the 
monomer gallic acid did not induce any change in gene expression compared to the 
control animals (Table 2). In the colon there was no modification either by GSPE or the 
GA treatment (Table 2).  
The amount of GLP-1 protein was also measured in intestinal tissue of GSPE-treated 
and control animals. GSPE did not significantly modify GLP-1 protein either in the 
ileum or in the colon (Table 2).  
We previously showed that an increase in GLP-1 secretion by an acute GSPE treatment 
was in part due to inhibition of DPP-IV activity. Therefore we measured this activity in 
different intestinal segments. Our results showed no difference in any of the segments 
due to GSPE treatment. Curiously, gallic acid increased DPP-IV activity in the 
duodenum (Table S1).   
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Table 1 
Enterohormone levels in plasma, morphometric, plasmatic, food intake and SCFA parameters at 
the sacrifice day for rats in the control, gallic acid and GSPE treatments.  Values are represented 
as mean ± SEM. * P ≤ 0.05 vs. control, # P ≤ 0.1 vs. control, T test. OWAT: ovarian WAT; RWAT: 
retroperitoneal WAT; MWAT: mesenteric WAT; BAT: Brown adipose tissue. 
  Control Gallic acid GSPE 
Enterohormones active GLP-1 (pM)   0.59 ± 0.0 0.72 ± 0.1      0.95 ± 0.1 * 
PYY (pg/ml) 105.48 ± 22.9 149.4 ± 28.2 162.75 ± 46.9 
CCK (ng/ml)   1.31 ± 0.2 7.1 ± 1.69 *      6.45 ± 2.89  
active Ghrelin 
(pg/ml) 
303.92 ± 29.8 236.1 ± 29.41  465.61 ± 47.5 * 
Plasma 
parameters 
Glucose (mM) 9.86 ± 0.74 9.61 ± 0.83 8.33 ± 0.84  
TAG (mM) 0.21 ± 0.08 0.31 ± 0.08  0.07 ± 0.03 
Insulin (ug/L) 2.31 ± 0.43 2.59 ± 0.36  2.57 ± 0.34 
Morphometric 
parameters 
Final weight (g) 263.11 ± 3.40 266.56 ± 5.80 253.44 ± 4.30 # 
MWAT (g) 2.82 ± 0.23 3.65± 0.39 3.33 ± 0.28 
OWAT (g) 3.34 ± 0.35 3.77 ± 0.42 2.67 ± 0.18 # 
RWAT (g) 6.39 ± 0.59 8.76 ± 0.89 * 6.56 ± 0.89 
BAT (g) 0.41 ± 0.03 0.51 ± 0.05 0.36 ± 0.04 
Sum WAT (g) 12.55 ± 0.81 15.77 ± 1.25 * 12.55 ± 1.18 
Food intake kcal (sum total intake) 373.62 ± 6.10 378.15 ± 10.30 342.28 ± 10.90 * 
Short chain fatty 
acids (µmol/g 
wet intestine 
content) 
Acetic acid  17.639 ± 1.87 17.491 ± 0.97 15.568 ± 1.88 
Propionic  2.815 ± 0.24 2.464 ± 0.08 3.346 ± 0.3 
Butyric acid  9.867 ± 1.02 10.018 ± 0.94 5.595 ± 0.98 * 
Valeric acid  0.149 ± 0.04 0.202 ±0.01 0.143 ± 0.03 
 
In the conditions in which the animals were sacrificed, neither GSPE nor gallic acid 
significantly changed other biochemical plasmatic parameters, i.e. glucose, insulin and 
triglycerides (Table 1). It was also found that in this model, GSPE but not gallic acid 
reduced food intake. Actually, gallic acid-treated animals had higher white adipose 
tissue (sum of different fractions except subcutaneous). Specifically, retroperitoneal 
white adipose tissue weight was significantly different than the controls. Ovarian WAT 
of GSPE-treated rats tended to be lower (p≤0.1) than in the controls, and was 
significantly lower (p≤0.05) than that in the gallic acid-treated rats. 
GSPE reduces butyrate in cecal content 
Short chain fatty acids were measured in the cecal content of treated animals. GSPE led 
to a reduction in butyrate concentration (Table 1), while no differences were observed 
for acetic, propionic nor valeric acid. This led to significant differences (p≤0.05, 
Student T-test) in the ratio of acetate:propionate:butyrate, which was 58.0 ± 2: 9.4 ± 0: 
32.6 ± 2 for controls and   63.7 ± 1: 14.4 ± 1: 21.9 ± 2 for GSPE. Gallic acid (GA) did not 
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induce any change compared to controls in SCFA cecal content (Table 1) nor in the 
ratio acetate:propionate:butyrate (58.6 ± 2: 8.4 ± 1: 32.9 ± 2).  
Table 2 
Enterohormone gene and protein expression in ileum and colon. Gene expression values are 
represented as 2-ΔΔCt vs. control rats. * P ≤ 0.05 vs. control, T test. NA: not analyzed. 
  ileum colon 
  Control GA GSPE Control GA GSPE 
      
mRNA GLP-1 1.12 ± 0.2 0.96 ± 0.2  1.24 ± 0.1 1.11 ± 0.2 0.65 ± 0.2  0.96 ± 0.2 
CCK 0.87 ± 0.1 1.15 ± 0.3  2.25 ± 0.2 
* 
1.63 ± 0.5 3.03 ± 1.1  0.61 ± 0.1 
protein GLP-1  
(pmol/g 
tissue) 
355.36 ± 
18.8 
NA 365.95 ± 
47.6 
186.08 ± 
59.1 
NA 234.64 ± 
17.4 
 
GSPE changes microbiota profile, while gallic acid does not 
Several diversity indices (Shannon's, Simpson's, Simpson's Reciprocal, Simpson’s 
evenness) and richness estimators (Chao1, observed OTUs) were significantly lower in 
the GSPE group compared to both Control and Gallic groups, whereas no differences 
were detected between the control and Gallic groups (Fig. 1). 
 
Fig. 1. Alpha diversity indices (Shannon’s, Simpson’s, Simpson’s Reciprocal index, Simpson’s evenness) 
and richness estimators (Chao1 index, observed OTUs) of the gut microbiota from different treated rats, 
grouped as control, gallic and GSPE, after 8 days of treatment. Different superscripts indicate significant 
differences (P < 0.05) calculated by Wilcoxon rank sum tests. 
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Bacterial composition in cecal content as revealed by PCoA was significantly different 
in the GSPE group compared to both Control and Gallic groups using both unweighted 
(P<0.001) and weighted (P<0.001) UniFrac distances (Fig. 2 A, B).  
Concerning taxonomic phyla, Firmicutes was significantly higher in the control and 
Gallic groups compared to the GSPE group, while Bacteroidetes and Proteobacteria 
were higher in the GSPE group (Fig. 3). Primarily, bacteria from the classes Clostridia, 
Bacteroidia and Alphaproteobacteria and Betaproteobacteria were responsible for 
these observed patterns (Fig. 3). The families S24-7, Bacteroidaceae and 
Porphyromonadaceae were the notable groups from the class Bacteroidia that were 
larger in the GSPE treatment compared to the other two treatment groups, while 
Alcaligenaceae (Betaproteobacteria) and Veillonellaceae (Clostridia) had similar trends 
(Fig. 3). In contrast, Ruminococcacea and Dehalobacteriaceae were larger in the Control 
and Gallic group compared to the GSPE (Fig. 3). Prominent bacterial genera that were 
significantly higher in the GSPE treatment compared to the Control and Gallic groups 
include Bacteroides, Parabacteroides, Sutterella and Phascolarctobacterium, while 
Bilophila was significantly higher in the GSPE group compared to only the control. 
[Ruminococcus] was significantly lower in the GSPE compared to the other 2 groups 
and Oscillospira, Coprococcus and Dehalobacterium were significantly lower in the 
GSPE treatment compared to the Gallic treatment (Fig. 3). 
 
 
Fig. 2. Principal coordinate analysis (PCoA) illustrating the treatment groups of control gallic acid, and 
GSPE based on unweighted (A) and weighted (B) UniFrac distances.  
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Fig. 3. Abundances of microbiota taxonomic groups which were significantly different among treatments 
control, gallic acid, GSPE. Different superscripts indicate significant differences (P < 0.05) calculated by 
Wilcoxon rank sum tests. 
Correlations between microbiota and morphometric and metabolic variables 
To identify whether bacterial taxa are associated with metabolic and morphometric 
variables, or with the different parameters that were measured in the intestine, we 
calculated the Spearman's rank correlation coefficient or Spearman's rho for these 
parameters. Significant correlations are shown in Fig. 4.  
We found significant correlations between the levels of short chain fatty acids and 
multiple bacterial taxa. Acetic acid positively correlated with some families that belong 
to the Firmicutes phyla, that is the Clostridiaceae (and more specifically with the 
Clostridium genera) and the Turicibacteraceae (and more specifically with the 
Turicibacter genera). Positive correlations for acetic acid were also found for the phyla 
Actinobacteria, and within it for the Bifidobacteriales. Butyric acid correlated positively 
with several genera of the families Dehalobacteriaceae and Ruminococcaaceae within 
the Firmicutes phylum, as well as with the Rikenellaceae family of the Bacteroidetes 
phylum. In contrast, butyrate levels negatively correlated with the families 
Veillonellaceae (Firmicutes) and Porphyromonadaceae and Bacteroidaceae 
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(Bacteroidetes). Valeric acid also negatively correlated with this last family, and 
specifically with the Bacteroides genera. 
 
Fig. 4.  Heatplot of correlations between the abundance of selected bacterial taxonomic groups with 
observed concentrations of metabolites, enterohormones and plasmatic parameters. The relative color 
indicates the value of Spearman's rho. P-values were adjusted with the false discovery rate method for 
multiple comparisons. *: adjusted P-value < 0.05.  Only taxonomic groups that displayed significant 
correlations with selected parameters are shown.  
Fig. 4 also shows significant correlations between some enterohormones and bacterial 
taxa. Plasma levels of CCK were positively associated with the genera Oscillospira 
(family Ruminococcaceae) and the genera rc4-4 (family Peptococcaceae) within the 
Firmicutes phylum. Instead, negative correlations were found between active GLP-1 
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levels in plasma and the genera Lactobacillus, Ruminococcus, and the unclassified 
Peptococcaceae, all of them belonging to the Firmicutes phylum. 
We also found negative correlations between DPP-IV activity in the colon and the 
phylum Verrucomicrobia, as well as with the genera Blautia (phylum Firmicutes). 
Ovarian WAT also positively correlated with the genera Clostridium, [Ruminococcus] 
and Dehalobacterium (Firmicutes phylum), and negatively correlated with the S24-7 
family (within Bacteroidetes phyla). In contrast, retroperitoneal WAT positively 
correlated with the Veillonella genera (Firmicutes). 
Finally, the only metabolic parameter that significantly correlated with bacterial taxa 
was the plasma triglycerides, which showed a strong positive association with the 
genus Clostridium, and also correlated with Veillonella, and Dehalobacterium (from the 
Firmicutes phylum), and the family Rikenellaceae (from the Bacteroidetes phylum). 
DISCUSSION 
Grape seed proanthocyanidins have several demonstrated beneficial effects including a 
potential to alleviate metabolic syndrome parameters. They modulate body weight 
gain and lipidemia through several different mechanisms 26. In fact, an 8-day treatment 
with 500 mg/kg bw of GSPE was demonstrated to reduce body weight gain through 
inhibition of food intake and activation of energy expenditure 27. Provided the 
emerging acknowledged role of microbiota in obesity and the few studies showing that 
phenolic compounds might have some effect on its composition, in the present paper 
we analysed whether such GSPE treatment (500 mg/kg bw) during 8 days could 
modulate microbiota. Concomitantly we investigated other effects at the intestinal 
level, i.e. regulation of enterohormones, which could help to explain the effects of the 
GSPE treatment on food intake and body weight gain. We also compared the effects of 
the whole extract with that of one of its compounds, gallic acid, which is rapidly 
absorbed in upper intestine to identify the active components in the gut ecosystem. 
We found that GSPE changes the microbiota profile, and our results are in agreement 
with the general view that polyphenols increase Bacteroidetes and decrease 
Firmicutes phyla 7. Although there is controversy in regard to whether the 
Firmicutes/Bacteroidetes ratio is a microbiome-marker of  obesity, this ratio has been 
shown to have some health implications, in particular, higher values of this fraction 
have been associated with obesity and type 2 diabetes in different human and animal 
studies 28–30. The few studies concerning flavanols and microbiota modulation suggest 
that acting on intestinal flora could be a mechanism for flavonoids to exert beneficial 
effects, as suggested for red wine 31,32 or by cocoa flavanols 33. Conclusions of these 
reviews agree that more evidence is required to define the relationship between 
flavanols, microbiota and health effects. Our results clearly support the hypothesis that 
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flavanols act at least partly by modulating  gut microbiota composition, and such 
modulation might contribute to explain the previously shown beneficial effects that 
exert a similar GSPE treatment  27.  
In mice fed a high-fat-sucrose diet, highly polymeric procyanidins (PP) from apple 
increased the Firmicutes/Bacteroidetes ratio to the level observed in the standard-fed 
mice after 20 weeks of treatment 34. In that study, PP increased proportions of 
sequences assigned to the Adlerceitzia, Roseburia, S24-7, Bacteroides, Anaerovorax, rc4-
4, and Akkermansia taxa. In contrast, the proportion of reads assigned to Clostridium, 
Lachnospiraceae, and Bifidobacterium were reduced by PP administration 34. Another 
study showed that grape polyphenols dramatically increased the relative abundance of 
A. muciniphila within the Verrucomicrobia phylum, in mice under a high fat diet after 
13-week treatment 35. Accordingly, in mice under a high-fat-sucrose diet, cranberry 
extract, rich in the flavanols group including procyanidins, increased the proportion of 
the mucin-degrading bacterium Akkermansia when administered to mice for 8 weeks 
14. Recently, it has been shown that a grape seed proanthocyanidin extract 
administered for 7 weeks together with a high fat diet increased Clostridium XIVa, 
Roseburia and Prevotella 36. All of these studies analyzed the effects of treatments that 
were several-weeks long together with a high fat or high-fat-sucrose diet. Instead, we 
describe that GSPE changed the microbiota composition after only one week of 
treatment and in animals fed a standard diet. Indeed the study of Ahne et al. showed 
that pretreatment with cranberry extract 1 week before high-fat-sucrose feeding was 
not associated with specific changes in the baseline metagenome 14. Differences with 
our results might be attributed to the different compounds of the extract (i.e. A-type 
procyanidin in cranberry versus B-type in grapes), dose (200 mg cranberry extract/kg 
bw versus 500 mg GSPE/kg bw) and animal model (mice versus rat). Furthermore, the 
specific taxonomic families and genera that we find significantly modified by GSPE are 
mostly different from the above mentioned, with the exception of the S24-7 family and 
the Bacteroides genera, that were previously described as a targets for polyphenols 34. 
Thus, we define several new target taxonomic groups, described at the genera level, 
influenced by proanthocyanidins, including Sutterella, Pharscolarctobacterium, 
Parabacteroides, Bilophila, and Ruminococcus. 
The study of Anhe et al. on cranberry extract, suggested that the related increase in 
Akkermansia population might be sufficient to prevent the negative metabolic 
phenotype associated with obesity-driven dysbiosis without major modifications in the 
proportions of Firmicutes and Bacteroidetes 14. To try to discern whether changes in 
microbiota were related to modulation of morphometric and metabolic parameters, 
we performed correlation tests. Our results showed positive correlations between the 
genera Clostridium, and Dehalobacterium (both Firmicutes), and negative correlation 
for S24-7 with ovarian WAT. Changes in these specific taxa by GSPE could be linked to 
an impairment of adipose weight increase, despite that in the present conditions 
(standard diet, 8–day treatment) we do not find significant modulation of total visceral 
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WAT as expected from this experimental model. Actually, the same GSPE treatment 
(500 mg/kg bw, 8 days) has previously been shown to increase energy expenditure 
through increased lipid oxidation in adipose tissue 27. Furthermore, we found a 
positive correlation of circulating plasma TAG with Clostridium, Dehalobacterium and 
Veillonella. GSPE has previously been shown to reduce plasma triglycerides (reviewed 
in Salvadó et al., 2015) despite that in the present study we do not find statistically 
significant differences, again probably due to the short-term treatment and standard 
diet used in the study. Administration of a putative probiotic Lactobacillus rhamnosus 
for 28 days in diet-induced hyperlipidemic rats led to a positive correlation between 
Clostridium leptum and serum triglycerides, which were reduced by the treatment 37. 
For other types of putative prebiotics, reduction in Clostridium has been observed 
together with reduction in blood lipids 38. In our experiment, reduction by GSPE of 
several taxa that belong to Firmicutes is accompanied with a reduction in butyrate, an 
energy source for colonocytes. Our results in fact show a positive correlation between 
butyric acid and several genera, that are reduced by GSPE (e.g. Dehalobacterium, 
Ruminococcus), but also negative correlation with other genera within the 
Bacteroidetes phylum, that are increased by GSPE. In this sense, proanthocyanidins’ 
modulation of the microbiota profile is associated with a reduction of butyrate, that is, 
of energy harvest from the diet. These results led us to hypothesize that it could be a 
mechanism to protect from increased  TAG accumulation in cases of diet induced-
obesity, at least complementary to other well described mechanisms 26. Further studies 
on GSPE treatments in high fat diet-fed animals are required to discern whether the 
genera that we describe as new targets for being modulated by GSPE, are also involved 
in the beneficial metabolic effects of GSPE.  In humans, consumption of red wine 
polyphenols for 4 weeks significantly increased the number of Enterococcus, Prevotella, 
Bacteroides, Bifidobacterium, Bacteroides uniformis, Eggerthella lenta, and Blautia 
coccoides–Eubacterium rectale groups 13, suggesting that the possible prebiotic effect of 
proanthocyanidins could be extended to humans. 
In the present study, we found increased active GLP-1 in plasma after an 8-day GSPE 
treatment. Our results of intestinal GLP-1 gene and protein expression suggest that the 
effect on circulating GLP-1 levels is not due to a modification of GLP-1 production, but 
of its secretion. Since the last GSPE dose was administered 80 minutes before sacrifice, 
it could be that the previously shown acute GLP-1-stimulatory GSPE effects 8,10 are 
maintained after 8 days of treatment, as has been described for ghrelin 27. In humans, 
the intake of a specific strain of Lactobacillus (i.e. L. reuteri) has been shown to 
increase GLP-1 secretion 39. However, we found that the levels of active GLP-1 
negatively correlated with three genera (Lactobacillus, Ruminococcus and Unclassified 
Peptococcaceaea) within the Firmicutes phylum. Although the Lactobacillus genus 
identified in our study was not further classified to the species level, it appears that not 
all strains of Lactobacillus demonstrate the same GLP-1 secretion patterns in the host. 
It has been shown that the gut microbiota fermentation of specific prebiotics or other 
non-digestible carbohydrates is associated with the secretion of enteroendocrine 
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peptides produced by L-cells 40. One possible mechanism is that SCFAs produced by the 
fermentation of dietary fibers bind to the G-protein-coupled receptors (GPCRs) GPR41 
and GPR43, thereby triggering GLP-1 secretion by the L-cells 40. Our results show that 
GSPE significantly reduced cecal butyrate content, and modulated the ratio of acetate: 
propionate: butyrate, although whether these changes could signal to enhance GLP-1 
secretion should be further assessed. Alternatively, a direct link between gut 
microbiota and intestinal bioactive lipids related to the endocannabinoids and 
involved in enteroendocrine peptide secretion has been suggested as another 
mechanism for enhanced GLP-1 secretion observed with prebiotics 40. To our 
knowledge, there is no information concerning the possible relationship between these 
three genera and endocannabinoids, thus future studies will reveal whether this may 
be a mechanism for GSPE. 
GSPE is a mixture of different compounds. Matsumoto et al. demonstrated that 
modification in the proportion of Akkermansia in the gut microbiota is due to non-
absorbable PPs and that the degree of PP polymerization is an important factor 34. In 
the present paper we show that gallic acid, one of the main acids found in the extract 
does not induce significant modification of microflora or short chain fatty acids, at least 
in the concentration assayed, which is equivalent to that found in 500 mg GSPE/kg. 
Moreover we show that gallic acid does not mimic the changes in enterohormone 
profile induced by GSPE. Furthermore, in this model it does not reduce food intake, and 
concerning adiposity, it leads to a significant increase in visceral adipose tissue, due to 
the increased retroperitoneal fraction.  
We had previously shown that gallic acid reduced CCK secretion after an acute 
treatment in a rat duodenum ex vivo model 9. Now we found that an 8-day treatment 
with gallic acid increased CCK plasma levels. These differences might be due to the 
different length of time of each treatment (acute vs 8 days). Despite our results 
showing no significant modulation of CCK gene expression in ileal and colonic tissue of 
gallic acid-treated rats, suggesting that the effect is not due to an increased production, 
we also observed a correlation between plasma CCK levels and some microbiota taxa. 
Plasma CCK positively correlated with the Oscillospira genus and the corresponding 
Ruminococcae family. The mechanism and whether there is a relation with CCK 
secretion remain unresolved, but results confirm that gallic acid is not the main active 
molecule in the GSPE extract to explain its effects at the gastrointestinal tract.   
CONCLUSION 
In conclusion, our results show for the first time a clear short-term effectiveness of 
GSPE at modifying microbiota, increasing the amount of Bacteroidetes and reducing 
that of Firmicutes, and altering specific genera within these phyla. Modifications in the 
microbiota led to changes in the short chain fatty acid profile from the cecal content. 
Our correlation analysis suggests that these changes in the microbiota may be linked to 
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the modulation of plasma TAG, adiposity, and enterohormone secretion induced by 
GSPE. 
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SUPPLEMENTARY MATERIAL 
 
Table 1S. DPP-IV activity/mg protein in different intestinal segments for rats in the 
control, GSPE and gallic acid treatments. Values are represented as normalized by each 
control. * P ≤ 0.05 versus control, T test. 
  Control Gallic acid GSPE 
Duodenum 1.00 ± 0,1 1.63 ± 0.3 *  0.91 ± 0.1 
Jejunum 1.00 ± 0,1 0.99 ± 0.1  0.97 ± 0.1 
Ileum 1.00 ± 0,1 1.21 ± 0.1  1.15 ± 0.1 
Distal colon 1.00 ± 0,1 1,01 ± 0.1  0,93 ± 0.05 
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PREFACE 
In the last manuscript, we aimed to discover a new source of natural bioactive 
compounds that could act at intestinal level. Specifically we analyzed whether 
chicken feet hydrolyzate modulates the incretin system (objective 4). 
The in vitro evaluation of DPP-IV inhibition enabled us to screen different chicken 
feet hydrolyzates obtained by enzymatic hydrolysis. Moreover, we used in vitro 
and ex vivo models to show that the selected hydrolyzate (with the higher DPP-IV 
inhibitory activity) was able to modulate the incretin system by another 
complementary mechanism, the direct effect on enteroendocrine cells, and 
thereby on GLP-1 secretion.  
Finally, we checked whether the selected hydrolyzate had in vivo effect improving 
glucose homeostasis in disrupted- glucose homeostasis rat models. 
Results detailed in the manuscript, as well as subsequent studies that have led us 
also to define the main peptide sequence responsible of DPP-IV inhibition are 
reported in related patent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antihyperglycemic effect of chicken feet hydrolyzate 
 
163 
 
Antihyperglycemic effect of chicken feet hydrolyzate via 
incretin system: DPP-IV-inhibitory activity and GLP-1 release 
stimulation. 
Àngela Casanova-Martía1, Francisca Isabel Bravo b1, Joan Serranoa, Anna Ardévola, 
Montserrat Pinenta and Begoña Muguerzab 
aMoBioFood Research Group. Departament de Bioquímica i Biotecnologia, Universitat 
Rovira i Virgili 
bNutrigenomics Research Group. Departament de Bioquímica i Biotecnologia, 
Universitat Rovira i Virgili 
1These authors contributed equally to this work 
ABSTRACT  
The incretin therapies provide a novel approach to be used in the treatment of type 2 
diabetes. In the present study, the potential as natural dipeptidyl-peptidase IV (DPP-
IV) inhibitor of 12 hydrolyzates generated from hydrolysis of chicken feet proteins 
with Neutrase® and Protamex® were investigated. Three hydrolyzates were selected 
due to their high DPP-IV inhibitory capacity (>80%), showing IC50 values around 300 
µg/mL. The hydrolyzate obtained from chicken feet proteins treated with a 
pretreatment (50°C, pH3, 1.5h), followed by a hydrolysis with Neutrase® (25°C, pH7.0, 
24h) (which was named p38H) was selected for posterior analysis. Glucose tolerance 
test was performed on healthy and two types of glucose-intolerance (diet-induced and 
age-induced) rat models to study the antihyperglycemic effect of the p38H. The dose of 
300 mg protein/kg body weight (BW) p38H improves the plasma glucose profile in 
both glucose-intolerance models. The p38H had no significant effect in rats with 
normal glycemia. In addition, p38H induced a strong stimulation of active GLP-1 
release in enteroendocrine STC-1 cells and in rat ileum tissue. In conclusion, our 
results point out that proteins of chicken feet treated by Neutrase® and Protamex® are 
a good source of bioactive peptides as DPP-IV inhibitors. Moreover, our results also 
highlight the potential of the selected hydrolyzate (p38H) for the management of type 
2 diabetes due to the dual function of inhibiting DPP-IV activity and inducing GLP-1 
release.   
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INTRODUCTION 
The prevalence of lifestyle-related diseases such as obesity and type 2 diabetes 
mellitus (T2DM) has become a healthcare problem in developed societies. Therefore, 
effective strategies are needed to prevent the development of T2DM and the associated 
pathologies. A recent focus has pointed out to the biology of incretin hormones such as 
GIP and GLP-1 for glycemic regulation [1].   
GLP-1 is an incretin hormone that is released from intestinal L-cells in response to 
nutrient ingestion that exerts glucoregulatory action through the stimulation of insulin 
secretion and inhibition of glucagon secretion [2, 3]. In addition to its insulinotropic 
actions, GLP-1 also improves beta-cell mass, delays gastric emptying, enhances satiety 
and reduces food intake [4, 5].  Due to their physiological effects, a number of 
antidiabetic agents targeted towards the so-called incretin therapies have emerged. 
These therapies are mainly based on the use of GLP-1 mimetics and dipeptidyl 
peptidase IV (DPP-IV) inhibitors, which protect cleavage of active GLP-1 by DPP-IV [6]. 
DPP-IV is a serine protease which is widely distributed among many tissues in the 
body and it is expressed as both membrane and soluble form in a variety of cell types. 
This enzyme principally cleaves proline or alanine containing dipeptides from the N-
terminus of a polypeptide; thereby GLP-1 and GIP are potential DPP-IV targets. The 
concentration of GLP-1 in plasma rises rapidly after food intake and it is immediately 
degraded by DPP-IV because of the presence of the enzyme at their site of production. 
In recent years, DPP-IV inhibitors have been reported to prevent the cleavage of 
incretins by DPP-IV and to increase the half-life of the active hormones, and hence are 
available for management of glucose homeostasis [2]. Recently, another potential 
approach has been postulated, the stimulation of the endogenous secretion of GLP-1 
stored in L-cells to improve glycemia [7]. 
The development of food protein-derived peptides has become a novel strategy for the 
prevention and management of T2DM.  The hydrolyzates rich in bioactive peptides are 
well metabolized and confer fewer side effects than synthetic pharmaceutical drugs. 
Furthermore, there is a wide range of available under-utilized resources of the food 
industry, which could be potential sources of bioactive peptides. Altogether, these 
characteristics could lead to expand the use of bioactive peptides in the nutraceutical 
food section [8]. Recent in silico analysis revealed that sequences are contained within 
dietary proteins that present structural features which make them natural precursors 
for generation of potent inhibitors of DPP-IV [9, 10]. Previous studies have described 
that hydrolyzates obtained from milk proteins [11, 12], as well as other animal and 
vegetal sources [13–15] exhibit DPP-IV inhibitory activity in vitro. However, only a few 
studies have evaluated the effects of biopeptides as DPP-IV inhibitors in vivo. Acute 
studies show that biopeptides can decrease plasma glucose concentration relative to 
the control in an oral glucose tolerance test (OGTT) in rodents [16, 17]. While Mochida 
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et al. showed that ZeinH (a hydrolyzate prepared from corn zein) administration into 
the ileal loop produces an inhibition of DPP-IV activity in the ileal vein in rodents [18].  
Regarding GLP-1 secretion by dietary proteins, it has been reported that meat 
hydrolyzates stimulate GLP-1 release in the enteroendocrine cell lines NCI-H716 [19], 
STC-1 [20], and GLUTag [21] as well as it is a potent secretor of GLP-1 in rodents [22]. 
Moreover, GLP-1 secretion triggered in response to whey protein has been observed in 
humans [23]. Even though, human studies have shown that this incretin secretion 
highly depends on the origin of the protein and its level of digestion [24, 25], as it was 
also observed in STC-1 cells [26]. It is also interesting the fact that a dual bioactive role 
has been suggested for protein hydrolyzates, such as DPP-IV inhibitor and α-
glucosidase inhibitor [27], or stimulator of GLP-1 secretion [18, 28], highlighting their 
promising action in the prevention and management of glucose-intolerance 
pathologies. 
Therefore, the aim of this study was to obtain bioactive hydrolyzates that are able to 
inhibit DPP-IV activity in vitro from proteins of chicken feet using in vitro enzymatic 
treatment. Furthermore, we selected a hydrolyzate with high capacity to inhibit DPP-IV 
activity in vitro and evaluated the effect of this hydrolysate on the secretion of GLP-1 in 
in vitro and ex vivo models. Finally, we aimed to demonstrate whether this could lead 
to antihyperglycemic properties in rats. 
MATERIALS AND METHODS 
Chemicals 
Dipeptidyl peptidase IV (from porcine kidney) was purchased from Sigma-Aldrich, Co. 
(St. Louis, Mo., USA). Gly-Pro-7-amido-4-methylcoumarin hydrobromide (Gly-Pro-
AMC) and Pro-p-nitroanilide (Ala-Pro-pNA) were obtained from Bachem AG. Diprotin 
A (Ile-Pro-Ile) was from Enzo Life Sciences International (New York, USA) and 
Vildagliptin was form Axon Medchem (Groningen, The Netherlands). Neutrase® 0.8L 
and Protamex® was received as a kind gift from Novozyme (Copenhagen, Denamark). 
Hydrolysis of chicken feet proteins 
Chicken feet hydrolyzates were made from chicken feet from Gallus gallus domesticus 
as previously described [29]. Chicken feet were washed, triturated, lyophilized and 
sieved using 2mm pore size sieve to obtain a powder. This powder was heated in water 
at different pH (3.0 and 7.5) and temperature (25, 50 and 100°C) for 1.5 hours. After 
pretreatment, the mixture was hydrolyzed at pH 7.0 and different temperature (25 or 
50°C) for 2 hours or 24 hours, and using two different commercial mixes of proteases 
from Bacillus amyloliquefaciens (E.C. 3.4.24),  and Bacillus licheniformis and Bacillus 
amyloliquefaciens (E.C. 3.4.21.62 and EC 3.4.24.28) so-called as Neutrase® and 
Protamex®, respectively.  In all hydrolysis treatment, the ratio of enzyme:substrate 
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used was 0.4 Anson Units (AU)/g.  To stop the hydrolysis reaction, enzymes were 
inactivated by heating at 80°C for 10 min in a water bath. Solutions were centrifuged at 
10000 x g for 24 min at 4°C. The supernatant was collected and was kept at -20°C until 
further analysis.  
Determination of DPP-IV Inhibitory Activity 
The inhibition assay was performed using 96-well microplates. The DPP-IV enzyme 
(diluted with 100 mM Tris HCl buffer ph 8.0 to 0.26 mU per well) and 10 µl of different 
concentration of test sample was pre-incubated for 10 min at 37°C. The enzymatic 
assay was initiated by adding the chromogenic substrate Gly-Pro-pNA (final 
concentration 0.2mM). The mixture was measured at 405 nm at 37°C for 30 min in a 
microplate reader. DPP-IV inhibition is expressed as a percentage which is the 
difference of the activity in presence of test peptides versus total activity of the 
enzyme. The IC50 values were calculated for hydrolyzates that achieved the selection 
criteria: inhibition activity of 80%. Diprotin A (Ile-Pro-Ile), a well-known DPP-IV 
inhibitor, was used as reference inhibitor and positive control. The protein 
concentration of the hydrolyzates was assayed by the Kjeldahl method [30]. 
Animal studies 
Female Wistar rats weighing 180-200g and male Wistar rats weighing 450-500g were 
obtained from Harlan (Barcelona, Spain). The studies in male groups occurred at the 
facilities of the Technological Center of Nutrition and Health (www.ctns.cat).  Upon 
arrival, the animals were housed singly in animal quarters at 22ºC with a 12-h 
light/12-h dark cycle and with free access to food and water. After an adaptation 
period of one week, the animals were used for the experiments. 
On the experimental day, the animals were randomized into different groups 
depending on the treatment received. To study the effect of the selected hydrolyzate 
p38 (p38H) on a healthy model, female rats were divided into two groups (n=7): the 
control group, treated with the vehicle (tap water), and the group receiving p38H, at 
300 mg protein/kg of body weight (BW). To study the effect of the p38H on an obesity 
model, the rats followed a washing period and then they were fed a cafeteria diet 
(carrots, bacon, and milk with sugar) plus the standard laboratory chow, as previously 
described [31, 32]. After ten weeks, the animals were distributed into a cross-over 
experimental design with two groups (n=7), the control group and the p38H group 
(300 mg protein/kg BW). Finally, p38H was also tested in a model of glucose-
intolerance due to age (7-month) [33]. Male Wistar rats were divided into three 
experimental groups (n=6 rats/group): control group, treated with the vehicle (tap 
water); p38H group, treated with 300 mg protein/kg BW; and a positive control group, 
treated with the commercial DPP-IV inhibitor vildagliptin (1 mg /kg BW). 
For all the studies, the animals were fasted overnight before experimental treatment. 
At 9 a.m. on the experimental day, the treatment was administered by intragastric 
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gavage (i.g). After 40 minutes of treatment, animals underwent an intragastric glucose 
load (2 g of glucose/kg of BW). Tail blood samples were collected into a heparinized 
capillary tube immediately before and at 15, 30, 60, and 120 minutes after glucose 
administration. The plasma was immediately separated from the blood by 
centrifugation (2500 x g, 4ºC, 15 min) and stored at -80°C until analysis. 
The Animal Ethics Committee of the University Rovira i Virgili (Tarragona, Spain) 
approved all of the procedures. 
Plasma analysis 
The glucose plasma levels were assayed using an enzymatic colorimetric kit (Glucose 
Oxidase-Peroxidase method from QCA, Tarragona, Spain) and DPP-IV plasma activity 
was measured by a fluorimetric assay following the method as previously described, 
with some modification based on the fluorimetric substrate and the DPP-IV 
concentration of the plasma samples. 
Cell culture 
The STC-1 clonal cell line was received as a kind gift from Dr. B. Wice (Washington 
University, St. Louis, USA) with the permission of Dr. D. Hanahan (University of 
California, San Francisco, USA). This enteroendocrine cell line was originated from a 
double-transgenic mouse tumor [34]. Cells were cultured in DMEM with GlutaMAX 
containing 4.5 g/l D-glucose, without sodium pyruvate (GIBCO), supplemented with 
17.5% fetal bovine serum, 100 U/ml penicillin, and 100 mg/l streptomycin 
(BioWhittaker) and incubated in a 5% CO2-humidified atmosphere at 37°C. At least 
three replicates using different cell passage numbers were performed for each 
experiment, including at least three wells of each condition in every replicate. Cells 
were used between passage numbers 30 –50. 
Ex vivo explants 
Intestinal tissue was obtained from healthy female Wistar rats (n=6). Animals were 
sacrificed and their intestines were dissected out. To acquire the distal ileum segment, 
an incision was made in the ileocecal junction and the distal 8 cm of intestine from the 
ileocecal junction was excised. The ileum was rinsed with ice-cold Hank’s balanced salt 
solution (HBSS; Thermo Fisher Scientific, Madrid, Spain) and was dissected in 
segments of tissue (0.75 cm2), which were placed on a 24-well plate and kept on ice 
until the start of secretion studies. 
GLP-1 secretion studies 
STC-1 cells were seeded in 24-well culture plate at a density of 2.0 × 105 cells/well for 
2 days until they reached 80-90% confluency. On the day of the experiment, cells were 
washed twice with HEPES (20 mM HEPES, 140 mM NaCl, 4.5 mM KCl, 1.2 mM CaCl2, 
and 1.2 mM MgCl2 at pH 7.4), and p38H dissolved in HEPES buffer with 10 mM glucose 
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(5 mg/mL) was added to each well. After an incubation period of 2 hours at 37°C, 
supernatants were collected, centrifuged to remove remaining cells and stored at -80°C 
until it was used for determination of active GLP-1 concentration. 
For the ex vivo explant experiments, tissue segments of ileum were placed in 
prewarmed (37ºC) KRBS buffer (containing 4.5 mmol/L KCl, 138 mmol/L NaCl, 4.2 
mmol/L NaHCO3, 1.2 mmol/L NaH2PO4, 2.6 mmol/L CaCl2, 1.2 mmol/L MgCl2 and 10 
mmol/L HEPES (adjusted to pH 7.4 with NaOH)) with 10 mM glucose, 0.1 mM diprotin 
A and supplemented with 15mg/mL p38H. Tissue segments were incubated for 1 hour 
in a humidified incubator at 37°C and 5% CO2. After the incubation, the solutions were 
collected, centrifuged to remove remaining cells and stored at -80°C until it was used 
for determination of active GLP-1 concentration.  
Tissue viability was checked by an absence of the cytoplasmic marker lactate 
dehydrogenase (LDH) in the incubated solutions. LDH was analyzed using an LDH kit 
(QCA; Tarragona, Spain).  
Active GLP-1 concentration was measured with a GLP-1 7-37 amide ELISA kit 
(Millipore; Billerica, MA, USA). 
Data analyses 
The results are expressed as the mean±SEM. The repeated measurements of glucose 
were performed using a two-way ANOVA test and significant differences among mean 
values were determined by post hoc Bonferroni. Differences in the glucose area under 
the curve (AUC) between groups were determined by using one-way ANOVA, followed 
by a Bonferroni test. GLP-1 measurement was analyzed using a Student’s t-test. All 
calculations were performed using SPSS software (SPSS, Chicago, USA). P-values < 0.05 
were considered significant in all cases. 
RESULTS 
DPP-IV inhibitory activity of chicken feet hydrolyzates 
Chicken feet were subjected to different conditions (pretreatments at different 
temperature and pH followed by treatments with different enzymes, temperature and 
time) to obtain a panel of different hydrolyzates. Then the DPP-IV inhibitory activity of 
these hydrolyzates was assayed. Table 1 shows that 3 hydrolyzates out of the 12 
tested achieved the selected threshold of 80% inhibition. The hydrolysis treatment 
was essential to obtain hydrolyzates with DPP-IV inhibition property since the chicken 
feet powder that was not subjected to hydrolysis (named p86H, Table 1) did not show 
inhibitory activity. DPP-IV inhibitory activity was dependent on the conditions of 
pretreatment and hydrolysis treatment. The results showed that the hydrolysis of 
protein solution subjected a pretreatment in basal conditions (25°C and pH 7.5) led to 
samples with DPP-IV inhibitory capacity, achieving the threshold of around 40%, in all 
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the hydrolysis treatment conditions (p103H, p115H, p111H). Modification of 
pretreatment conditions, by reducing the pH to 3 and increasing temperature (50°C 
and 100°C) (samples p38H, p16H, p68H in Table 1) exhibit a higher DPP-IV inhibitory 
activity (80-100%) than the hydrolyzates subjected at pH 7.5 and lower temperatures 
in the pretreatment.  
TABLE 1  
Chicken feed hydrolyzates with dipeptidyl peptidase IV inhibitory activity. 
Hydrolyzate 
Pretreatment 
(1.5 h) 
Treatment (pH 7) 
DPP-IV 
Inhibition (%)a Temp 
(°C) 
pH Enzyme Temp 
(°C) 
Time 
(h) 
p86H 25 7.5 No 0 
p103H 25 7.5 Neutrase® 25 24 48.39 
p39H 50 7.5 Neutrase® 25 24 44.40 
p102H 25 3 Neutrase® 25 24 60.48 
p38H 50 3 Neutrase® 25 24 83.22 
p115H 25 7.5 Neutrase® 50 24 40.22 
p19H 100 7.5 Neutrase® 50 24 77.19 
p114H 25 3 Neutrase® 50 24 55.24 
p16H 100 3 Neutrase® 50 24 100 
p111H 25 7.5 Protamex® 50 2 44.05 
p70H 100 7.5 Protamex® 50 2 60.49 
p110H 25 3 Protamex® 50 2 53.30 
p68H 100 3 Protamex® 50 2 93.30 
a Dipeptidyl peptidase IV inhibitory activity of 100% sample fraction under assay conditions 
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The IC50 of the three selected was calculated and expressed in volume (µL) and protein 
concentration (µg/mL). The IC50 given in microlitres measure the hydrolyzate 
pharmacological potency since this value signifies the volume required to inhibit the 
enzyme by 50% under the assay condition. The expression of IC50 in protein 
concentration means the specificity of peptide pool mixture against DPP-IV, hence it is 
an indicator of the pharmacological specificity [35, 36]. All of them showed similar 
values between 4.03 and 4.82 μL or 297.4 and 302.9 µg protein/mL (Table 2). Since 
the temperature of pretreatment and hydrolysis were lower to obtain p38H, which 
could imply an industrial production less expensive, this hydrolyzate was selected for 
posterior experiments.  
TABLE 2 
Comparison between protein content and DPP-IV Inhibitory Activity of hydrolyzates of chicken 
feet produced by enzymatic treatments. 
hydrolyzate Protein content 
(mg/mL) a 
IC50  
(μL)b 
IC50  
(µg/mL)b 
p16H 6.83 4.42 297.4 
p38H 6.24 4.82 302.9 
p68H 6.62 4.45 300.1 
a Protein was measured by Kjeldahl method. 
b IC50 values are reported as the mean from duplicate assays. 
 
Effects of chicken feet hydrolyzate on plasma glucose 
The effect of an acute administration of p38H was tested in two different models of 
rats with glucose intolerance: diet-induced and age-induced.  
In a cafeteria-induced obese rat model, the administration of 300 mg/kg BW p38H 
together with a glucose load reduced the peak of glucose and tended to normalize the 
glucose values (Fig. 1.A.) Concomitantly, the glucose AUC values after an OGTT was 
lower in the p38H-treated animals than in the cafeteria group (Fig. 1.B). Similarly, 
aged rats had glucose intolerance (in non-treated animals, values at 120 min did not 
return to initial levels) and a p38H treatment ameliorated the plasma glucose profile 
similarly to what the positive control vildagliptin did (Fig. 2).  
The effects of the hydrolyzate in rats with normal glycemia were also tested. Actually, 
this was performed in the same group of rats that were subjected to a cafeteria diet, 
but previously to the cafeteria treatment. In this case, the p38H had no significant 
effect (Δ Glucose AUC (arbitrary units): 2658.50 ± 902.25 and 3201.28 ± 504.41, 
control and p38H-treated group, respectively).  
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Fig 1. Plasma glucose levels during OGTT after gavage administration of water or p38H (300mg 
protein/kg BW) (A) and evaluation of the post-prandial areas under the plasma glucose curves (B) in the 
standard group (solid square or open bar), cafeteria group (solid circles or grey bar) and p38H-treated 
cafeteria group (solid triangle or solid and points bar). The data are given as the mean±s.e.m (n=5-7). 
Mean values with unlike letters were significantly different among groups (A, two-way ANOVA and 
Bonferroni post hoc comparison and B, one-way ANOVA and Bonferroni post hoc comparison, p < 0.05). 
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Fig. 2. Plasma glucose levels during OGTT after gavage administration of water, vildagliptin (1 mg /kg 
BW) or p38H (300mg of protein/kg BW) (A) and evaluation of the post-prandial areas under the plasma 
glucose curves (B) in the standard group (white circles or open bar), p38H-treated group (solid triangle or 
solid and points bar) and vildagliptin-treated group (white squares or grey bar). The data are given as the 
mean±s.e.m (n=5-7). Mean values with unlike letters were significantly different among groups (A, two-
way ANOVA and Bonferroni post hoc comparison and B, one-way ANOVA and Bonferroni post hoc 
comparison, p < 0.05). 
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GLP-1 release was stimulated by Chicken hydrolyzate  
Finally, we tested in vitro and ex vivo the capacity of the p38H to stimulate GLP-1 
release. In STC-1 enteroendocrine cells, treatments with 5 mg/mL p38H for 2 hours led 
to a strong (7-fold) increase in GLP-1 levels in the media compared to controls (Fig. 
3.A). Similarly, GLP-1 secretion from ileum tissue segments was stimulated in 
response to the 15 mg/mL p38H (Fig. 3.B).  
 
FIG 3. Selected hydrolyzate (p38H) effect on active Glucagon-like peptide-1 (GLP-1) secretion 
from STC-1 cells (A) and ileum tissue segment (B).  The data are displayed as the means±s.e.m. 
Stadistically significant difference at p < 0.05 calculated using Student t-test. 
DISCUSSION 
In this paper, we focused on finding natural peptides that act as DPP-IV inhibitors and 
inductors of the endogenous secretion of GLP-1, which could be a useful strategy 
against Type 2 diabetes, pathology with a great incidence in developed countries [1, 7]. 
We define for the first time that chicken feet protein hydrolyzates are able to inhibit 
DPP-IV activity. Other food proteins had previously been shown to be sources of DPP-
IV inhibitors, such as whey [37], milk [38], salmon skin [39] and quinoa [40]. We 
performed a screening in which chicken feet were subjected to different hydrolysis 
protocols. Our results show that not all treatments functioned equally, indicating the 
importance of the treatment conditions in the hydrolyzates behaviour. Three protocols 
leading to hydrolyzates with DPP-IV inhibitory activity were found. The pretreatment 
for 1.5 hours at 50°C or 100°C and pH value of 3 was crucial to achieving hydrolyzates 
with high DPP-IV inhibitory capacity (p38H, p16H, and p68H). In fact, the three 
selected hydrolyzates presented similar pharmacological potency, since IC50 values 
expressed as microliter are similar (around 4 μL), and also similar pharmacological 
specificity, shown by similar IC50 values expressed as micrograms protein per millilitre 
(around 300 µg/mL). The IC50 that we obtained is 10-fold lower than that found in a 
previous study which used collagen obtained from chicken-feet and hydrolyzed using 
Streptomyces collagenase (45°C, pH 7.5, 17 hours) [41]. Thus working with the whole 
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chicken feet source, and using the appropriate conditions (here defined) can lead to 
solutions with much more DPP-IV inhibitory potency. 
The obtained IC50 values are within the range of that observed by other food 
hydrolyzates [13, 42, 43]. Lower IC50 values of the hydrolyzates compared to purified 
peptides have been found in other studies [38]. Hence, those results suggest that the 
concentration of bioactive peptide in the hydrolyzate is low and different bioactive 
peptides or a different combination of them might be involved in DPP-IV inhibitory 
activities. Although a further identification of the bioactive peptide would be of 
interest, we here present important clues to prepare hydrolyzates from chicken feet 
for a use as antihyperglycemic.  
We next selected one of the chicken feet hydrolyzate, p38H, to demonstrate its 
bioactivity in vivo. It must be taken into account that high DPP-IV inhibitory activity in 
vitro could not correspond with high antihyperglycemic effect in vivo. This could be 
because the bioactive peptides contained in the hydrolyzates can be hydrolyzed and 
transformed into inactive peptides during the gastrointestinal digestion. For this 
reason, it is essential to validate the hydrolyzate bioactivity in vivo. We tested the p38H 
effects at reducing glycemia in a model of rats fed a cafeteria diet. Our results show 
that the p38H treatment led to a lower glucose initial peak and a lower glucose curve, 
with a tendency to reach levels of standard-fed animals. Instead in the healthy rats 
(assayed previously to the cafeteria treatment), p38H did not modify the AUC of the 
glucose load. This could be related to the fact that in the cafeteria-fed rats the initial 
glucose peak was greater (an increase of around 80 mg/dL at 15 min) than before the 
cafeteria treatment (glucose increase of around 50 mg/dL) because of their disorder in 
glucose homeostasis. This disorder induced by diet underscored in 120 min after the 
OGTT when the cafeteria-fed animals glycemia did not return to basal levels, while 
previously to the cafeteria treatment these rats showed normal OGTT curves. The 
p38H effects were tested in another model that showed glucose-intolerance, aged rats. 
In this model, p38H also lowered the plasmatic glucose curve. This is the first trail that 
acute dose of peptide hydrolyzates influence glucose homeostasis in rat models that 
present glucose intolerance, while only a few potential DPP-IV inhibitor-peptides have 
previously been tested in vivo for their glucose lowering capacity in healthy models. 
Uchida et al. tested a ß-lactoglobulin hydrolyzate in mice and observed that glucose 
levels were reduced at 15 min after an OGTT. It worth mentioning that the glucose 
dose administered was 10 g/Kg BW, much higher than the one we have tested (2 g/kg 
BW) and that in agreement led to a great (around 3-fold) increase in glucose peak at 
this time point [16], reinforcing that the effects are dependent on the amount of 
circulating glucose. This might be linked to the modest potency of the hydrolyzates 
compared to commercial purified DPP-IV inhibitors, which we and others [16] 
observed. Interestingly in aged control animals, the comparison of p38H-treated and 
vildagliptin-treated animals showed a different glucose pattern: the p38H was not as 
effective as vildagliptin at reducing the initial glucose peak but normalized its glycemia 
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at 120 min in a similar way. These results suggest that p38H might act through 
different mechanisms to ameliorate hyperglycemia. 
It must be stated that we measured DPP-IV activity in plasma from the tail and found 
no effect of p38H in any of the animal experiments (results not shown). However, it has 
been shown that the main GLP-1 degradation occurs immediately at the site of 
secretion, and its short half-life generates that only 10-15% active GLP-1 levels remain 
in the systemic circulation [3, 44]. Although various hydrolyzates have been reported 
to reduce plasma DPP-IV activity after chronic treatments [45–47], few studies have 
shown that effect in acute treatments. Actually, whey protein has been reported to 
attenuate hyperglycemia in part by inhibition of DPP-IV activity in the small intestinal 
tissue, but not in orbital vein [48]. It has also been shown that ileal administration of 
Zein and rice protein hydrolyzates decreased plasma DPP-IV activity in ileal vein [18, 
28]. And in fact, none of the other papers describing in vivo antihyperglycemic effects 
of protein hydrolyzates shows DPP-IV activity in peripheral blood [16, 17]. Therefore,  
it cannot be excluded that, despite the lack of DPP-IV inhibition in peripheral blood, 
p38H lead to an amelioration of glucose profile due to the inhibition of local intestinal 
DPP-IV. 
Previously, it has been shown that Zein and rice protein hydrolyzates have 
antihyperglycemic effects by a dual mechanism of action, both inhibiting DPP-IV 
activity as well as increasing GLP-1 release [18, 28]. Actually, Mochida et al. showed 
that Meat hydrolyzate (acquired from Sigma, no description of the meat origin) was 
also tested and shown to induce intestinal GLP-1 secretion after ileal administration, 
but it has not the dual effect. Other protein hydrolyzates have been tested as GLP-1 
stimulator in vivo, in situ and in vitro models [19, 23, 49, 26]. We reproduced this 
approach and tested whether chicken feet hydrolyzate could also modulate GLP-1 
release in in vitro and ex vivo model. Our results show a strong significant increase in 
GLP-1 levels after p38H treatment in both models. Despite the form in which the 
hydrolyzate might reach the enteroendocrine L-cells in vivo might differ from that used 
in in vitro or ex vivo, these results suggest that this might also be a mechanism that 
helps to reduce glycemia in animals. This additional mechanism could help to explain 
the differences found between the DPP-IV inhibitor vildagliptin and the p38H in the 
aged-rats experiment, since it could be that after 120 minutes the p38H reached the 
intestinal regions where GLP-1 secreting cells are located (mainly ileum and/or colon) 
and a stimulation of GLP-1 would explain the reduced glucose levels. Further 
experiments will be required to confirm this hypothesis.  
In conclusion, we here report that chicken feet hydrolyzates obtained by Neutrase® 
treatment reduced glycemia in glucose-intolerant rats and that this might be mediated 
through their DPP-IV inhibitory capacity. In addition, a stimulation of endogenous GLP-
1 secretion could also be involved in the antihyperglycemic effects of the p38H.   
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1. Thesis summary and general discussion 
The increased prevalence of overweight and obese individuals, in both developing and 
developed societies, highlights the need to find preventative therapies, as well as 
treatments for obesity and its metabolic-associated diseases. The gastrointestinal tract 
is the largest endocrine organ in the body producing hormones that act as important 
mediators of glucose homeostasis and food intake. The focus of type 2 diabetes 
mellitus (T2DM) treatments is keeping blood glucose levels within the normal 
physiological range [1]. With regards to body weight management, focusing on the 
regulation of food intake is one potential strategy as it is well known that the main 
causes of obesity is increased food intake coupled with decreases energy expenditure 
[2].  
In the last decade, scientific advances have aided the investigation of natural bioactive 
compounds to reduce obesity and related pathologies, such as cardiovascular disease, 
T2DM, osteoarthritis and some cancers (colon, endometrial and breast cancers) [3–5]. 
The use of natural bioactive compounds to modulate gut hormone secretion, and 
consequently appetite and glucose homeostasis, might be a potential strategy to 
prevent or/and treat obesity and one of the most associated disease, T2DM. In the field 
of natural bioactive compounds, the scientific evidence of their action has to be 
approved as a health claim [6]. Additionally, the complete description of their 
mechanisms is important if they are to be recommended for the reduction of disease 
risk in a target population. Thus, this thesis was focused on defining the mechanisms of 
a known bioactive compound at the intestinal level, i.e. grape seed proanthocyanidin 
extract (GSPE), specifically on the different mechanisms involved in enteroendocrine 
system modulation, as well as finding new ones, i.e. bioactive peptides derived from 
chicken feet, that might act through modulation of these intestinal mechanisms. To 
achieve our objective different models of study, including in vitro, ex vivo and in vivo 
models, were used.  
The in vivo release of enterohormones occurs through direct sensing of luminal 
components, and also indirectly by vagal and humoral stimulation [7]. Therefore, one 
important mechanism to understand plasma intestinal hormone levels is the direct 
interaction of the luminal content with enteroendocine cells (EECs). In vitro and ex vivo 
models were used to study the direct effect of compounds on hormone release. In ex 
vivo model, our results showed that GSPE (170 mg phenolics/L) and metabolites of 
GSPE (~188 mg phenolics/L) increased active GLP-1 levels in ileum and colon 
segments, respectively. Previous studies done in our research group described that 
GSPE has antihyperglicemic properties that were attributed to the proanthocyanidins 
insulin-like effect in adipose tissue [8] and also the proanthocyanidins modulation of 
insulin secretion and production [9, 10]. However, antihyperglicemic properties are 
also associated with the incretin effect. Previous studies of our group reported that 
acute dose of 1g/Kg BW grape seed proanthocyanidin extract (GSPE) increases active 
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GLP-1 plasma levels after an oral glucose load in healthy rats. Such increase could, in 
part, explain the increased plasma insulin levels and the decreased plasma glucose 
levels which were also reported in the same study [11]. Therefore, the increased active 
GLP-1 plasma levels could be derived, in part, due to the direct effect of GSPE on 
hormone secretion. In contrast to the results that we observed ex vivo, previous results 
done in our research group reported that 50 mg/L of GSPE decreased active GLP-1 
secretion in the STC-1 cell line [12]. Different results when using different models were 
also reported in studies of short chain fatty acids. Valeric acid induced PYY secretion in 
STC-1 [13], but no changes were observed in ileum and colon intestinal segment after 
incubation with valeric acid [14]. These controversial results could possibly be 
explained by the different features that the models used exhibit. The study of the local 
effect of the compounds on the intestine is a complicated issue due to the complexity of 
the intestinal architecture. In the intestinal cell line model, the limitations that warrant 
consideration are the lack of interaction between EEC and other epithelial cells, and 
the lack of polarity of the cell. On the contrary, the ex vivo model, enables us to study 
the hormone release from enteroendocrine cells that are situated in their normal 
epithelial environment. Due to their advantages over in vitro cell lines, the ex vivo 
model has been optimized at our laboratory to study enterohormone secretion, and 
the results found are in agreement with previous in vivo observations. At this point, it 
should also be stated that both models present a disadvantage, lack of discrimination 
between apical and basolateral sides. There are other study models using ex vivo 
samples that overcome this limitation, such as ussing chambers or InTESTineTM [15], 
but their viability to allow the study of enteroendocrine secretions has not been fully 
demonstrated yet. 
The results obtained in vitro (STC-1 cell line) and using ex vivo models also elucidated 
to the direct effect of a selected chicken feet hydrolyzate that is a source of bioactive 
peptides, on GLP-1 release. It has been suggested that the capacity of protein 
hydrolysates to enhance GLP-1 secretion depends on the nature of their source 
precursor [16], their hydrolysis rate [17] and their amino acid profile [18]. Although 
the specific amino acid motif that triggers GLP-1 secretion stimulation has not yet been 
determined, it has been reported that peptide transporter-1 (PEPT1) and the calcium-
sensing receptor (CaSR) are involved in GLP-1 secretion of di-, tri and oligopeptides 
[19]. Moreover, the apical localisation of PEPT1 emphasises its possible role in the 
direct effect of bioactive peptide sequence from chicken feet hydrolyzate on GLP-1 
release. 
While the direct interaction of bioactive compounds with EECs is a possible 
mechanism to modulate GLP-1 plasma levels, acting on GLP-1 cleavage through 
inhibiting DPP-IV enzyme is also an important strategy to enhance active GLP-1 plasma 
levels. Previous studies reported that GSPE inhibits DPP-IV activity in vitro assays. In 
this thesis, we hypothesized that hydrolysates from chicken feet could also be potential 
DPP-IV inhibitors, due to the structural characteristics of peptides, which can mimetic 
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the sequence of DPP-IV substrates. The potential capacity of chicken feet as natural 
source of DPP-IV inhibitor was employed to screen an array of different chicken feet 
hydrolyzates obtained by different enzymatic treatments. The different hydrolysates 
were analysed and the most potent was selected. The in vitro results determined that 
chicken feet hydrolyzates inhibit DPP-IV, but not all treatments functioned equally, 
indicating the importance of production conditions to liberate the bioactive peptides 
sequence. In the DPP-IV inhibitors classified in peptide-derived peptidomimetic 
inhibitors, the hydrolysis treatment and the source of the natural precursor used to 
obtain the hydrolysate are important factors (reviewed in [20]). Given that GLP-1 is an 
important mediator of glycemic homeostasis, the inhibitory DPP-IV action of chicken 
feet hydrolyzate as well as the capacity to enhance active GLP-1 secretion, explain the 
in vivo results obtained that show an improvement of glucose levels in disrupted-
glucose homeostasis animals. Thus in this thesis we define a novel source of bioactive 
natural compounds, a novel method to obtain the hydrolysate, and its novel 
antihyperglicemic property. Actually subsequent studies have led us also to define the 
main peptide sequence responsible of DPP-IV inhibition (manuscript in preparation). 
The ex vivo model also confers the possibility to study the region-specific architecture 
and specific hormone release patterns of different subtypes of EECs, and thereby 
investigate other enterohormones related with glucose homeostasis and food intake. 
Our results showed that GSPE treatment directly decreased CCK release in duodenal 
segments, in agreement with previously observed changes in plasma levels of acute in 
vivo study [21]. GSPE also directly acted on GIP secretion in duodenum segment, 
inducing an increase of GIP release. This is in contrast with the previously observed 
reduction in GIP plasma levels in an acute in vivo study [11].  The distinct results could 
be given to other elements of the metabolism, which are not monitored in study 
models based on local intestinal hormone release, such as ex vivo model. These 
elements could also contribute to gut hormone secretion in vivo and thereby the 
enterohormone levels measured in plasma. Specifically, the feedback regulation 
between insulin and GIP secretions could be this other signal element [22]. Finally, our 
results also indicated that GSPE and metabolites of GSPE directly increase PYY 
secretion in ileum and colon segments, respectively. Only few studies reported the 
effect of flavonoids on PYY release and all of these studies performed were chronic 
treatments [23, 24]. Therefore, this is the first time that an acute effect of flavonoids on 
PYY secretion is reported. Recently, it has been described that ghrelin release was also 
modulated by GSPE treatment in ex vivo and in vitro (ghrelinoma cell line) models [25]. 
The same study reported that monomeric flavanols present in GSPE composition 
stimulate ghrelin release via activation of bitter taste receptors. Given that monomeric 
flavanols are reported as agonists of the bitter receptors hTAS2R14 and hTAS2R39 
[26–28] and these receptors have been shown to be involved in CCK and ghrelin 
secretion [25, 29], it is reasonable to postulate that these receptors could be involved 
in direct effect of GSPE on enterohormone release. However, the heterogenous 
structural composition of GSPE needs to be considered. For example, it has been 
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reported that monomeric flavanols enhance ghrelin secretion whereas oligomeric 
structures inhibited its secretion [25]. Therefore, others receptors and others signals 
could also be involved in regulating gut hormone release by GSPE. 
Once we determined the direct modulation of enterohormone release by an acute dose 
of bioactive compounds, we wanted to determine which mechanisms could be involved 
in regulating enterohormone release in mid-term GSPE treatments. In this context, a 
three dimensional organoids model was used to elucidate whether GSPE affect 
intestinal differentiation. The organoids model is a self-renewing in vitro culture in 
which single intestinal stem cells generate villus-like epithelial domains in which all 
differentiated intestinal cell types are present [30, 31]. Therefore, organoids, unlike 
cell line and ex vivo model, enabled us to investigate intestinal cell development in real 
time and whether GSPE modulates their differentiation in the normal epithelial 
environment. Moreover, the evaluation of enterohormone secretion in mid-term 
treatments can also be studied. In addition, we also analyzed the mid-term effects of 
GSPE on the endocrine system in an 8-day study using healthy rats.  The in vivo model 
enabled us to analyse the gut microbiota, which is an important element of the 
intestinal environment and could be subject to alterations by diet components in a mid 
or long-term consumption. Furthermore, the crosstalk between the changes in gut 
microbiota and host metabolism can also be studied in the in vivo model. 
Chromogranin A (ChgA) is a member of the granin family of acidic secretory 
glycoproteins that are expressed in endocrine cells and neurons. Chga plays a role in 
the biogenesis of secretory granules and influences peptide hormone transport into 
secretory granules [32]. Therefore, the expression of this gene is associated with 
endocrine cells and it is commonly used as marker of endocrine intestinal cells. 
Previous results reported that 25 mg/kg BW of GSPE during chronic treatment (12 
weeks) counteracts down-regulation of Chga gene levels induced by a cafeteria diet in 
rats, suggesting a role of GSPE in enteroendocrine cell differentiation [33]. In mid-term 
treatments, our results showed that 5 mg/L of GSPE up-regulate Chga gene expression 
in ileum organoids culture. Accordingly, Chga gene expression was also increased by 
0.5 g/kg BW of GSPE administered during 8 days in ileum rats. Our results also showed 
that colonic Chga gene expression is increased after an acute dose of GSPE in in vivo 
studies. Such increase observed in acute treatments could be related with the function 
of Chga in the biogenesis of secretory granules rather than the promotion of EEC 
differentation. To further explore the differential effects of GSPE, transcription factors 
associated with EECs development were studied in ileum organoid culture. Our results 
suggested that the modulation of the early-transcription factor (Ngn3) and late-
transcription factors (Pax4, Pax6, Foxa1/2, Arx) by GSPE leads to L-cell differentiation. 
Moreover, we analysed the effect of GSPE on L-cell gene expression markers: GLP-1 
and PYY. In accordance with Chga gene expression, an up-regulation of ileal PYY 
expression was observed in organoids culture and healthy rats. Ileal GLP-1 expression 
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was also increased during GSPE treatment in organoid culture, but no changes were 
observed in GLP-1 expression in rats after 8 days of GSPE treatment. It must be 
considered that the evaluation of intestinal differentiation was mainly performed in an 
in vitro model, and thus extrapolation to in vivo effects must be performed carefully. 
Actually, the organoid cells are constantly interacting with GSPE molecules for the 
duration of the 72 hours, instead, in vivo the molecules of GSPE pass through the GI 
tract each day when the dose is administered and thereby there is not a constant 
interaction. Therefore, the length and dose used in the studies may play a main role in 
the modulation of gene expression. In fact, our results in organoids culture showed 
that lower doses of GSPE show different effects on the modulation of enteroendocrine 
cell differentiation depending on the dose.  Given that it is difficult to estimate the dose 
in vivo that would be equivalent to the assayed in vitro, more studies will be required 
to fine tune the optimal range of dose-time that reflects in vivo conditions. However, 
the results obtained in organoids culture suggesting an effect on EE cell differentiation 
agree with the previous results done in our research group that showed that the down-
regulation of Chga, GLP-1 and PYY gene levels, induced by a cafeteria diet, are 
neutralized by a chronic dose of GSPE [33].   
Furthermore, recent studies refute the classical concept of separate cells for separate 
hormones [34–36]. These studies showed that L-cells from the upper small intestine 
resemble upper intestine K-cells or I-cells more than colonic L-cells, judging from 
hormone expression profiling. Therefore, the EECs express an overlap of gut hormones 
along the gastrointestinal tract. It has been reported that most L-cell populations in the 
upper small intestine contained CCK, and 10-20 % contained GIP and PYY, together 
with GLP-1. In the same study, the authors also observed that L-cells of the lower small 
intestine also co-express GLP-1 together with GIP and CCK genes, but the levels 
expression are lower compared with proximal small intestine. Moreover, the number 
of L-cells that co-express PYY are increased progressively between proximal and distal 
intestine [36]. Altogether, this might be correlated with our findings regarding the ileal 
GLP-1, CCK and PYY gene expression in rats.  However, pools of PYY-, GIP-, or CCK 
positive cells that do not also express proglucagon have not been reported yet. 
Therefore, further studies using immunohistochemistry or flow cytometry would be 
interesting to study the array of hormones that EECs modulated by GSPE express. 
GSPE could also affect the entroendocrine system in mid-term treatments through the 
gut micobiota. Several studies reported that flavanols unabsorbed by the upper 
intestine pass through the large intestinal lumen reaching the colon where they 
accumulate at high concentrations and are metabolised by the gut microbiota [37]. 
There is evidence that the gut microbiota act on flavanols, however, little research has 
been published about the inverse relation the effect of flavanols on gut microbiota. The 
results obtained in this thesis revealed that the dose of 0.5g/kg BW of GSPE changed 
the gut microbial composition after 8-days of treatment in animals fed a standard diet. 
Only few studies reported the modulation of gut microbiota by flavonoids [38]. 
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Moreover, all of these studies analyse the effects of chronic polyphenol treatment in 
combination with an energy-dense diet, on the other hand, this thesis found GSPE was 
able to modulate gut microbiota in only 8 days in rats fed a standard diet. We 
demonstrated that 0.5g/kg BW of GSPE decreases the ratio of 
Firmicutes/Bacteroidetes in agreement with the general results obtained with 
polyphenols [38]. Moreover, our results indicated that GSPE acts on lower levels of 
microbiome classification, altering specific genera. In this study, new target taxonomic 
groups influenced by proanthocyanidins were defined, including Sutterella, 
Pharscolarctobacterium, Parabacteroides, Bilophila, and Ruminococcus.  In parallel to 
studying the modulation of gut microbiota, we analysed the crosstalk between the 
modulation of gut microbiota and host metabolism using correlation analysis. The 
study of the alteration of the gut microbiota and its relationship with the host 
represents a real challenge, due to its heterogeneous composition and the complexity 
in understanding the gut microbiota-host interactions. However, we described some 
interaction where alterations in gut microbiota induced by GSPE are correlated with 
some metabolism parameters, especially with the increased active GLP-1 plasma 
levels. It has been reported that the intake of Lactobacillus reuteri results in an increase 
GLP-1 secretion in humans. It has also been shown that the administration of VSL#3 
probiotic promotes GLP-1 secretion through changes in the gut microbiota which were 
associated to increased levels of short chain fatty acids (SCFA) [39]. SCFAs can bind to 
GPCR41 and GPR43 receptors expressed by enteroendocrine cells and induce GLP-1 
secretion [40, 41]. Our results showed a decrease of butyrate content, although other 
pathways link gut microbiota and GLP-1 secretion, such as the endocannabinoid 
system [42] or bile acid metabolism [43]. However, further studies are needed to 
elucidate whether increased active GLP-1 levels in mid-term treatment is a causal 
effect of gut microbiota alterations by GSPE. 
Recent studies described the gut microbiota’s direct influence on the expression of 
genes involved in intestinal epithelial proliferation and differentiation [44, 45]. 
Moreover, it has also been shown that the fermentation of non-digestible 
carbohydrates can promote differentiation in the proximal colon and consequently 
increase the number of L-cells in rats, suggesting that the fermentation end-products 
of SCFA could be responsible [46]. This points towards the gut microbiota playing an 
important role in the regulation of colonic differentiation either directly or indirectly 
through SCFA. Therefore, in addition to a possible direct effect of GSPE on intestinal 
differentiation, GSPE could also affect intestinal differentiation through the modulation 
of microbiota. It must be mentioned that no changes in colonic gene expression were 
observed after 8-days of treatment in rats, suggesting that further work is required to 
determine whether GSPE modulates differentiation through changes in the microbiota. 
Whether this could explain the previously mentioned GSPE effects in long-term 
treatments, that is counteraction of the down-regulation of Chga, GLP-1 and PYY gene 
levels induced by a cafeteria diet after 12 weeks, should be further assessed. Moreover, 
the effects of metabolites of GSPE produced by the microbiota should be considered in 
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colon tissue. Therefore, further studies are needed to determine the effects of GSPE on 
colon sections and the mechanisms underlying these effects. 
Recent studies done in our group showed that the acute increase of active GLP-1 
plasma levels induced by 1g/Kg BW of GSPE is also an effective satiety signal in rats 
[21]. Importantly, the loss of 0.5 g/Kg BW GSPE’s satiating effect following GLP-1 
receptor blockade using exendin, suggests that  GSPE’s satiating effects are mediated 
by an enhancement in GLP-1 signalling [47]. As above mentioned, such increase in 
GLP-1 plasma levels is due to a direct effect of GSPE on hormone secretion and also due 
to the inhibition of DPP-IV enzyme [48]. Moreover, the satiating effect was also 
observed in rats treated with 0.5 g/Kg BW GSPE for 8 days. These animals also gained 
less weight and had an increased energy expenditure [49]. An equivalent dose of gallic 
acid that contains 0.5 g/Kg BW GSPE also showed an acute satiating effect. However, 
the satiety effect of gallic acid was not extended after 8-day treatment, like with GSPE 
[47]. As above mentioned, we observed that 0.5 g/Kg BW GSPE modulates the gut 
microbiota after 8 days, and such modulation correlated with increased active GLP-1 
levels. However, our results showed that an equivalent dose of gallic acid doesn’t 
modulate the microbiota composition nor the GLP-1 secretion. Considering these 
results, we hypothesized that the modulation of the gut microbiota might be a 
mechanism by which mid-term GSPE treatments have a satiety effect. 
Like gallic acid used in in vivo treatment, other pure compounds contained in GSPE 
were also evaluated in an attempt to identify molecules responsible for the acute and 
mid-term local effect of GSPE on intestinal tissue. Our results showed that monomeric 
and dimeric structures (epicatechin gallate, dimer B2, dimer B2 gallate, gallic acid) 
could contribute to the acute CCK secretion induced by GSPE. In mid-term treatments 
using organoids model, our results showed that epicatechin and gallic acid are not the 
responsible for all the effects produced by GSPE. However these molecules showed 
some bioactivity, such as the modulation of the expression of some transcription 
factors; Pax4 gene expression by gallic acid and FOXA ½ by epicatechin and the modest 
increase of total GLP-1 secretion after mid-term treatment. These results suggest that 
gallic acid and epicatechin might be, in part, responsible for the increased GLP-1 
secretion observed in mid-term GSPE treatments. The results are obtained using only 
part of the molecules that form GSPE because some of the other components could 
only be obtained in very small amounts. However, we conclude that the effects of GSPE 
are attributed to the complex mixture of compounds present in this extract. In 
consequence, treatments using pure molecules alone present few effects compared to 
the effects generated by the whole GSPE. Previous results done in our research group 
showed that catechin, gallic acid and B2 dimer molecules of GSPE inhibit DPP-IV 
activity in vitro, but no effect was observed in epicatechin treatment. The combination 
of them potently inhibit DPP-IV [11], suggesting a synergic effect of these molecules. 
On the other hand, GSPE has been reported to inhibit octanoyl ghrelin in ghrelinoma 
cell line; in accordance oligomeric molecules also inhibit ghrelin release. In contrast, 
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monomeric molecules of GSPE enhanced ghrelin secretion, suggesting antagonistic 
effects of pure molecules on ghrelin secretion [25]. Therefore, each bioactive molecule 
of GSPE could present different effects and thereby GSPE action could be a result of 
additive, synergic or antagonistic effects of each molecule on different targets.  In 
accordance, it has been reported that vitamin C in apples contributed to only 0.4% of 
the total antioxidant activity of the whole apple; most of the antioxidant activity comes 
from phytochemicals presents in apple skin. Therefore, the whole fruit is more potent 
than the administration of one pure compound (reviewed in [50]). Moreover, it has 
been described that the combination of bioactivity of different sources of natural 
compounds potentiates the effect of each sources administered individually, such as 
the combination of omega-3 polyunsaturated fatty acids and GSPE [51–54]. Therefore, 
treatments using mixture of bioactive compounds are more effective than a treatment 
with one pure molecule. 
Taking into account the effects of GSPE and chicken feet hidrolyzates on GLP-1 
enterohormone levels and thereby on glucose homeostasis, the study of the effect of 
the combination of these two natural sources on enteroendocrine system would be 
interesting. Different studies have reported the use of proteins as carriers of 
flavonoids, without impairing their bioavailability (milk and catechins) [55], to reduce 
the bitter taste induced by flavonoids [56, 57]. Therefore, the combination of chicken 
feet hydrolyzates with GSPE could be a good approach to develop a functional food. 
However, future studies should evaluate the interaction between proanthocyanidins 
from GSPE and proteins from chicken feet hydrolyzates and whether such interaction 
affects the direct action of GSPE on the enteroendocrine system. 
Furthermore, the promising results obtained in acute treatment of chicken feet 
hydrolyzate related with glycemic homeostasis open a new line of research which 
could be further studied concerning the effect of chicken feet hydrolyzate on other 
enterohormones related with glucose homeostasis and food intake. It has been 
reported that pea protein increased fullness and decreased food intake in an ad libitum 
meal in humans [16], and whey protein is also associated to increased GLP-1 plasma 
levels and reduced energy intake in humans [58]. Hence, future experiments studying 
the action of chicken feet hydrolyzate on food intake in vivo would be interesting, as 
well as, evaluating the mid-term and long-term effects of chicken feet hydrolyzate on 
enteroendocrine system related with glucose homeostasis and food intake.  
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SUMMING UP: MAIN CONCLUSIONS 
The main conclusions obtained from this thesis are: 
1. GSPE modulates gut hormone secretion by directly acting on 
enteroendocrine cells in acute treatments.  
 
 An acute dose of GSPE and GSPE metabolites increases active GLP-1 
secretion in ex vivo ileum and colon segments, respectively. 
 The direct release of GLP-1 following GSPE stimulation requires 
glucose. 
 GSPE’s effect on gut hormone secretion varies along the gastrointestinal 
tract 
- GSPE increase GIP and decrease CCK release in ex vivo duodenum 
segments. 
- GSPE and GSPE metabolites increase PYY release in ex vivo ileum 
and colon segments, respectively. 
 The reduction of CCK secretion, following GSPE administration, is partly 
mediated by GA. 
 
2. The modulation of intestinal differentiation is a mid-term effect of GSPE. 
 
 GSPE enhances the gene expression of L-cell differentiation markers 
Chga, Gcg, and PYY in organoids. 
 GSPE modulates early-transcription factors (Ngn3) and late-
transcription factors (Pax4, Pax6, Foxa1/2, Arx) involved in EEC 
differentiation. 
 GSPE does not only enhance differentiations markers for L-cell, it also 
up-regulates markers for enterocyte and goblet cells, while reducing 
the marker for stem cells. 
 
3. GSPE modulates the composition of the gut microbiota and such 
modulation is related to host metabolism in rats. 
 
 GSPE decrease the ratio of Firmicutes:Bacteroidetes. 
 New target of microbial taxonomic groups influenced by 
proanthocyanidins are defined: Sutterella, Pharscolarctobacterium, 
Parabacteroides, Bilophila, and Ruminococcus. 
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 The GSPE-induced changes of the gut microbiota led to a modulation of 
the acetate:propionate:butyrate ratio.  
 The gut microbiota profile, following GPSE treatment, correlates with 
host metabolic parameters, and notably with increased active GLP-1 
plasma levels. 
 
4. Chicken feet hydrolyzate modulates the incretin system through different 
mechanisms. 
 
 An acute dose of chicken feet hydrolyzate stimulates GLP-1 release in ex 
vivo and in vitro model. 
 DPP-IV activity is inhibited by chicken feet hydrolyzate in vitro. 
 Chicken feet hydrolyzate improves glucose plasma levels in disrupted-
glucose homeostasis rat models. 
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CONCLUSIONS GENERALS 
Les principals conclusions obtingudes en aquesta tesi són: 
1. GSPE modula la secreció de les hormones intestinals mitjançant un efecte 
directe sobre les cèl·lules enteroendocrines en tractaments aguts. 
 
 Una dosi aguda de GSPE i dels seus metabòlits augmenta la secreció de 
GLP-1 actiu en segments ex vivo d’ili i de colon, respectivament. 
 La secreció de GLP-1 produïda per una directa estimulació de GSPE 
requereix glucosa. 
 L’efecte de GSPE sobre la secreció d’hormones intestinals varia a través 
del tracte gastrointestinal. 
- GSPE augmenta la secreció de GIP i disminueix la secreció de 
CCK en segments ex vivo de duodè.  
- GSPE i els seus metabòlits augmenten la secreció de PYY en 
segments ex vivo d’ili i de colon, respectivament. 
 La disminució de la secreció de CCK, després de l’administració de 
GSPE, és causada, en part, per GA. 
2. La modulació de la diferenciació intestinal és un efecte subcrònic del 
GSPE. 
 
 GSPE promou la expressió de gènica dels marcadors de la diferenciació 
cel·lular de les cèl·lules L en organoids: Chga, Gcg i PYY. 
 GSPE modula els factors de transcripció primerencs (Ngn3) i els factors 
de transcripció tardans, involucrats en la diferenciació de les EEC. 
 GSPE no solament augmenta els marcadors de diferenciació de les 
cèl·lules L, sinó que també promou l’increment dels marcadors dels 
enteròcits i de les cèl·lules calciformes, així com la disminució del 
marcador de les cèl·lules mare. 
3. GSPE modula la composició de la biota intestinal i aquesta modulació està 
relacionada amb el metabolisme de l’hoste en rates. 
 
 GSPE disminueix el rati Firmicutes:Bacteroidetes. 
 Es defineixen nous grups taxonòmics microbians com objectiu de 
l’acció de les procianidines: Sutterella, Pharscolarctobacterium, 
Parabacteroides, Bilophila i  Ruminococcus. 
 Els canvis de la biota intestinal induïts per GSPE deriven en la 
modulació del rati acetat:propionat:butirat.  
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 El perfil de la biota intestinal, posterior al tractament amb GSPE, 
correlaciona amb paràmetres metabòlics de  l’hoste, del qual destaca la 
correlació amb l’augment dels nivells de GLP-1 en plasma. 
4. L’hidrolitzat de pota de pollastre modula el sistema d’incretines 
mitjançant diferents mecanismes.  
 
 Una dosi aguda d’hidrolitzat de pota de pollastre estimula la secreció de 
GLP-1 en els models ex vivo i in vitro. 
 L’activitat de DPP-IV és inhibida per l’hidrolitzat de pota de pollastre in 
vitro. 
 L’hidrolitzat de pota de pollastre millora els nivells de glucosa en 
plasma en models de rates que presenten una homeòstasis de la 
glucosa alterada. 
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In the last decade, there has been an increasing prevalence of obesity and me-
tabolic-associated diseases. In view of this fact, önding preventive therapies, 
as wel as treatments for these diseases is of great interest for public health. 
Gut hormones secreted from enteroendocrine cels (EECs) play a key role in 
the regulation of food intake and glucose homeostasis. In this context, the re-
search of this thesis has focused on the role of natural bioactive compounds 
on the enteroendocrine system.
 
Our research group reported in previous studies that grape seed proanthoc-
yanidin extract (GSPE) increased GLP-1 plasma levels in rats. In this thesis, we 
elucidated that such increase might be in part explained by the direct action 
of GSPE on EECs. Moreover, we demonstrate that GSPE also modulates the se-
cretion of the main gut hormones by directly acting on EECs, inducing an in-
crease of GIP and PYY release, while reducing CCK release.
The results obtained in this thesis using organoids culture demonstrated that 
GSPE up-regulate the main markers of L-cel and modulate transcription fac-
tors involved in L-cel diﬀerentiation, and thereby point out that the promo-
tion of L-cel diﬀerentiation is a mechanism by which GSPE act in prolonged 
treatments. Moreover, our öndings in mid-term treatments revealed that gut 
microbiota composition is modulated by GSPE and such composition proöle 
corelates with host metabolic parameters, and remarkably with increased 
active GLP-1 plasma levels.
Furthermore, we found a new source of natural bioactive compounds, chicken 
leg hydrolyzate, and demonstrated that it acts as antihyperglycemic agent in 
disrupted-glucose homeostasis animals due to the capacity of inhibiting 
DPP-IV activity and enhancing endogenous GLP-1 release.
In conclusion, the öndings obtained in this thesis show that natural bioactive 
compounds act through diﬀerent mechanisms on the enteroendocrine 
system, and thereby could be good therapeutic agents to treat obesity and 
glucose homeostasis disruption.
